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SUMMARY 
Postsynaptic scaffolding proteins like SHANK1-3 stabilize the formation, organization and signal 
transmission at the glutamatergic synapses through numerous protein interactions. All three SHANK 
genes are expressed in multiple isoforms that cooperate to form a complex and a developmental-
dependent scaffold organization at glutamatergic synapses. Those modulatory proteins are involved 
in the spatial organization of postsynaptic receptors, the efficiency of synaptic transmission and the 
plasticity of synapses. As a consequence, the synaptic transmission is responsive to structural 
changes within the SHANK scaffold, as evidenced by (I) the high number of ASD patients with 
mutations and copy number variations in the SHANK genes, (II) the diverse clinical phenotypes 
ranging from ASD to mania-like phenotypes in numerous Shank knock-out mouse models and (III) 
the 4-fold higher prevalence of ASD in males, which might be explained in some cases by the sex 
dimorphic expression of SHANK. Indeed, the here presented investigation of Shank expression in 
mice revealed significantly higher SHANK levels both in late stage male embryos and early-
postnatal male pups during their peak of testosterone level. Moreover, the treatment of human 
neuroblastoma cells with dihydrotestosterone and 17β-estradiol increased the expression of all three 
SHANK genes, demonstrating a direct sensitivity of SHANK genes to the sex hormones.  
For the functional analysis of specific SHANK isoforms in mice, the endogenous regulation of the 
Shank scaffold was blunted in favor of a strong constitutive, doxycycline-regulated overexpression of 
transgenic SHANKs. The spatiotemporal-controlled overexpression of either SHANK2A or the 
truncated SHANK2A(R462X) in the mouse glutamatergic forebrain neurons was correlated with 
specific ASD-like phenotypes including hyperactivity, repetitive behavior and impairments in social 
and novelty behaviors. When the transgenes were switched off in adulthood, specifically the 
impaired sociability was unexpectedly rescued in mice of both mouse lines. The effect of SHANK2A 
but not SHANK2A(R462X) overexpression inhibited the developmental-dependent AMPAR subtype 
switch in the basal dendrites of the hippocampus. In addition, the synaptic protein components were 
altered differently in both mouse lines, indicating mainly presynaptic components in 
SHANK2A(R462X) and more postsynaptic components in SHANK2A overexpressing mice. These 
results identified the differential regulation of endogenous SHANK as critical modulators of neuronal 
networks that are critically involved in learning and social behaviors. 
 
 
                                                                                                               
 
 
ZUSAMMENFASSUNG 
Das postsynaptische Proteingerüst der SHANK1-3 Proteine stabilisiert die Bildung, Organisation und 
Signalübertragung glutamaterger Synapsen durch zahlreiche Proteininteraktionen. Dabei ermöglicht 
die Vielzahl von SHANK Isoformen eine entwicklungsabhängige Reifung des postsynaptischen 
Netzwerks und somit eine räumliche Umorganisation postsynaptischer Rezeptoren, die für die 
synaptische Übertragung wesentlich sind. Dies wurde zum einen durch die vergleichsweise hohe 
Zahl von ASD-Patienten mit Veränderungen in den drei SHANK Genen deutlich und durch die 
extrem hohe phänotypische Variabilität der Patienten und der zahlreichen Shank-Knock-out-
Mausmodelle. Weiterhin ist eine 4-fach höhere Prävalenz von ASD bei Männern beschrieben, was in 
einigen Fällen durch die geschlechtsdimorphe Expression von SHANK erklärt werden könnte. 
Tatsächlich zeigten Mäuse signifikant höhere SHANK Expressionslevel bei männlichen Embryonen 
in späten Stadien und männlichen Jungtieren während früher postnataler Stadien, wenn der 
Testosteronspiegel besonders hoch ist. Darüber hinaus führte die Behandlung von menschlichen 
Neuroblastomzellen mit Dihydrotestosteron und 17β-Östradiol zu einer erhöhten Expression aller 
drei SHANK-Gene, was den direkten Einfluss der Sexualhormone auf die Regulation neuronaler 
SHANK-Gene zeigen konnte.  
Zur Funktionsanalyse definierter SHANK-Isoformen in Mäusen wurde die endogene Regulation des 
SHANK-Gerüsts zugunsten einer konstitutiven, Doxycyclin-regulierten Überexpression transgener 
SHANKs in den Hintergrund gedrängt. Die räumlich und zeitlich kontrollierte Überexpression von 
SHANK2A, oder des verkürzten SHANK2A(R462X), in den glutamatergen Vorderhirnneuronen 
korrelierte dabei mit mauslinienspezifischem, ASD-ähnlichem Verhalten wie Hyperaktivität, 
repetitives Verhalten und Beeinträchtigungen des Sozial- und Neuheitsverhaltens. Wenn die 
Transgene im Erwachsenenalter ausgeschaltet wurden, konnte bei adulten Tieren beider Mauslinien 
erstaunlicherweise ein normales Sozialverhalten beobachtet werden. Im Gegensatz zu SHANK2A 
(R462X) hemmte die Wirkung der Überexpression von SHANK2A den entwicklungsabhängigen 
Austausch von AMPAR-Subtypen in Basaldendriten des Hippokampus. Auch die 
Proteinzusammensetzung der Synapsen in beiden Mauslinien war unterschiedlich verändert: bei 
SHANK2A (R462X) waren überwiegend präsynaptische Komponenten, bei SHANK2A-
überexprimierenden Mäusen überwiegend postsynaptische Komponenten betroffen. Diese 
Ergebnisse belegen eine entscheidende Rolle der SHANK Proteine als kritische Modulatoren 
neuronaler Netzwerke, die Lernvorgänge und soziales Verhalten beinflussen.  
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         Chapter 1 
             Introduction 
 
1.1 Autism spectrum disorder (ASD)  
Autism spectrum disorder (ASD) is a heritable complex neurodevelopmental disorder 
1
. It refers 
to a constellation of clinical conditions with two main phenotypic characteristics: impairment in 
social communication and patterns of repetitive restrictive behaviors 
2,3
 with a 40% prevalence of 
developmental delay and intellectual disability (ID) 
4
. Along with the core symptoms of ASD, 
comorbidities including hyperactivity, anxiety, epilepsy, hypotonia, sleep disruption and 
gastrointestinal disorders usually occur in ASD patients 
5-8
. Moreover, other genetic disorders 
such as fragile X syndrome, tuberous sclerosis and Rett syndrome often present autistic features 
9-17
. ASD symptoms are usually noticed before the age of three and persist throughout life, 
suggesting that prenatal impairments in brain development can turn into postnatal manifestations 
18
. It has been suggested that specific brain regions mediate the phenotype observed in ASD 
patients: the frontoparietal cortex, amygdala, hippocampus, basal ganglia and striatum 
19
.  
In ASD, information processing in the brain is disrupted by the altered connectivity of nerve 
cells and their functional network organization. There is also an excess of neurons, causing local 
over-connectivity and an abnormal formation of synapses and dendritic spines 
20
. In the last 
decade, mutations in several genes that encode proteins required in synapse formation, 
development, plasticity and pruning were linked to ASD. This supports the hypothesis that ASD 
is, to a large extent, the consequence of a developmental synaptopathy. These genes include 
NLGN3 
21
, NLGN4 
21
, NRXN1 
22,23
, CNTNAP2 
24
 and SHANKs 
4,25,26
. In addition to the genetic 
risk factors, a combination of different environmental factors influencing early brain 
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development likely contributes to ASD. These environmental triggers include maternal physical 
and mental health 
27
 as well as exposure to medication during pregnancy and hypoxia during 
birth 
27
 (for reviews, see 
28-30
). 
1.1.1 Sex bias in ASD 
ASD affects more males than females in a 4:1 ratio and with a worldwide prevalence of about 
1% 
31-34
. The mechanism behind this sex-differential risk is not well understood. In part, the risk 
difference can be explained by a diagnostic bias as ASD symptoms are more visible and easier 
diagnosed in males 
35
, whereas female ASD patients are better at masking social challenges in 
school 
36-38
. Since genetics play a major role in ASD, an increasing number of studies have 
proposed hypotheses related to the level and pattern of gene expression as a reason for the ASD 
sex-differential risk 
31,39-44
. One hypothesis suggests that ASD risk genes are sex-differentially 
expressed due to genes on the X or Y chromosomes, skewed X inactivation or sex-specific 
imprinting defects on autosomes. A growing number of studies support this hypothesis by 
revealing that sex chromosomes aneuploidies modulate ASD risk with an increased rate of ASD 
diagnosis in Turner syndrome (XO, 3% ASD) 
45-47
, Klinefelter syndrome (XXY, 10% ASD) 
48,49
, 
and 47,XYY syndrome (20% ASD), but no increased rate in X chromosome trisomy 
50,51
. This 
may indicate that the Y chromosome is a risk factor for ASD, while a second X chromosome is 
protective, possibly via genes that escape X-inactivation 
39
. Another hypothesis suggests that 
ASD risk genes are expressed at the same level in both males and females, but they interact with 
sexually dimorphic pathways 
44,52
. Due to the fact that early (prenatal and neonatal) brain 
development is influenced by sex hormones, a central role of sex hormones in the ASD sex-
differential risk has been proposed 
31
. One example is estrogen, which is known to enhance 
synaptogenesis and to modulate synaptic plasticity 
53,54
. This, in turn, may have a protective 
effect against ASD 
55
. Fetal testosterone levels, in contrast, are correlated with autistic traits 
56,57
 
(for a review, see 
58
). In addition, a subset of adolescent and adult patients with ASD showed 
elevated androgen levels 
59
. Therefore, high levels of testosterone during early and late 
development have been hypothesized as an ASD risk factor due to a hypermasculinization of the 
brain (also known as the androgen theory of ASD 
52,60
). However, the precise cellular and 
molecular mechanisms by which sex hormones interact with ASD pathways are not well 
understood. One potential mechanism of sex hormones was observed in the cortices of adult 
ASD patients. Here, the expression of genes involved in the immune system and glia function 
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were upregulated 
61
 and modulated by estradiol levels 
62,63
. Another potential mechanism 
involves the expression of Retinoic acid-related orphan receptor alpha (RORA), a gene known to 
be associated with ASD 
64,65
. RORA expression has been shown to be activated by estradiol and 
inhibited by testosterone hormones 
66
 via the estrogen receptor (ER) and androgen receptor (AR) 
67
. Moreover, the expression of  RORA displayed a pattern of sex-bias in certain brain regions in 
humans and mice 
68
. The expression of ASD risk genes that encode synaptic proteins might also 
be regulated by sex hormones during brain development 
69
. However, the effect of sex hormones 
on the expression of these genes have not been thoroughly investigated so far.  
1.2 The excitatory glutamatergic synapses 
At the most fundamental level, brain function is based mainly on computations performed by 
neurons that receive input through their synapses. The synapses permit the flow of 
electrochemical signals from one neuron to another 
70
. The glutamatergic synapses are the most 
abundant type of excitatory synapses. They are composed of pre- and postsynaptic sides, 
separated by a 15-25 nm synaptic cleft 
71
. The presynaptic region contains vesicles filled with the 
neurotransmitter glutamate. Glutamate is released when the presynaptic membrane is depolarized 
by an action potential 
72
. The released glutamate binds to the fast ionotropic glutamatergic 
receptors including N‐methyl‐d‐aspartate (NMDA), α‐amino‐3‐hydroxy‐5‐methylisoxazole‐4‐
propionic acid (AMPA) and kainate as well as to metabotropic glutamatergic receptors (mGluRs) 
73
. Binding of glutamate to the ionotropic glutamatergic receptors usually induces an influx of 
positively charged ions such as Na
+
 and sometimes Ca
2+
, which, in turn, triggers the 
depolarization of the postsynaptic membrane 
74
. At a depolarized postsynaptic membrane, the 
glutamate activation of NMDA receptor (NMDAR) leads to a very selective Ca
2+
 influx, a 
subsequent activation of second messenger cascades and finally to a long lasting change of 
synaptic transmission at this synapse. This is a central mechanism for the plasticity of the 
neuronal system, which is underlying learning and memory 
75
.  
Fine-tuning of synaptic transmission and synaptic plasticity requires a rigorous spatiotemporal 
organization of the proteins at the excitatory synapses. Also, the specific coupling of the 
postsynaptic receptors to their downstream signaling pathways has to be orchestrated. Therefore, 
it is not surprising that the analysis of the molecular organization of the excitatory glutamatergic 
postsynapse in humans via mass spectrometry revealed around 1500 proteins including 
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intercellular cell adhesion molecules (Neurologins, N-cadherin) and a variety of signaling 
proteins (kinases, phosphatases, etc.) 
76,77
. In the excitatory postsynapse, intracellular scaffolding 
proteins regulate the organization and the dynamics of those multiple protein complexes that are 
usually composed of several subunits and associated proteins 
78
. These scaffolding proteins 
feature multiple protein- and/or cytoskeleton-binding domains that enable the trafficking, 
anchoring and clustering of receptors and adhesion molecules in the postsynaptic density (PSD) 
78
. They also support and mediate the cellular processes critical for synaptic transmission and 
plasticity 
79
. The most important scaffolding proteins include the postsynaptic density molecule 
95 (PSD95) and the members of the SH3 and multiple ankyrin repeat domains (SHANK) protein 
family, which are involved in multiple aspects of synaptic function 
34,80-82
.  
1.3 The SHANK family as major scaffolding proteins 
The human SHANK family embodies three known synaptic scaffolding proteins, SHANK1, 
SHANK2 and SHANK3, with ~2000 amino acid residues in length and >200 kDa in molecular 
mass 
34
. SHANK proteins are localized at the interface between the membrane receptors and 
cytoskeleton (24-26 nm inside the membrane) 
83
. They organize a cytoskeleton-associated 
signaling complex at the PSD of nearly all excitatory glutamatergic synapses in the mammalian 
brain 
84-87
. Thus, the SHANK proteins play an important role in the formation, organization and 
signaling of the glutamatergic synapses. For instance, they connect NMDAR and AMPA 
receptors (AMPAR) to the actin cytoskeleton of the PSD 
34
. Several studies identified more than 
30 synaptic proteins interacting with SHANKs by binding to their domains 
87
, which accounts 
for the complexity of SHANK protein function. A full-length SHANK protein contains five 
protein-protein interaction sites: the N-terminal multiple ankyrin (ANK) repeats, the Src 
homology 3 (SH3) domain, the PSD-95/Discs large/zona occludens (PDZ) domain, the long 
(>1000 residue) proline-rich region (PRR) and the sterile alpha motif (SAM) in the C-terminal 
domain 
34
 (Figure 1). The ANK repeat domain is a 33-residue sequence motif 
88
 and interacts 
with the cytoskeletal protein α-fodrin 
89
 and SHANK-associated RH domain interactor 
(SHARPIN) that plays a role in the dendritic spine development 
90
. The SH3 domain binds to the 
glutamate receptor-interacting protein (GRIP) that is required for AMPAR trafficking 
91
. It also 
binds to Densin-180 for dendritic spines remodeling 
92
 and to Cav1.3a for the synaptic clustering 
of Cav1.3 L-type Ca
2+
 channels 
93
. The PDZ site in SHANK proteins binds to the C-terminal of 
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the adaptor protein guanylate kinase-associated protein (GKAP) (Naisbitt et al., 1999). GKAP 
itself can bind to PSD95 
94
 which, in turn, is in contact with NMDAR 
95
 and AMPAR 
96,97
 (for a 
review, see 
98
). The combined interaction of the PDZ domain and GKAP allows SHANK protein 
recruitment to the postsynaptic sites. Moreover, the PDZ domain recognizes a consensus C-
terminal sequence X-T/S-X-L that is prevalent in many membrane proteins such as the group I 
mGluRs and the somatostatin receptor type 2 (SSTR2) 
99
. However, the binding of the PDZ 
domain to SSTR2 was confirmed neither in vitro nor in vivo 
85,100
. Importantly, the SHANK 
proteins have been shown to interact with Homer via the PRR 
86,101
. This interaction allows the 
coupling of mGluRs to Ca
2+
 release from the endoplasmic reticulum in the PSD, which helps the 
assembly of signaling complexes in excitation-Ca
2+
 coupling 
102
. Cortactin, a molecule involved 
in the actin cytoskeleton organization and polymerization in the cell cortex and dendritic spine 
86
, 
has been shown to bind to the PRR as well 
103
. The SAM domains of SHANK proteins can bind 
to each other in homomeric and heteromeric manners, enabling the SHANK proteins to 
multimerize tail-to-tail by a Zn
2+
-dependent mechanism 
104,105
. In addition, the SAM domain is 
also essential for the localization of SHANK2 and SHANK3 proteins to the PSD 
106
. Thus, the 
oligomerization of SHANK protein permits the cross-linking of multiple sets of protein 
complexes at the postsynaptic sites. In summary, the full-length SHANK proteins exert their 
versatile functions by binding directly to multiple synaptic proteins via their protein-binding 
domains and interacting indirectly with three major classes of postsynaptic glutamate receptors: 
NMDAR by the GKAP complex, mGluRs by Homer and AMPAR by GRIP.  
 
Figure 1: Simplified model of SHANK proteins in the PSD of the excitatory glutamatergic synapses 
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Schematic diagram of SHANK proteins, their protein-protein interaction sites (the N-terminal ANK repeats, 
the SH3, the PDZ, the PRR and the C-terminal SAM domain) and their direct partners. The figure and figure 
legend are adapted from 
87
. 
Another layer of complexity in the SHANK protein function is added by a multitude of 
alternative splice variants as well as multiple internal promoters in their genes (SHANK1: 2; 
SHANK2: 3 and SHANK3: 6 internal promoters) 
87
, resulting in several isoforms 
84,107
. The 
splicing appears to be regulated during brain development, albeit the functional significance of 
the alternative splicing of the SHANK genes is still unknown 
87
. The differential spatiotemporal 
expression of the SHANK proteins adds another layer of complexity. Although SHANKs are 
predominantly expressed in the brain 
108,109
, SHANK2 mRNA is also expressed in peripheral 
tissues like liver and kidney 
84,110-112
, and SHANK3 mRNA is expressed in all tissues, 
predominantly in the heart and moderately in the brain and spleen 
34,84
 (see 
http://www.proteinatlas.org). In the brain, all three SHANK proteins are co-expressed in the 
cortex and hippocampus, whereas other brain regions showed differential expression 
34
. The 
temporal expression of SHANK patterns identified by the in situ RNA hybridization studies in 
rats revealed the co-expression of SHANK1 and SHANK2 during the early days of development, 
whereas SHANK3 reaches its maximum expression at postnatal day (P) 16 
113
.  
Although all SHANK proteins can respond to synaptic events, there is still functional divergence 
between these three proteins. SHANK1 lacks the capability to localize to immature/inactive 
synapses, which seems to be SAM domain/Zn
2+
-dependent. Therefore, it is recruited to the PSD 
to a pre-formed scaffold via its PDZ domain 
104,105,114
. In contrast, SHANK2 and SHANK3 seem 
to be essential elements for the proper organization of the PSD by their localization via the SAM 
domain, which can be enhanced by the activity and synaptic release of Zn
2+
 
115
. Interestingly, on 
the electrophysiological level, the knockdown of SHANK1 and SHANK2, but not SHANK3, 
showed a decrease in the AMPAR responses at CA3-to-CA1 synapses in acute hippocampal 
slice cultures 
116
, which further supports their functional divergence.  
1.4 SHANK2 mutations and neuropsychiatric disorders 
Mutations in the human SHANK genes are associated with a wide range of severe 
neuropsychiatric disorders including ASD, ID, schizophrenia (SCZ) and mania 
117
, likely 
reflecting the importance of a correctly organized PSD. These mutations include copy-number 
variations (CNVs), microduplications of nucleotides, as well as nonsense, missense and 
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frameshift mutations. Semi-identical SHANK mutations were found in patients with very distinct 
behavioral outcomes. First, the SHANK genes were associated with neurodevelopmental 
disorders by the studies of the Phelan-McDermid Syndrome which is characterized by autistic-
like behaviors 
118
. In nearly all reported Phelan-McDermid Syndrome cases, a deletion of 
SHANK3 was identified 
119,120
. Thereafter, SHANK3 mutations have also been identified in 
genetic screenings of patients with ASD 
121,122
 and SCZ 
123
. CNV deletions encompassing the 
SHANK1 gene have been shown to segregate only in male carriers with high-functioning autism 
26
. One explanation for this correlation between the mutation and the degree of cognitive 
impairment has to do with the expression pattern of this particular mutated SHANK gene  
124
. 
The SHANK2 gene, also known as ProSAP1, is the largest gene among the SHANK gene family 
(450 kb long, 25 exons). Its mRNA is enriched in the cortex, thalamus, hippocampus (CA1, CA3 
and dentate gyrus (DG)) and Purkinje cells 
125
. SHANK2 loss-of-function mutations are assumed 
to result in synaptic dysfunction and were first identified in patients with ASD and ID 
4
. Several 
other studies have described further variations in the SHANK2 gene loci in patients with ASD 
and ID, which solidifies the causal link of SHANK2 variants to neuropsychiatric disorders 
110,124,126-132
 (for a review, see 
133
). Interestingly, an association between SHANK2 gene mutations 
and SCZ was first described in 2015 
134
. By sequencing the SHANK2 gene in 481 SCZ patients 
and 659 unaffected individuals, Peykov et al. identified several non-synonymous variants 
exclusively in SCZ patients 
134
. This association was confirmed by a study reporting seven 
siblings in a family with SCZ spectrum disorders carrying a missense variant in SHANK2 
135
 (for 
a review, see 
133
). 
1.5 Possible explanations for the divergent phenotypes in patients with 
SHANK2 variants 
One explanation for the wide range of neuropsychiatric disorders caused by SHANK2 mutations 
could be the unreliability of clinical data due to imprecise clinical diagnoses. Another 
explanation might be the nature of the SHANK2 variants which might lead to an increase or 
decrease in the SHANK2 protein expression, altered SHANK2 protein domains or truncated 
SHANK2 protein products lacking one or more interaction domains. This, in turn, can alter the 
protein-protein interactions and the organization of the postsynaptic protein network. Therefore, 
different SHANK2 mutations could potentially lead to different alterations in molecular and 
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cellular processes in neurons, resulting in a range of behavioral phenotypes 
133
. This perspective 
finds support in the rescue experiment of SHANK2 knockdown by the overexpression of three 
different human SHANK2A variants (R462X, T1127M, L1008_P1009dup) in rat primary 
cultures 
136
. These variants showed distinct localization patterns different to that of the 
SHANK2A-WT overexpression one 
136
, indicating that they can lead to a decrease in the total 
final amount of SHANK2 present at the synapse. They may also have other effects, e.g. in the 
soma and dendrites, which could be another important factor in the pathophysiology of 
neuropsychiatric disorders 
133
. Moreover, the overexpression of SHANK2 variants revealed 
different degrees of rescue of the reduced spine volume caused by the SHANK2 knockdown 
136
, 
which indicates different influences of different SHANK variants on the regulation of spine size.  
Other genetic, epigenetic and environmental factors have also a strong impact on the expression 
of SHANK2 variant-mediated neuropsychiatric disorders. For example, the same SHANK2 
variants were found in patients with different clinical features (Table 1). Additionally, 
synonymous variants were detected in patients with ASD, ID and SCZ, but not in healthy 
controls 
4,134,137
. The effects of other genes on the phenotypic expression of SHANK2 variants 
became most obvious in patients with an inherited SHANK2 variant-associated ASD or SCZ, 
which have not been diagnosed in their parents. For example, the SHANK2A577V variant was 
found in 7 SCZ male brothers and inherited from a healthy mother 
135
. This was also the case for 
other SHANK2 variants identified in SCZ 
134
 and ASD 
133
 patients, suggesting that sexually 
dimorphic pathways have an effect on the penetrance of SHANK2 variants. Additionally, 
epigenetic factors are suggested to affect SHANK2 expression 
133,138
, which, as well, may lead to 
different penetrances of similar SHANK2 variants.  
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Table 1: Identical SHANK2 variants causing different clinical features in patients 
 
Five different single point mutations in the coding region of the human SHANK2 gene leading to five amino 
acid residue exchanges were associated with different neuropsychiatric disorders. n.a= not available. The table 
and table legend are adapted from 
133
. 
To fully understand the function of SHANK2 and the effects of SHANK2 mutations on synaptic 
function, mouse lines of Shank2 were generated and characterized on electrophysiological, 
molecular and behavioral levels. Analyzing genetically comparable male and female inbred mice 
is suggested to minimize the environmental factors, especially when mice are raised and housed 
under similar conditions. This should help to reveal the influence of SHANK2 mutations solely 
on the synaptic function and the behavioral outcomes. However, the analysis of SHANK2 
mutations in mice finds a challenge by the set of the available behavioral experiments. In 
particular, since the establishment of psychiatric diagnoses in physiological diseases in humans 
(e.g. hallucinations, delusions, sadness and guilt) cannot be convincingly ascertained in mice. On 
the other hand, mice are still considered a first entry point to study mutations found in human 
patients and thus are important to establish useful genotype-cellular phenotype correlations. They 
have the advantages of the multiple ways for genetic manipulation, a short reproduction cycle 
and a high breeding capability together with the possibility of molecular, cellular, physiological 
and behavioral analysis of the genetically modified mice. Most of our knowledge of the 
influence of SHANK2 mutations on the anatomy and physiology of the mammalian CNS was 
derived from genetically-modified mice, as model organisms for Shankopathies. 
1.6 Shank2 knock-out mouse models 
1.6.1 Generation of Shank2 knock-out mouse models 
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The SHANK2 protein isoforms are suggested to have different functions during different 
developmental stages in different brain regions 
87
. Therefore, the detailed knowledge of different 
SHANK2 isoforms and their expression patterns in the mouse brain was a prerequisite for the 
generation of Shank2 gene-targeted mice. According to the NCBI database, 21 putative isoforms 
are predicted to be expressed by the Shank2 gene locus on chromosome 7 in mice 
133
. The 
expression of three SHANK2 isoforms was confirmed in the rat brain 
108,109,139
. SHANK2E is the 
full-length SHANK2 isoform which is generated by a 5‘ located promoter and contains a 5‘-
untranslated exon, designated as exon 1 
133
. SHANK2E contains ANK, SH3, PDZ, PRR and 
SAM domains (Figure 2) 
106
. It is expressed at different levels in different brain regions with the 
highest expression in the cerebellum 
110
. The SHANK2A isoform is expressed by a promoter 
located in intron 10, and its transcript translation occurs by an intron-located translational start 
codon which opens the translational reading frame 
133
. It seems to be underrepresented in 
peripheral tissues and primarily expressed in the brain 
110,140
. It contains SH3, PDZ, PRR and 
SAM domains (Figure 2). The SHANK2B isoform (named as SHANK2C in 
125
, Figure 2) is 
generated by a promoter located in intron 14, and its transcript translation occurs by an intron-
located translational start codon. SHANK2B contains just PDZ, PRR and SAM domains (Figure 
2). It showed differential expression in all brain regions in rat 
140
 and human 
110
. Another 
SHANK2 isoform was obtained by an alternative splicing event of exon 22 in humans. However, 
it could not be detected in the transcriptome of mice or rats 
87,110
. 
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Figure 2: Schematic view of the full-length Shank2 gene and the three transcripts produced by 
intragenic promoters 
Shank2E is the full-length transcript and encodes for the SHANK2E isoform with 5 protein-protein interaction 
sites. The Shank2A transcript encodes for a brain-specific SHANK2A isoform which lacks the ANK domain. 
Shank2C encodes for a protein with 3 protein-protein interaction sites. Images are drawn to scale; each break 
symbol represents 10 Kb of intron sequence that has been deleted for simplification. The size of each total 
break deletion in Kb is indicated below each break. The image scale bar is 10 Kb. The figure and figure legend 
are adapted from 
125
. 
Seven gene-targeted mouse lines of Shank2 are listed in the mouse genome informatics (MGI) 
database (Table 2). For most of these lines, the molecular, behavioral and physiological analyses 
have been published. The strategies for the published Shank2 gene knock-out mouse models are 
schematically depicted (Figure 3). Although these mouse lines were generated and characterized 
by the genetic deletion of Shank2 exons encoding important protein domains, none of the gene-
targeted events could confirm a complete knock-out of all putative SHANK2 isoforms 
133
. 
Table 2: List of Shank2 gene-targeted mouse lines in the MGI database 
 
Seven genetically modified mouse lines encoding gene-targeted mutations of the endogenous Shank2 were 
made public in the MGI database (http://www.informatics.jax.org). Mouse lines in blue are not published but 
commercially available. The table and the table legend are adapted from 
133
. 
 
 
Figure 3: Gene structure and gene segment deletions in Shank2 knock-out mouse models 
The structure of the Shank2 gene is depicted with exons given in rectangles and alternative spliced exons 
shown in dashed lines. The positions of promoters (Pr) for the expression of the different isoforms of the 
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Shank2 gene loci are indicated as well as those of the neomycin (neo) selection marker, loxP and Frt sites in 
the targeted alleles. Targeted gene segments flanked by two loxP elements can be removed or inverted by 
tissue-specific expression of Cre to generate conditional Shank2 knock-out models. oen = neo selection 
marker, reverse orientation. References for the first publication of the mouse lines are given. The figure and 
figure legend are adapted from 
133
. 
1.6.2 Characterization of Shank2 knock-out mouse lines 
As shown in Figure 3, the first two conventional Shank2 knock-out mouse models (Shank2
–/–
) 
were generated in 2012 and resembled two PDZ domain-encoding exons microdeletions found in 
two patients 
4
. They were generated by replacing the exons 15-16-encoding gene segment by a 
loxP site flanked inverse-oriented neomycin resistance selection marker (Shank2
Δex15-16
) in one 
mouse model 
141
 and by deleting exon 16 (Shank2
Δex16
) in the other 
142
. In 2017, a third 
conventional Shank2 knock-out mouse model was generated by the out-of-frame deletion of 
Shank2 exon 24 (Shank2
Δex24
) which removed the proline-rich region 
143
 (Figure 3). Although 
both Shank2
Δex15-16 
and Shank2
Δex16
 mouse models displayed comparable ASD-like phenotypes 
with social impairment and repetitive behaviors (Table 3), Shank2
Δex24
 mice exhibited bipolar-
associated mania-like behaviors with hyperactivity and a decrease in the repetitive behavior, with 
no social preference in the social affiliation test as well as anhedonia-like behaviors and 
disturbed circadian rhythms (Table 3). Moreover, the molecular, electrophysiological, synaptic 
composition and anatomical analyses revealed differences between the three Shank2
–/–
 mouse 
lines despite their similar genetic background (C57Bl/6N and C57Bl/6J) (Table 3). By the direct 
comparison between Shank2
Δex15-16 
and Shank2
Δex16
 mouse models in a mixed C57Bl/6N x 
C57Bl/6J background, the differences in gene expression were correlated with the type of 
mutation as shown by the reduced expression of the GABA receptor gene, Gabra2, in 
Shank2
Δex15-16
, but not Shank2
Δex16
 mice 
144
. Moreover, the inhibitory signaling, the 
AMPA/NMDA ratio and the long-term potentiation (LTP) analyses revealed significant 
differences between the two lines 
144
.  
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Table 3: Distinct endophenotypes in genetically very similar gene-manipulated, conventional Shank2 
knock-out mice (Shank2
–/–
) 
 
The behavioral, electrophysiological, synaptic composition and anatomical analyses revealed differences 
between the three conventional Shank2
–/–
 mouse lines despite their similar genetic background. n.a= not 
available, Green = no alteration; blue = decrease; red = increase. The table and table legend are adapted from 
133
. 
Interestingly, a similar discrepancy between the phenotypic expression of Shank2 Δex16, Δex15-
16 gene and Δex24 deletions was found when the three gene deletions were restricted to 
cerebellar Purkinje cells (PC) 
143,145,146
. These mouse lines were generated by combining the 
floxed Shank2 Δex16, Δex15-16 or Δex24 gene segments, with transgenic Cre-expressing mouse 
lines that used the PC-specific Pcp2 promoter, also called L7 promoter, for PC-specific 
inactivation of the Shank2 gene. Shank2
Δex15-16–Pcp2-Cre 
mice exhibited impaired motor 
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coordination and learning in the Erasmus ladder test, but normal motor performance in the 
rotarod test as well as normal social interaction without repetitive behavior and only mild 
anxiety. In contrast, Shank2
Δex16–L7–Cre 
mice exhibited normal motor performance in the Erasmus 
ladder with no anxiety, but deficits in social interaction. In contrast, Shank2
Δex24-Pcp2-Cre 
mice 
showed an impaired motor performance in the rotarod. Thus, similar inactivation of the Shank2 
gene in cerebellar Purkinje cells produced distinct phenotypes at the molecular and up to the 
behavioral levels. This finding in cell type-specific Shank2 knock-out mice underlines the 
observation that very similar SHANK2 mutations in human can lead to different phenotypes 
133
. 
Similarly, in two recent mouse models restricting the Δex15-16 deletion to two specific cell 
types: excitatory neurons (Shank2
Δex15-16–CaMK2a-Cre
) and GABAergic inhibitory neurons 
(Shank2
Δex15-16–Viaat-Cre
) 
147
, differences on the electrophysiological level were obvious as shown 
by the reduced mEPSC frequency in hippocampal CA1 neurons in Shank2
Δex15-16–CaMK2a-Cre
, but 
not in Shank2
Δex15-16–Viaat-Cre 
mice. On the behavioral level, Shank2
Δex15-16– CaMK2a-Cre 
mice 
exhibited increased anxiety but no repetitive behavior in contrast to Shank2
Δex15-16–Viaat-Cre 
mice 
that showed no anxiety but increased repetitive behavior.  
The variability of the phenotype in the generated Shank2 knock-out mouse models, despite 
similar genetic alterations, cannot be solely explained by the haploinsufficiency of SHANK2, but 
may rather indicate the presence of other protein isoforms or truncated versions that can manifest 
dominant-negative effects (Figure 4) 
133
. This, in turn, might disrupt the structure and/or the 
flexibility of the SHANK and postsynaptic protein organization, leading to synaptic dysfunction. 
The impairment in synaptic function might vary in different neurons or even in different 
synapses of the same neuron, which may explain the divergent outcomes of the tested Shank2 
knock-out mice.   
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Figure 4: Putative pre-mRNA transcripts in homozygous Shank2 knock-out mouse models 
Schematic view of the Shank2 gene and the putative pre-mRNA that can be expressed by the four different 
gene-targeted alleles of the Shank2 mouse models with very distinct phenotypes. Symbols are the same as in 
Figure 3.  The figure and figure legend are adapted from 
133
. 
1.6.3 Limitations of the previous studies on Shank2 knock-out mouse models 
The gene-targeted conventional and conditional Shank2 knock-out mouse models could not fully 
dissect the complex function of SHANK2. This complexity is also represented in the high 
similarity of SHANK2 to other SHANK proteins and by sharing evolutionarily conserved protein 
domains. Moreover, SHANK2 generates several isoforms, some of which lack the conserved 
SHANK2 protein domains of the full-length isoform. Three of the SHANK2 isoforms were 
confirmed in mice; however, other putative isoforms may still be present and could play 
additional roles. The different isoforms of the SHANK2 protein are suggested to determine the 
different organization of the postsynaptic proteins at different developmental stages and/or in 
different brain regions 
87
. The cellular and subcellular or activity-regulated expression of the 
SHANK2 isoforms in neurons have not been studied in detail yet. 
The gene-targeted Shank1, 2 and 3 knock-out mouse models displayed recurrent features 
observed in animal models for ASD along with other neuropsychiatric-like phenotypes. 
However, whether these phenotypes are due to a complete loss of function of SHANKs or 
dominant negative effects by their truncated versions remains to be resolved. The different 
dominant negative effects exerted by the truncated SHANK versions may account for the distinct 
phenotype of genetically-similar mouse models. Until now, no mouse model with a compound 
loss of the three Shank members has been generated. Therefore, in the generated Shank knock-
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out mouse models, other Shank members may compensate for the lack of some functions and 
might mask the functional analysis of the deleted Shank2 gene or SHANK2 isoforms.  
Although some behavioral phenotypes were rescued in adult Shank2 knock-out mice using 
pharmacological approaches: e.g. social interaction using NMDAR agonist 
141
 and memory 
deficits using an allosteric modulator for the GABAA receptor (GABAAR) 
144
, the reversibility of 
the phenotype via the genetic modification of Shank2 and the rescue of the SHANK2 level was 
not analyzed. These mice could not provide any detailed insight into the dysfunction of the 
neuronal network communication nor the homeostasis impairments of the brain function. Also, 
the identities of the cell types contributing to the phenotypes in Shank knock-out mice and the 
exact molecular mechanisms have not been deciphered yet. 
Another major issue with the previous Shank2 knock-out mouse model studies was the 
comparison of the behavioral phenotypes determined in different laboratories 
148
. Moreover, in 
most cases, the complete behavioral ethogram of Shank2 knock-out mice was not performed: e.g. 
learning and memorizing fear in Shank2 knock-out mice was not investigated. Multiple 
neuropsychiatric-like phenotypes can happen simultaneously and should only be addressed with 
a full behavioral ethogram. 
Deletions or mutations in Shank2 could affect the molecular structure and composition in various 
ways on different levels. Therefore, the generation of innovative animal models and an in-depth 
analysis of synaptic alterations are required to examine the multiple roles of Shank2 mutations on 
multiple scales and to relate the synaptic defects to specific pathological behaviors. This goal can 
be achieved by combining proteomics to understand the synaptic protein composition, super-
resolution imaging techniques to decipher the nanoscale organization of the synapse, as well as 
electrophysiology to link the synaptic structure and function. 
1.7 Aim  
Early brain development is strongly influenced by sex hormones which are suggested to play a 
role in the sex bias of ASD. However, the direct link between sex hormones and ASD remains 
unclear, and the effect of sex hormones on the expression of ASD risk genes has been poorly 
investigated. Therefore, the first aim of this thesis was to analyze whether the expression of 
SHANK genes is different in female and male embryos and pubs since it is known that sex 
hormone levels are very different between males and females during early development. The 
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analysis of Shank expression in mice lacking the androgen receptor in all neurons and the 
sensitivity of SHANK expression to sex hormone in a human cell line should clarify the direct 
effect of sex hormones on SHANK expression. 
Due to the ethical limitations of studies with patients and the limitations of the previous Shank2 
knock-out mouse models, the second major aim of this thesis was to dissect the developmental 
and transient effects in Shankopathies associated with ASD in mice using another powerful 
technique. In a pilot study, rAAV-mediated overexpression of two isoforms, SHANK2A or 
SHANK2A(R462X) was performed in the forebrain of P0 mice. SHANK2(R462X) is a de novo 
nonsense mutation found in an ASD patient with a severe behavioral impairment and is 
suggested to lead to premature termination of SHANK2 translation by producing a truncated 
protein 
4
. Of note, the viral-mediated gene transfer led to a high variation and a strong mosaic 
expression of the transgene due to the variation in the virus injections. This made it hard to 
differentiate whether the number of neurons expressing the transgene or its expression level was 
crucial for the phenotype. Therefore, mouse models with well-defined SHANK2A and 
SHANK2A(R462X) were required to reveal whether the observed behavioral phenotypes in the 
viral-transduced mice could be recognized as a suitable experimental model for autistic disorder 
in humans. To this end, two transgenic mouse lines which allowed the spatiotemporal controlled 
overexpression of either SHANK2A or SHANK2A(R462X) in the glutamatergic neurons of the 
forebrain were generated in order to disturb the balanced and regulated expression of the 
endogenous SHANK2 protein. This can potentially disrupt the whole SHANK organization by 
shifting it into a scaffold structure which is mainly determined by the transgenically 
overexpressed SHANK2 isoform. By analyzing these mice on behavioral, electrophysiological 
and molecular levels, I aimed to identify signaling pathways affecting the SHANK-dependent 
organization of postsynaptic proteins. Moreover, I wanted to test whether the transient synaptic 
dysfunction of the glutamatergic system in the forebrain was sufficient for the behavioral 
impairment in ASD and reveal which behavioral phenotypes could be rescued in adulthood.  
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                Chapter 2 
        Materials & Methods 
 
2.1 Investigating the influence of sex hormones on SHANK expression 
2.1.1 Animals 
The mice used in this study were housed in the Interfacultary Biomedical Facility (IBF) at the 
Heidelberg University under a 12 hrs light-dark cycle and with ad libitum access to water and 
food. All procedures were conducted in strict compliance with the National Institutes of Health 
Guidelines for the Care and Use of Laboratory Animals and approved by the German Animal 
Welfare Act. Experiments on mice were performed according to the regulations of animal 
experimentation within Heidelberg University and the European Union (European Communities 
Council Directive 2010/63/EU (local license number: T-03/16, T-24/14)). CD1 (ICR) mice from 
Charles River were used for the sex-differential expression analyses in the cortex at two different 
developmental stages (E17.5 and P7.5) (n= 16 mice of each sex). The embryonic stage was 
calculated by vaginal plug check and by controlling the morphological parameters which accord 
to the respective Theiler stage. The day of birth was defined as postnatal day (P) 0.5. Neuron-
specific androgen receptor knock-out mice (Ar
NesCre
) were generated by crossing female 
homozygous floxed androgen receptor Ar
flox
 mice (B6N.129-Ar
tm1Verh
/Cnrm) 
149
 with male 
Nestin-Cre deleter mice (Tg
(Nes-cre)1Kln
; MGI:2176173) 
150
 hemizygous for the floxed Ar allele. 
Ar
flox
 mice were obtained from the European Mouse Mutant Archive (EMMA, #02579) and 
backcrossed into the C57Bl/6N background for over 12 generations prior to the arrival at the IBF 
as published previously 
151
. 
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2.1.2 Polymerase chain reaction (PCR) for genotyping 
The genotyping of the mice was performed on tail biopsies and detected by PCR. Five mm of 
mouse tail were digested by adding 300 μl 10x PCR buffer (Qiagen, 203203) combined with 
proteinase K enzyme with a final concentration of 0.1 mg/ml. Samples were placed at 57°C 
shaking at 1000 rpm overnight. For tail PCR, 1 μl digested tail solution was amplified in a 
standard PCR reaction. For the sex genotyping of CD1 mice: Sry-F and Sry-R primers were used 
[cycling = 1 x 94°C 5 min, 35 x (94°C 50 sec, 65°C 45 sec, 72°C 30 sec), 1 x 72°C 5 min]. For 
the genotyping of Ar
NesCre
 mice for floxed androgen receptor: Flox-F and Flox-R primers were 
used [cycling = 1 x 95°C 5 min, 40 x (95°C 30 sec, 56°C 45 sec, 72°C 60 sec), 1 x 72°C 7 min]. 
For the genotyping of Ar
NesCre
 mice for Nestin-Cre: Cre-F and Cre-R primers were used [cycling 
= 1 x 95°C 5 min, 40 x (95°C 30 sec, 60°C 30 sec, 72°C 30 sec), 1 x 72°C 5 min]. 
The amplified gene fragments were separated and visualized via gel electrophoresis (2% agarose 
in 1x TAE buffer). The PCR primer sequences used for the genotyping of CD1 and Ar
NesCre
 mice 
are indicated in Appendix 1. For the TAE buffer recipe, refer to Appendix 2. 
2.1.3 Cell culture 
The human neuroblastoma cell line (SH-SY5Y) was obtained from the DSMZ (Leibniz Institute 
German collection of Microorganisms and Cell Cultures, no. ACC 209). Cells were seeded on 75 
cm flasks in Dulbecco‘s modified Eagle medium (DMEM, Thermo Fisher Scientific), 
supplemented with 15% fetal calf serum, 1% non-essential amino acids and 1% Penicillin-
streptomycin and incubated at 37°C in a humidified environment with 5% CO2. Cells were split 
at 80-90% confluence and resuspended in phenol red-free DMEM (Thermo Fisher Scientific) 
containing 1% charcoal dextran-treated calf serum. 8 x 10
5 
cells were plated per well on a 6 well 
cell culture plate and incubated at 37°C for 24 hrs. In each experiment, six replicates per 
condition were analyzed. Cells were treated either with 100 nM dihydrotestosterone (DHT) 
(dissolved in methanol) (Sigma-D-073-1ML), mock (100% methanol with the same dilution 
factor as DHT), 100 nM DHT combined with 1 μM flutamide (Sigma-F9397) or mock and 
flutamide together 
152
. To investigate the effect of 17β-estradiol, cells were treated either with 
100 nM 17β-estradiol dissolved in 100% ethanol (Sigma-E8875), mock (100% ethanol with the 
same dilution factor as 17β-estradiol), 100 nM 17β-estradiol combined with 100 nM MPP (1,3-
Bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole 
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dihydrochloride) (Sigma-M7068), mock together with MPP, 100 nM 17β-estradiol plus 100 nM 
PHTPP (4-[2-Phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol) (Tocris-
2662), mock plus PHTPP, 100 nM 17β-estradiol plus both MPP and PHTPP or mock plus both 
MPP and PHTPP 
152
. Treatments of cells were followed by incubation at 37°C. Cells were 
harvested after 4 hrs of treatment for mRNA and 48 hrs for protein analyses. 
2.1.4 Quantitative PCR (qPCR) 
Total RNA from SH-SY5Y cells, CD1 and Ar
NesCre
 mouse cortices at E17.5 and P7.5 was 
extracted using TRIzol (Invitrogen) according to the manufacturer's instructions. Reverse 
transcription was performed using the SuperScript™ VILO™ cDNA Synthesis Kit 
(Invitrogen). qPCR was performed using the SensiFAST™ SYBR® Lo-ROX (Bioline) kit in the 
7500 Fast Real-Time PCR System (Applied Biosystems). All samples from SH-SY5Y cells and 
CD1 mice were measured in technical triplicates, and their relative expression was assessed via 
the relative standard curve method by the normalization to the following reference: ribosomal 
18S RNA, glyceraldehyde 3-phosphate dehydrogenase (GAPDH) mRNA, heat shock protein 
family D (HSP60) member1 (HSPD1) mRNA, succinate dehydrogenase complex subunit A 
(SDHA) mRNA and hypoxanthine phosphoribosyltransferase 1 (HPRT1) mRNA. For the SH-
SY5Y cell treatment with 17β-estradiol, only 18S, HSPD1 and SDHA were used as references, as 
GAPDH and HPRT1 mRNA levels were reported to be influenced by estradiol 
153
. The relative 
expression values for mock treatment and male CD1 mice were set to 1.  
For Ar
NesCre
 mice and their littermate wild-type (WT) controls, Cre induced site-specific 
recombination was checked on the brain cortical cDNA at two developmental stages, E17.5 and 
P7.5, using a specific reverse primer residing in the floxed exon 2 of Ar gene in order to confirm 
the absence of Ar expression in Ar
NesCre
 mice due to exon 2 deletion. The relative expression was 
assessed via the relative standard curve method by normalization to ribosomal 18s RNA, and the 
relative Ar expression values in WT mice were set to 1. The qPCR primer sequences for the 
oligonucleotides used are given in Appendix 1. The qPCR amplification protocol was [cycling = 
1 x 94°C 2 min, 40 x (94°C 5 sec, 60°C 10 sec, 72°C 20 sec), 1 x 72°C 5 min]. 
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2.1.5 Protein analysis 
2.1.5.1 Immunofluorescent histology 
SH-SY5Y cells were fixed using 4% paraformaldehyde (PFA) for 20 min at RT. Cells were then 
permeabilized with Day 1 buffer (1% BSA, 0.3% Triton X-100 in PBS), supplemented with 4% 
normal goat serum (NGS), for 1 hr. Immunofluorescence staining was carried out overnight 
using the primary antibodies, anti-androgen receptor (Abcam, ab74272, 1:100 dilution) and anti-
estrogen receptor α (Abcam, ab661002, 1:100 dilution), in Day 1 buffer, supplemented with 1% 
NGS, at 4°C. In the next day, cells were washed three times with PBS in intervals of 10 min 
before applying the secondary antibodies, Alexa fluor 488 conjugated goat anti-rabbit or Alexa 
fluor 488 conjugated goat anti-mouse (Thermo Fisher Scientific, 1:1000 dilution), in Day 2 
buffer (1:3 Day 1 buffer diluted with PBS). Cells were incubated with the secondary antibodies 
for 1 hr in the dark. Next, they were washed twice in PBS in intervals of 10 min followed by 
incubation with DAPI (1:5000 dilution) for 5 min. Cells were again washed twice with PBS in 
intervals of 10 min and covered by coverslips using Aqua Poly/Mount (Polysciences Cat. Nr. 
18606) and allowed to dry overnight at 4°C in the dark. Images were taken using Leica 
DMI4000 B microscope and Leica application suite advanced fluorescence software. 
2.1.5.2 Immunoblots 
Protein extraction from SH-SY5Y cells and mouse cortices (using the Polytron PT1200E, 
Kinematica AG) was performed at 4°C using 1% RIPA buffer (diluted in PBS), supplemented 
with SIGMAFAST protease inhibitor (Sigma, S8820). The mixture was left for 20 min and then 
centrifuged at 13000 rpm at 4°C for another 20 min, and the supernatant was collected and 
measured for protein concentration with the BCA protein assay kit (Pierce). Western blot 
analysis was executed using the Odyssey Infrared Imaging System (LI-COR Biosciences). 
Around 20 μg of proteins were denatured in 5x SDS protein loading dye, boiled at 94°C for 3 
min and separated on Novex WedgeWell 4-12% Tris-Glycine gels (Thermo Fisher Scientific) 
using a standard program at 130V and 35mA for 1.5 hr together with two size markers, the Page 
Ruler Prestained Protein ladder (10-180 kDa) and the Spectra Multicolor High Range Protein 
ladder (40-300 kDa) (Thermo Fisher Scientific). Wet transfer of proteins was performed for 2 hrs 
at 500V and 250mA onto PVDF membranes (Millipore). Blocking was performed in Odyssey® 
Blocking Buffer for 1 hr at room temperature. PVDF membranes were probed with mouse anti-
pan-SHANK (1:500; Neuromab), mouse monoclonal β3-tubulin (1:20000; Promega-G7121), 
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anti-SHANK1 (Synaptic Systems, polyclonal rabbit purified antibody, 1:500 dilution), anti-
SHANK2 (Synaptic Systems, polyclonal guinea pig antiserum, 1:500 dilution) and anti-
SHANK3 (ab140030, Abcam, 1:1000 dilution) and incubated overnight at 4°C. IRDye 800CW 
donkey anti-mouse, IRDye 680LT donkey anti-guinea pig or IRDye 680RD donkey anti-rabbit 
(1:15000 dilution; LI-COR Biosciences) immuno-positive signals were quantified using the 
Image Studio Lite 3.1 software (LI-COR Biosciences). Shank protein expression was normalized 
to the amount of β3-tubulin and the values obtained for the male cortices were set to 1. Western 
blot solution recipes are listed in Appendix 2. 
2.1.6 nCounter analysis 
Total RNA from conditional Ar
NesCre
 mouse cortices was extracted with TRIzol (Invitrogen) 
according to the manufacturer's instructions. Gene expression profile was investigated at the 
nCounter Core Facility, Heidelberg University, using the nCounter Dx analysis system GEN1 
(NanoString Technologies). A customized Elements codeset with 7 target genes (Shank1, 
Shank2, Shank3, Mecp2, Psd95, Erα and Erβ) as well as 4 reference genes (Gapdh, Hspd1, Sdha 
and Hprt1) was applied. The detailed workflow is described at 
https://www.nanostring.com/support/product-support/support-workflow. Background correction 
and normalization of data were performed using the nSolver Analysis Software 3.0 (NanoString 
Technologies). A positive control and reference gene normalization was performed according to 
the Gene expression analysis guideline from NanoString Technologies 
(https://www.nanostring.com/application/files/7715/1251/5220/Gene_Expression_Data_Analysi
s_Guidelines.pdf; accessed June 2018). All reference genes in the customized Elements codeset 
were found to be stable and were selected for normalization based on the geNorm method 
154
. 
The unit of measurement is given in ‗codeset counts‘, and the codeset counts of the WT mice 
were set to 100%. The designs of the probes are indicated in Appendix 3. 
2.1.7 Statistical analysis 
Data analysis was performed using IBM SPSS STATISTICS 21, Prism 6 software (GraphPad 
Software) and Microsoft Office Excel software. The two-way ANOVA statistical test was used 
for the comparison between hormone-treated and mock-treated SH-SY5Y cells, and the 
biological replicate was used as a covariate. To compare gene expression levels between male 
and female cortices, the two-way ANOVA statistical test was used assigning litters and sex as 
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influencing factors. According to Bonferroni correction for multiple testing, a P-value threshold 
of ≤ 0.01 was considered significant (n = 5 different tests). For the expression analysis of the 
conditional Ar
NesCre
 mouse model using nCounter and for the quantification of Shank proteins in 
male and female cortices of CD1 mice in the western blot experiments, unpaired two-tailed 
Student‘s t-test was used, with a P-value of ≤ 0.05 considered as nominal significant. All data are 
presented as mean values ± standard error of the mean (SEM).  
2.2 Functional analysis of SHANK2A and SHANK2A(R462X) overexpression 
in the glutamatergic neurons in the mouse forebrain  
2.2.1 Animals 
The tTA responder transgenic mice were generated by the pronuclear injection of either 
SHANK2A or SHANK2A(R462X) constructs as described in the Master Thesis from Markus 
Hüser (2015, Hochschule Mannheim). The transgenic vectors contain a bidirectional 
tetracycline-responsive promoter element (Ptet-bi) which controls the expression of the lacZ 
gene on one side and a fusion transcript composed of green fluorescent protein variant (Venus), 
2A self-cleaving peptide and either SHANK2A or SHANK2A(R462X) on the other side (Figure 
12). The responder transgenic mice were backcrossed with C57BL/6J mice for 5 generations, 
followed by mating with Tg
αCaMKII-tTA 
mice (activator mice) in a C57BL/6J background, which 
express the doxycycline-dependent transactivator (tTA) under the control of an 8.5 kb fragment 
of the αCaMKII promoter 
155
. In turn, the Tg
SHANK2A/tTA
 and Tg
SHANK2AR462X/tTA
 double transgenic 
mice were generated (Figure 12). The mouse lines expressing tTA in addition to either 
SHANK2A or SHANK2A(R462X), are referred throughout this thesis as either Tg
SHANK2A
 or 
Tg
SHANK2AR462X
, respectively. Littermate mice with
 
a single transgene, either the activator or the 
responder transgene, were included in the control population along with the non-transgenic 
littermate controls to avoid any effect due to the insertion of the transgene. The mice were 
housed at the IBF of the Heidelberg University, under a 12-hrs light-dark cycle and given ad 
libitum access to water and food. The mice maintenance and procedures were performed 
according to the animal welfare guidelines of the Max Planck Society (Charles River). 
Transgenic animals were generated under the license number 35-9185.81/G-219/11 
(Regierungspräsidium Karlsruhe). Killed mice were registered as (T28/1) at the IBF of the 
Heidelberg University. Behavioral analysis was performed at the INBC under the license number 
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35-9185.81/G-100/16. Within the last two years, a 50% death rate within the first month of life 
was noticed in Tg
SHANK2A
 mice. This early postnatal lethality was facilitated either by the massive 
inbreeding of the line for five years or directly by the SHANK2A overexpression. The 
histological analysis of the 'survivors' showed no signs of cell loss or gliosis (data not shown), 
which is in favor of the inbreeding hypothesis. 
To stop the transgene expression in Tg
SHANK2A
 and Tg
SHANK2AR462X
 adult mice, doxycycline 
hydrochloride (dox) (Sigma-Alderich, Deisenhofen, Germany) at a concentration of 2 g/l was 
dissolved in water, supplemented with 5% sucrose,  and provided to adult mice in light-protected 
bottles. To switch on the transgene overexpression only after the prenatal and early postnatal 
stages, 50 mg/l dox were provided in water, supplemented with 5% sucrose, to pregnant mice 
until the day of delivery.  
2.2.2 PCR for genotyping 
The mice were genotyped by PCR of mouse tail genomic DNA with specific primers. Five mm 
of mouse tail was obtained and submerged in 300 μl of 50 mM NaOH. Samples were shaken at 
850 rpm and 99°C for 2 hrs followed by a short session of mixing via vortex. Subsequently, 30 
μl of 1 M Tris pH 8 were added to each tube, and the tubes were mixed again. Afterward, the 
samples were centrifuged for 10 min at 13000 rpm, and the supernatant containing the DNA was 
collected. Two PCR mixtures were prepared to identify the activator and the responder 
transgenes. The PCR amplification protocol was [cycling = 1 x 95°C 5 min, 40 x (94°C 20 sec, 
55°C 30 sec, 72°C 50 sec), 1 x 72°C 5 min].  
As the last step, the PCR samples were analyzed via gel electrophoresis (3% agarose in 1x E-
buffer). The PCR primer sequences used for genotyping are indicated in Appendix 1, and the E-
buffer recipe is listed in Appendix 2. 
2.2.3 Behavioral assays 
The behavioral analysis of adult mice (4-9 months) was performed under the license number 35-
9185.81/G-100/16 at the Interdisciplinary Neurobehavioral Core (INBC) of the Heidelberg 
University. One week prior to the start of the behavioral experiments, the mice were single-
housed in the animal room with a constant temperature (22°C) and free access to food and water. 
They were handled extensively (10 min per mouse per day) to get acquainted with the testing 
environment 
156
. Behavioral studies were performed during the light phase between 9 a.m. and 6 
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p.m. except for the nesting and burrowing tests. All behavioral tasks were performed in a blind 
manner to the mice genotype. The behavioral studies were performed in the following order:  
SHIRPA, LABORAS, activity in the home cage, as well as the following tests: open field, dark-
light box, burrowing, nesting, three-chamber social, novel object recognition, cliff avoidance 
reaction, puzzle box, neophobia, direct social interaction and fear conditioning. Before 
experiments and between different trials, all equipment was cleaned and wiped with 70% ethanol 
and allowed to evaporate completely. The automatic tracking of the mouse behavior was 
analyzed using the SYGNIS tracking software. 
2.2.3.1 SHIRPA 
SHIRPA (SmithKline Beecham, Harwell, Imperial College School of Medicine, Royal London 
Hospital, Phenotype Assessment) provided a behavioral and functional profile by observational 
assessment of mice 
157
. First, the body weight of the mouse was measured. Then, the mouse was 
placed in a new transparent arena for 30 sec. Body position, spontaneous activity, tremor, 
twitches, defecation and urination were observed and scored. Next, the mouse was suspended via 
its tail and transferred from the arena to a horizontal wire-grid. While descending toward the 
grid, the mouse was evaluated and scored for visual placement. Once the mouse was on all four 
limbs on the grid, it was evaluated for body tone, pinna reflex, corneal reflex, withdrawal reflex 
after toe pinch and crossed extensor reflex of the hindlimbs. Subsequently, from a standing 
position, the mouse was held by tail suspension for 15 sec. While in mid-air, it was assessed for 
hindlimbs splay, trunk-curl and limb-grasp. After being suspended, the mouse was lowered again 
via its tail towards the horizontal wire-grid. Once the mouse had grasped the wire with only its 
forelimbs, it was rotated horizontally by the tail. The ability of the mouse to maneuver and to 
negotiate its position in the horizontal wire platform was scored, based on the hindlimbs 
response. Afterward, the mouse was placed on a vertical wire-grid with its head upward, then 
downward, and evaluated and scored for catalepsy and negative geotaxis, respectively. 
2.2.3.2 LABORAS 
LABORAS (Laboratory animal behavior observation registration and analysis system) is an 
advanced and non-invasive system that automatically recognizes several different behaviors of 
mice by analysis of the forces that are induced by their movement 
158
. Each tested mouse was 
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caged individually on the system for 24 hrs to detect the duration and the frequency of 
locomotion, immobility, climbing, rearing, self-grooming, drinking and eating.  
2.2.3.3 Activity in the home cage 
Repetitive behaviors of mice in their home cage with fresh bedding were assessed during 6 min. 
These repetitive behaviors include jumping, defined as the behavior of a mouse when it rears on 
its hind legs in the corner of the cage and jumps, so that one or both hind legs come off the 
ground; self-grooming, defined as stroking or scratching of the face, head, body or tail with the 
both forelimbs, or licking of their body parts, whereas digging behavior is defined as the 
behavior of a mouse, who is coordinately using two forelegs or hindlegs to dig out or displace 
bedding materials.  
2.2.3.4 Open field test 
The mouse was placed in a corner of a white acryl open-field box (40×40×40 cm) and allowed to 
explore the arena freely for 10 min, while its path was monitored and tracked using a video 
camera placed 1 m above the center of the arena. Automatic detection of the mouse‘s traveled 
distance and the time spent in the central zone (15 cm apart from the walls) was recorded. 
2.2.3.5 Dark-light box test 
The dark-light box is an open white rectangle (30 x 20 x 20 cm), attached to a 3 x 3 cm opening 
to a dark chamber (with a lid and painted black) (15 x 20 x 20 cm). The light chamber was 
illuminated at 600 lux. Each mouse was put in the dark chamber, and the latency as well as the 
number of visits to the light chamber within 10 min were measured. Only when all four limbs of 
the subject crossed the entrance, it was considered as an entry to the light chamber.  
2.2.3.6 Burrowing test 
The burrowing test is based on the mouse‘s behavior regarding the displacement of items from 
the tube within their home cage 
159,160
. The tube was filled with 200 g of food pellets covered 
with 60 g of bedding. The test was performed at 5 p.m. and the pellets remaining in the tube was 
weighted after 2 hrs, then put back again on the tube. After 12 hrs, the weight of the remaining 
pellets in the tube was assessed again. 
2.2.3.7 Nesting test 
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The mouse was placed in a new home cage with a cotton nesting material at 5 p.m. The nest that 
was then built was checked the next day at 7 a.m., and its quality was assessed with a complexity 
score from 1 (no nest) to 5 (complex nest with a wall surrounding the mouse) 
160,161
. 
2.2.3.8 Three-chamber social test 
The test was performed as described previously 
162-165
, only with modifications. A social 
interaction box (Harvard Apparatus) divided into 3 compartments was used. The social arena 
was made of a transparent box (42 x 60 cm) with two transparent sliding doors that divided the 
left, right and center chambers (42 x 20 cm). In the first 5 min session, the tested mouse was 
placed in the central chamber with the sliding doors open to offer access to the two chambers for 
habituation. In the second session, an empty cylindrical cage and another cylindrical cage 
housing an unfamiliar C57BL/6J mouse of the same sex and age as the tested mouse were 
located in the corners of the left and right chambers. The tested mouse was placed in the central 
chamber and allowed to explore the arena for 5 min. Once this session was completed, another 
unfamiliar C57BL/6J mouse (novel mouse) with the same sex and age as the tested mouse was 
put in the empty cylindrical cage. The tested mouse was then allowed to explore the arena for 5 
min. In the fourth session, the mouse in the cylindrical cage from session two was replaced by 
unfamiliar C57BL/6J mouse of the opposite sex, and the tested mouse was then allowed to 
explore the arena for 5 min.  The location of the cages was alternated between tests. The number 
of observed contacts of the tested mice with the cages was manually counted. 
2.2.3.9 Novel object recognition test 
Each mouse was placed in the corner of a new arena measuring (40 x 40 x 40 cm) and allowed to 
run around freely for 5 min. Afterward, the mouse was returned to its home cage for 1 min and 
introduced again to the arena with an object (cube) fixed in the center for another 5 min. The 
number of observed contacts with the object was counted manually. 
2.2.3.10 Balance test 
The apparatus was composed of 7 rods with diameters of 6, 8, 12, 15, 20, 25 and 32 mm, a 
length of 50 cm and a height of 20 cm. The tested mouse was put on each rod for 10 sec starting 
from the widest to the narrowest. The score was calculated by the number of rods from which the 
tested mouse did not fall. The test was performed twice for each mouse with a 1 hr interval. 
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2.2.3.11 Cliff avoidance reaction test 
The cliff avoidance reaction was assessed using a round wooden platform (diameter 20 cm; 
thickness 2 cm), supported by an iron rod (height 50 cm) 
166
. The floor below the platform was 
carpeted to prevent injuries of fallen mice. The test was initiated by gently placing a mouse on a 
platform such that the forelimbs would approach the edge. The latency from the initial placement 
on the platform until the fall was recorded. The test was performed for 1 hr. 
2.2.3.12 Puzzle box test   
The test was slightly modified from the one described in Berkel et. al., 2012 
136
. The puzzle box 
consisted of two compartments (a brightly-lit start zone and a smaller covered goal zone) 
separated by a barrier which had a narrow underpass (about 4 cm wide). Each mouse was 
introduced into the start zone, and the task was to enter the goal zone with bedding from its home 
cage. The mice underwent a total of 11 trials over 4 consecutive days, with three trials per day on 
the first three days, and two trials on the last day. On the first day, during trial 1, the underpass 
was left open, and the barrier had an open door above the underpass. During trials 2 and 3, the 
barrier had no doorway and the mice were supposed to enter the goal zone via the small 
underpass. On the second day, trial 4 was identical to trials 2 and 3. During trials 5 and 6, 
however, the underpass was filled with sawdust and they had to dig through the sawdust. On the 
third day, trial 7 was identical to trials 5 and 6. During trials 8 and 9, the mice were presented 
with the underpass which was blocked by a cardboard plug that mice had to pull with teeth and 
paws to enter the goal zone. Trial 10 on the fourth day was again carried out to repeat trial 9. At 
the end of the test, during trial 11, the task was to repeat trial 1 on the first day. After each trial, 
the mice were left for 1 min inside the goal zone. 
2.2.3.13 Neophobia test 
Each subject was placed in an arena with an unfamiliar drink (100 μl sweetened condensed milk) 
in the center. The mouse was allowed to explore the arena freely for 10 min, and the latency as 
well as the number of contacts with the drink were manually assessed. 
2.2.2.14 Direct social interaction 
Each mouse was placed in a white acrylic open-field box (40×40×40 cm) for 1 min before a 
same-sex, similar-age, unfamiliar C57BL/6J mouse was added to the arena. The number of 
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contacts made by the tested mouse with the unfamiliar mouse was counted manually within 5 
min. 
2.2.3.15 Fear conditioning test 
On the first day, the acquisition session started by putting each mouse in an arena and spending 
180 sec as a habituation phase. Then, an auditory tone was presented for 30 sec at a level of 90 
dB and frequency of 5000 Hz with a rise time of 50 msec. A mild foot shock (0.5 mA) was 
administered during the last 2 sec of the tone presentation and co-terminated with the tone. After 
the shock presentation, an intertrial interval of 90 sec preceded the second and third identical 
trials. Following the third shock presentation, the mouse was kept in the arena for an additional 
90 sec. On the second day, the contextual testing was conducted, similarly to the training session 
including lighting and odor, but without the tone and the foot shock. The experiments lasted for 
300 sec. On the third day, the cued memory was tested by placing the mouse in a new chamber 
with a different odor and lighting condition and allowing it to habituate for 180 sec. The same 
intensity tone cue used in the acquisition session was then activated for the next 30 sec. Then, an 
intertrial interval of 90 sec preceded the second and third trials. The third tone was activated for 
300 sec until the end of the experiment. The video freeze software was used to record and 
measure the freezing percentage and frequency. 
2.2.4 Protein analysis 
2.2.4.1 Staining methods 
2.2.4.1.1 Mouse brain dissection and slicing 
The mouse was first anesthetized with Isofluran (CP-Pharma). The abdominal wall and the 
thorax of the mouse were cut carefully not to injure the liver. Once the still beating heart was 
exposed, a hollow needle connected to two syringes, one with PBS solution and the other with 
4% PFA, was pierced in the left ventricle. First, the blood was washed out with PBS until the 
liver completely lost its red color. Then, PFA was channeled through the mouse as described for 
PBS. To access the brain, the mouse head was detached from the body, the skin and skull were 
cut open in a sagittal section, and the olfactory bulbs were removed from the bone structures. 
The brain was then detached from the skull and further preserved in 4% PFA for 2 hrs as a post-
fixation process. The brain was then embedded in 2% agarose in PBS and sliced into 100 μm-
thick coronal or sagittal slices using the microtome VT 1000 S by Leica Microsystems (serial 
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number 0804/12.2006). Once the hippocampus was showing, the slices were collected 
separately, one in each well of 24-well plates filled with cold PBS. 
2.2.4.1.2 Eosin/X-gal staining 
The enzymatic activity of β-galactosidase was assessed by Eosin/X-gal staining following a 
standard protocol of Aguzzi and Theuring 
167
, with modifications. First, the brain slices were 
washed in PBS for 20 min and incubated in LacZ solution (0.5 M K4Fe(CN)6, 0.5 M K3Fe(CN)6, 
0.2 M MgCl2, X-gal 20 mg/ml in PBS) for 2 hrs at 37°C. The slices were then washed three 
times with 1x PBS with intervals of 10 min and shortly in 10 mM TRIS (pH 7.6) before being 
mounted onto glass slides. After an overnight dry session at RT, 0.5% Eosin solution was used as 
a counterstain, and the slides were shortly washed in demineralized water, 70% EtOH, 80% 
EtOH and 100% EtOH, respectively. After drying, the slides were washed in Xylol, and one drop 
of Eukitt was put onto each slice. As the last step, the coverslip was placed onto the slide and 
allowed to air dry at RT overnight for polymerization. 
2.2.4.1.3 Immunohistochemical analysis 
2.2.4.1.3.1 Immunofluorescence staining 
The brain slices were permeabilized for 1 hr using 2% NGS in Day1 buffer (1% BSA and 0.3% 
Triton X-100 in PBS). Then, they were stained overnight with primary antibodies (anti-rabbit 
GFP, Abcam, 1:1000 dilution) or anti-parvalbumin (mouse, Sigma-Aldrich, 035M4879V, 
1:1000). On the following day, the brain slices were washed three times in Day 2 buffer (1:3 Day 
1 buffer diluted with PBS) with intervals of 10 min and incubated with secondary antibodies 
(Cy
TM
3-conjugated AffiniPure Goat Anti-Mouse IgG, 115-165-003, 1:300 in Day 2 Buffer), 
anti-rabbit (Cy
TM
3-conjugated AffiniPure Goat Anti-Rabbit IgG, 111-165-144, 1:300 in Day 2 
buffer) and anti-rabbit (FITC (Abcam) 1:200 in Day 2 buffer) for 2 hrs in the dark while 
shaking. The slices were again washed three times with intervals of 10 min in Day 2 buffer and 
mounted onto glass slides using Aqua Poly/Mount (Polysciences Cat. Nr. 18606).  
2.2.4.1.3.2 DAB staining 
The immunostaining of the brain slices was performed following the peroxidase immunolabeling 
standard protocol. Endogenous peroxidase activity was blocked with 0.5% H2O2 in PBS for 10 
min at RT. The slices were then washed twice in PBS with intervals of 10 min, and the 
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unspecific protein binding was blocked using 2% NGS in Day 1 buffer (1% BSA and 0.3% 
TritonX-100 in PBS) for 1 hr. Afterward, the slices were incubated overnight with the primary 
antibody (anti-mouse β-galactosidase (1:10000, Promega Z3783)) diluted in Day 1 buffer. On 
the following day, the slices were washed with Day 2 buffer (1:3 Day 1 buffer diluted with PBS) 
twice with intervals of 10 min and then incubated with a peroxidase-labeled secondary antibody 
(anti-mouse HRP, Vector Laboratories, 1:600) diluted in Day 2 buffer for 1 hr. Afterward, the 
brain slices were washed twice with PBS for 10 min and incubated with freshly prepared and 
filtered Diaminobenzidine solution (DAB: 20 mg/50 ml 20 mM Tris pH 7.6 and 12.5 µl 30% 
H2O2). DAB staining was stopped by washing slices with PBS three times and once in Tris pH 
7.6 for 10 min and mounted onto the glass slides. Dry slides were then shortly dunked in Xylol 
for 2 min. Lastly, Eukitt was put onto each slice and the coverslips were placed. 
2.2.4.1.4 Imaging 
Slices from Eosin/X-gal, DAB and immunofluorescence staining were imaged with Zeiss 
Axioimager M1 epi-fluorescence and bright-field microscope with the software AxioVision 
version 4.6. Image quantification and editing were done with ImageJ and Adobe Photoshop CC. 
2.2.4.2 Immunoblots 
All steps for total protein lysate preparation from different brain tissues were performed at 4°C. 
Cortex, hippocampus, olfactory bulb and cerebellum of the mouse brain were collected and 
homogenized in ice-cold buffer (25 mM HEPES, pH 7.4) containing a protease inhibitor cocktail 
(Complete, Roche, Pharma AG). After 5 min of centrifugation at 2000 rpm, the supernatant 
containing the total amount of proteins was collected. Fractions were aliquoted, frozen in liquid 
N2 and stored at -80°C for further analysis. Protein concentration was determined with the BCA 
protein assay kit (Pierce). Then, 5 mg of protein were separated by SDS–PAGE (8-12% 
separating and 4% stacking gels) and transferred to nitrocellulose membranes (Amersham
TM
, 
Sigma). Membranes were probed with monoclonal anti-GFP (1:10000, Abcam), monoclonal 
anti-Shank2 (1:1000, Neuromab, 75-088), monoclonal mouse anti-β-galactosidase (1:20000, 
Promega Z3783) monoclonal anti-β3-tubulin (1:20000, Promega-G7121), anti-5-HT2A (1:500, 
Abcam, ab66049), anti-GABAAR (1:10000, Abcam, ab33299), anti-mGluR1 (1:200, 
Thermofischer, PA1-4516), anti-mGluR5 (1:1000, Millipore „Merck―, MABN540), anti-OXTR 
(1:1000, Abcam, ab181077), anti-GluN2A (1:1000, Millopore „Merck―, 07-632), anti-GluN2B 
  2 Materials & Methods                                                                                                               
32 
 
(1:1000, Novus Biological, NB300-106), anti-GluA1 (1:1000, Chemicon international, 
LV1368418), anti-GluA2 (1:1000, Chemicon international, LV1350412), anti-GluA3 (1:1000, 
Abcam, ab40845), anti-GluN1 (1:1000, Millipore „Merck―, AB9864R), anti-Psd95 (1:1000, 
Millipore „Merck―, LV1824016), anti-Homer1 (1:1000, Synaptic Systems, 160011), anti-VGlut1 
(1:1000, Neuromab, 75-066) and anti-D2 (1:1000, Abcam, ab130295). The secondary antibodies 
(anti-rabbit IgG (1:10000)) and (anti-mouse IgG (1:10000)), conjugated with horseradish 
peroxidase, were used. Chemiluminescence was developed using a detection reagent (GE 
Healthcare, Amersham
TM
, ECLTM Prime Western Blotting Detection Regent, RPN2232) and 
scanned with the Fujifilm LAS-3000 Luminescent Image Analyzer (Object No.: B00000623). 
The Image Reader LAS-3000 software was used and the protein bands were quantified using 
ImageJ software. Western blot solution recipes are indicated in Appendix 2. 
2.2.5 nCounter analysis 
Total RNA from mice hippocampi was extracted with TRIzol (Invitrogen) according to the 
manufacturer‘s instructions. Gene expression profile was investigated at the nCounter Core 
Facility Heidelberg using the nCounter Dx analysis system GEN1 (NanoString Technologies). A 
customized elements codeset with 21 target and 6 reference genes was applied. The detailed 
workflow is described at https://www.nanostring.com/support/product-support/supportworkflow. 
Background correction and normalization of data were performed using the nSolver Analysis 
Software 3.0 (NanoString Technologies). A positive control and reference gene normalization 
was performed according to the Gene expression analysis guideline from NanoString 
Technologies 
(https://www.nanostring.com/application/files/7715/1251/5220/Gene_Expression_Data_Analysi
s_Guidelines.pdf; accessed June 2018). The most stable expressed genes Gapdh, Sdha, Hprt1, 
Glucose phosphate isomerase 1 (Gpi1), Hspd1 and phosphoglycerate kinase 1 (Pgk1) were 
selected for normalization based on the geNorm method 
154
. The unit of measurement is 
‗‗codeset counts‘‘, and the codeset counts of the control mice were set to 1. The designs of the 
used probes are indicated in Appendix 3. 
2.2.6 Electrophysiological analysis 
The electrophysiological analysis was performed in collaboration with Dr. Andrey Rozov from 
the Institute of physiology and pathophysiology at the Heidelberg University. Transverse 
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hippocampal 300 μm-slices were prepared from the brains of Tg
SHANK2A
, Tg
SHANK2AR462X
 and 
control mice at the age of 4-7 weeks, killed by cervical dislocation. The slicing chamber 
contained an oxygenated ice-cold solution (modified from 
168
 and composed of (in mM): K-
Gluconate, 140; N-(2-hydroxyethyl) piperazine-N′-ethanesulfonic acid (HEPES), 10; Na-
Gluconate, 15; ethylene glycol-bis (2-aminoethyl)-N,N,N′,N′-tetraacetic acid (EGTA), 0.2; and 
NaCl, 4 (pH 7.2). Slices were incubated for 30 min at 35°C before being stored at RT in artificial 
cerebrospinal fluid (ACSF) containing (in mM): NaCl, 125; NaHCO3, 25; KCl, 2.5; NaH2PO4, 
1.25; MgCl2, 1; CaCl2, 2; and D-glucose, 25; bubbled with 95% O2 and 5% CO2. During 
experiments, brain slices were continuously perfused with the same ACSF. Patch electrodes were 
pulled from hard borosilicate capillary glass (Sutter Instruments flaming/brown micropipette 
puller). Electrodes for the postsynaptic pyramidal cells were filled with a solution which 
consisted of (in mM): Cs-gluconate, 100; CsCl, 40; HEPES, 10; NaCl, 8; MgATP, 4; MgGTP, 
0.3; phosphocreatine, 10 (pH 7.3 with CsOH). The solution for the presynaptic interneurons 
consisted of (in mM): K-gluconate, 100; KCl, 40; HEPES, 10; NaCl, 8; MgATP, 4; MgGTP, 0.3; 
phosphocreatine, 10 (pH 7.3 with KOH). 
CA1 pyramidal cells were visually identified using IR-video microscopy. Whole-cell recordings 
from these neurons were taken at RT in voltage-clamp mode using a HEKA EPC-7 amplifier 
(List Elektronik) with a sampling rate of 100 μsec and filtered at 3 kHz. Excitatory postsynaptic 
currents (EPSCs) were evoked from two independent inputs, basal and apical dendrites, with two 
patch pipettes as stimulating electrodes located in stratum oriens and stratum radiatum, 
respectively. The two stimulus pipettes were > 200 μm apart, located below and above the soma 
of a CA1 pyramidal cell. All measurements were performed at -70mV membrane potential.  
The AMPA/NMDA current ratios were measured in Mg
2+
-free ACSF. AMPA and NMDA 
receptor-mediated EPSCs were pharmacologically isolated by sequential bath application of 
APV and NBQX (Sigma Alderich), respectively. First, the compound AMPAR and NMDAR-
mediated current was recorded in Mg
2+
-free ASCF. After collecting at least 100 sweeps, the 
AMPA-mediated component was blocked by the application of 10 μM NBQX. Then, additional 
100 sweeps of the putative NMDA-mediated currents were collected and the NMDA nature was 
confirmed by a subsequent application of APV. The AMPA-mediated component was then 
obtained by subtracting the averaged NMDA-mediated currents from the averaged compound 
  2 Materials & Methods                                                                                                               
34 
 
responses. For subsequent analysis, the mean amplitude of the AMPA currents was normalized 
to the level of the amplitude of the NMDA EPSCs. 
In the LTP experiments, the control pathway was measured by stimulating synapses of the basal 
dendrites when the apical dendrite input was potentiated and vice versa: the input in the stratum 
radiatum was used as a control pathway when the paired pathway was input to synapses of the 
basal dendrites. LTP was evoked and recorded according to Chen et. al., 1999 
169
 by voltage 
clamping the membrane potential of the postsynaptic pyramidal cell to 0 mV for 3 min while 
stimulating the paired pathway every 1.5 sec. The measured amplitudes were normalized to the 
mean EPSCs before pairing. The NMDA dependence was tested in the presence of 100 μMD‐
AP5.  
2.2.7 Proteomic analysis 
Large-scale proteomic analysis of synaptosome was performed in collaboration with Prof. A.B. 
Smit in the Center for Neurogenomics and Cognitive Research at VU University Amsterdam. 
Synaptic plasma membrane preparations from the hippocampus of Tg
SHANK2A
, Tg
SHANK2AR462X
 and 
control mice were produced according to the protocol described in 
170,171
. The crude 
synaptosomal fraction was analyzed using the SWATH technology as a data independent method 
of mass spectrometry for protein identification and quantification, which enabled the analysis of 
synaptic proteins with high sensitivity without the need of prior isotopic labeling. For the 
identification of affected pathways in Tg
SHANK2A
 and Tg
SHANK2AR462X
 mice, pathway and gene 
ontology analyses of the differentially abundant proteins in the synaptosomes were investigated 
using the online software ConsensusPathDB. 
2.2.8 Statistical analysis 
For the behavioral analysis, the two-way ANOVA test was used to compare the transgenic and 
control mice, assigning sex and genotype as influencing factors. For nCounter and protein 
quantification, the unpaired two-tailed student‘s t-test was used. Data were analyzed using 
Prism6 software (GraphPad Software). All data are shown as mean ± SEM. For the 
electrophysiological analysis, the paired two‐tailed student's t-test was used to compare the 
responses from the paired vs. unpaired input. Data between genotypes were compared by 
unpaired two‐tailed student's t-test and given as means ± SD. For the synaptosome analysis, the 
differential abundance analysis between genotypes was performed on log-transformed protein 
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abundances. Empirical Bayes moderated t-statistics with multiple testing corrections by False 
Discovery Rate (FDR) was used, as implemented by the eBayes and topTable functions from the 
limma R package. 
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         Chapter 3 
                Results 
 
3.1 Investigating the influence of sex hormones on SHANK expression 
3.1.1 Effect of DHT and 17β-estradiol on SHANK expression 
To test if sex hormones have an effect on SHANK gene expression, a human neuroblastoma cell 
model (SH-SY5Y) was employed. This cell model has the advantage of expressing all three 
SHANKs, as well as the androgen, estrogen α and β receptors (AR, ERα and ERβ) 
66,172-175
. First, 
the expression of AR and ERα in SH-SY5Y cells was confirmed by immunofluorescence 
staining (Figure 5). After stimulation with DHT for 2 hrs, the overall expression of AR 
increased in the cells. The stimulation of SH-SY5Y cells with 17β-estradiol for 2 hrs did not 
affect the expression level of ERα, but more protein was found to be localized in the nucleus 
(Figure 5) 
152
.  
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Figure 5: AR and ERα expression in SH-SY5Y cells 
Immunofluorescence staining showing the expression of AR and ERα in SH-SY5Y cells after 1 nM DHT and 
10 nM 17β-estradiol treatment, respectively. The expression of AR was increased after the DHT treatment. 
The expression of ERα was more localized in the nucleus after the 17β-estradiol treatment without an increase 
in the overall expression. DHT and 17β-estradiol treatments in SH-SY5Y cells were done for 2 hrs. Scale bar = 
50 μm. The figure and figure legend were adapted from 
152
. 
After the confirmation of AR and ER expression in SH-SY5Y cells and their response to DHT 
and 17β-estradiol, respectively, the regulatory influence of these sex hormones on SHANK gene 
expression was tested. Initially, SH-SY5Y cells were treated with two different concentrations of 
DHT, and the expression of SHANK was checked by qPCR and normalized against 18S. For this 
analysis, PSD95 was used as a positive control gene because its expression was found to be 
regulated by sex hormones 
176-178
. As DHT concentrations between 1 and 100 nM are within the 
physiological range and have been used in similar studies 
66,174
, 1 nM and 10 nM DHT 
treatments of SH-SY5Y cells for 4 hrs was initially performed and revealed a trend of increased 
expression of all SHANK and PSD95 genes without reaching statistical significance (Figure 6) 
152
.  
 
Figure 6: Effect of DHT treatment on SHANK expression in SH-SY5Y cells 
Gene expression analysis of SHANK1-3 after 4 hrs of treatment with 1 nM DHT (n = 3) and 10 nM DHT (n = 
4) revealed a non-significant increase of their expression. PSD95 was used as a positive control. Gene 
expression was normalized against 18S. Error bars indicate standard error of the mean (SEM). The figure and 
figure legend were adapted from 
152
. 
The effect of 100 nM DHT on SHANK gene expression in SH-SY5Y cells was then investigated 
and showed a strong increase of all three SHANKs and PSD95 expression after 4 hrs of treatment 
(about 35% upregulation, P-values ≤ 0.001) (Figure 7A) 
152
. MECP2, which shows a transient 
sex-specific expression difference in the developing rat brain 
179
, was included as an additional 
marker in the expression analysis, and its expression level was not influenced by the DHT 
treatment (Figure 7A). Gene expression was normalized to five androgen independent reference 
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RNAs: the ribosomal 18S RNA, the mRNAs for GAPDH, HSPD1, SDHA and HPRT1. The 
androgen independence of the reference genes was shown by their similar expression levels in 
DHT and mock-treated SH-SY5Y cells after normalization to 18S (Table 4) 
152
.  
The regulatory effect of DHT on SHANK gene expression on RNA level was confirmed by an 
increased SHANK immunosignal in western blots by 50%, using a pan anti-SHANK antibody 
after the treatment of SH-SY5Y cells with 100 nM DHT for 48 hrs (Figure 7B) 
152
. To test 
whether the effect of DHT treatment on SHANK expression is mediated by the stimulation of the 
androgen receptor, SH-SY5Y cells were treated with 100 nM DHT for 4 hrs combined with 1 
μM of the anti-androgen flutamide. The regulatory effect of DHT on SHANK and PSD95 mRNA 
levels was completely abolished (Figure 7A). Moreover, the regulatory effect of DHT on all 
SHANK proteins was absent in the presence of flutamide as shown with a pan-Shank antibody 
(Figure 7B). These results demonstrate the role of AR modulation by DHT treatment on the 
increased SHANK and PSD95 levels 
152
. 
 
Figure 7: Effect of DHT on SHANK gene expression in SH-SY5Y cells 
(A) Quantification of SHANK, MECP2 and PSD95 gene expression by qPCR after 4 hrs of treatment with 
either 100 nM DHT or a combination of 100 nM DHT and 1 μM flutamide (n = 5). Gene expression was 
normalized against 5 reference genes (18S, GAPDH, HPRT1, HSPD1 and SDHA) (Two-way ANOVA, * P ≤ 
0.05, *** P ≤ 0.001, versus mock; Bonferroni threshold: n = 5 tests, P ≤ 0.01). (B) An increase of SHANK 
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protein levels by 50% was shown after 48 hrs of 100 nM DHT treatment (n = 5) by western blot analysis, 
whereas no difference was determined after 48 hrs of treatment with DHT combined with flutamide (n = 5). 
Error bars indicate SEM. The figure and figure legend were adapted from 
152
. 
Table 4: Analysis of the influence of DHT treatment on reference gene expression 
 
 
 
Two-way ANOVA P-values are shown and showed no significant effect of 100 nM DHT treatment in SH-
SY5Y cells for 4 hrs on the expression of reference genes GAPDH, HPRT1, HSPD1 or SDHA. The analyzed 
reference genes were normalized against 18S. The table and table legend were adapted from 
152
. 
To elucidate if estrogens also regulate SHANK gene expression, SH-SY5Y cells were treated 
with 100 nM 17β-estradiol to stimulate the estrogen receptors. First, the expression of the 
reference genes was analyzed and revealed that GAPDH and HPRT1 expression was affected by 
17β-estradiol when normalized to 18S (Table 5) 
152
. Therefore, the gene expression analysis of 
SHANK, MECP2 and PSD95 genes in SH-SY5Y cells treated with 100 nM 17β-estradiol was 
normalized against 18S, HSPD1 and SDHA. A minor enhancement of SHANK, MECP2 and 
PSD95 expression could be observed on RNA level after 4 hrs of treatment (15% upregulation, 
P-value for SHANK1= 0.02; P-values for SHANK2, SHANK3, MECP2 and PSD95 ≤ 0.001) 
(Figure 8A) 
152
. The minor regulatory effect of 17β-estradiol on SHANK gene expression on 
RNA level could not be confirmed on protein level in immunoblots after the treatment of SH-
SY5Y cells with 10 and 100 nM 17β-estradiol for 48 hrs (Figure 8B) 
152
. When blocking the 
ERα or ERβ receptor subtypes with the selective ERα antagonist MPP or ERβ antagonist 
PHTPP, the effect of 17β-estradiol on SHANK mRNA expression by MPP was gone, whereas the 
blocking of ERβ with the antagonist PHTPP abrogated the effect on SHANK and PSD95 mRNA 
expression (Figure 8A) 
152
. The combined blocking of both ERs antagonized the 17β-estradiol 
stimulated expression of SHANK, PSD95 and MECP2 (Figure 8A). Thus, besides AR signaling, 
also ERα and ERβ signaling contribute to the expression of SHANK genes in the human SH-
SY5Y cell line 
152
. 
Table 5: Analysis of the influence of 17β-estradiol treatment on reference gene expression 
 
 
 
Two-way ANOVA P-values show no effect of 100 nM 17β-estradiol treatment of SH-SY5Y cells for 4 hrs on 
the expression of reference genes, HSPD1 and SDHA. In contrast, there was a significant and borderline 
  GAPDH HPRT1 HSPD1 SDHA 
DHT versus Mock 0.202 0.335 0.316 0.194 
  GAPDH HPRT1 HSPD1 SDHA 
17β-estradiol  versus Mock 0.097 0.032 0.229 0.64 
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significant effect on HPRT1 and GAPDH expression, respectively. The analyzed reference genes were 
normalized against 18S. As HPRT1 and GAPDH expression was influenced by 17β-estradiol, both genes were 
excluded from the 17β-estradiol treatment analyses. The table and table legend were adapted from 
152
. 
 
Figure 8: Effect of 17β-estradiol on SHANK gene expression in SH-SY5Y cells 
(A) Gene expression analysis of SHANK, MECP2 and PSD95 after 4 hrs of treatment with 100 nM 17β-
estradiol (n = 5). The expression was also analyzed after stimulation with 100 nM 17β-estradiol in combination 
with a selective blocking of ERα (100 nM MPP), ERβ (100 nM PHTPP) or a combination of both (n = 5 of 
each). Gene expression was normalized against three reference genes (18S, HSPD1 and SDHA). Error bars 
indicate SEM (Two-way ANOVA, * P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001, versus mock-treatment control; 
Bonferroni correction: n = 5 tests, P ≤ 0.01). (B) Western blot analysis did not show any significant effect of 
17β-estradiol treatment on SHANK protein expression in SH-SY5Y cells (10 nM, 100 nM 17β-estradiol, n = 3 
per treatment group). Error bars indicate SEM. The figure and figure legend were adapted from 
152
. 
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3.1.2 Expression analysis of Shank genes in neuron-specific conditional androgen receptor 
knock-out mice (Ar
NesCre
)   
To provide in vivo evidence for the Ar regulatory influence on Shank gene expression during 
neurodevelopment, a neuron-specific Ar knock-out mouse line (Ar
NesCre
) 
151
 was analyzed. Shank 
mRNA expression in the cortex of Ar
NesCre
 mice was investigated by the nCounter analysis at two 
stages during brain development, E17.5 and P7.5. First, the loss of Ar expression in cortical 
neurons in Ar
NesCre
 mice was confirmed by qPCR at both E17.5 and P7.5 (Figure 9) 
152
. Next, the 
effect of the absence of Ar expression was investigated in the cortex of Ar
NesCre
, which revealed a 
nominal significant reduction of mRNA expression of all three Shanks, Mecp2 and Erα at P7.5, 
but not E17.5, compared with WT mice (Figure 9) 
152
. Gene expression analysis was normalized 
against 4 stable reference genes, Gapdh, Hprt1, Hspd1 and Sdha based on the geNorm method 
154
. These results support the contribution of androgen receptor signaling in the specific 
regulation of the Shank gene expression during development. 
 
Figure 9: Comparative Shank gene expression by nCounter analysis in the cortex of wild-type and 
Ar
NesCre
 mice. (Left) Loss of Ar mRNA in the cortical neurons was confirmed by qPCR at E17.5 and P7.5. 
(Right) Gene expression analysis in the cortex of WT and Ar
NesCre
 mice at E17.5 (top) (n = 6 WT and 6 
Ar
NesCre
 mice, 3 male and 3 female animals in each group) and P7.5 (bottom) (n = 7 WT and 7 Ar
NesCre
 mice, 2 
male and 5 female animals in each group). The loss of Ar expression at E17.5 revealed no difference in the 
expression of the tested genes. In contrast, the loss of Ar expression at P7.5 resulted in a decreased expression 
of Shank, Mecp2 and Erα genes. The analysis could not be stratified by sex due to the low number of mice. 
Gene expression was normalized against four reference genes (Gapdh, Hprt1, Hspd1 and Sdha). Error bars 
indicate SEM (unpaired two-tailed Student‘s t-tests, * P ≤ 0.05). The figure and figure legend were adapted 
from 
152
. 
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3.1.3 Expression of Shank1-3 in the male and female mouse cortex at E17.5 and P7.5 
As sex hormone levels and the expression of Ar, Erα and Erβ differ between males and females 
during development 
180,181
, a sex-specific regulation of Shank expression was suggested. 
Therefore, the expression levels of Shank genes were investigated in the frontal cortices of male 
and female CD1 WT mice at two different developmental stages, E17.5 and P7.5. The sex-
independent expression of the reference genes was confirmed by showing equal levels of Gapdh, 
Sdha, Hprt1 and Hspd1 expression, normalized to 18s, in male and female mice cortices at the 
two investigated developmental stages (Table 6) 
152
. In the comparative qPCR analysis, 
significantly elevated Shank1, Shank3 and Mecp2 expression levels could be detected in the 
cortices of female compared with male mice at E17.5 (about 20%, Shank1 (P=0.001), Shank3 
(P= 0.007) and Mecp2 (P=0.0005)) (Figure 10) 
152
. At P7.5, the expression analysis revealed 
elevated Shank1 mRNA expression in the cortices of female mice with nominal significance, as 
well as significantly elevated Psd95 expression (about 20%, Shank1 (P= 0.03) and Psd95 (P= 
0.001) (Figure 10) 
152
. By comparing the expression of tested genes between E17.5 and P7.5, 
Shank1, Shank2, Mecp2 and Psd95 expression in both male and female mice increased in the 
cortex from E17.5 to P7.5 (Figure 10). In contrast, the expression of Shank3 decreased at P7.5 in 
both male and female mice (Figure 10). 
Table 6: Quantification of the relative reference gene expression in the cortex of male and female CD1 
mice during different developmental stages 
 
 
 
 
Two-way ANOVA P-values revealed no significant difference in the expression of reference genes, Gapdh, 
Hprt1, Hspd1 and Sdha, between male and female CD1 mice cortices at E17.5 and P7.5. The analyzed 
reference genes were normalized against 18s. The table and table legend were adapted from 
152
. 
 
  Gapdh Hprt1 Hspd1 Sdha 
E17.5 0.2055 0.8219 0.2179 0.9228 
P7.5 0.7953 0.1236 0.6343 0.9668 
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Figure 10: Shank gene expression analysis in the male and female CD1 mouse cortex 
qPCR analysis revealed gene expression differences in the male and female mouse cortex at E17.5 for Shank1 
(P= 0.001), Shank3 (P= 0.007) and Mecp2 (P= 0.0005) (n = 16 male, 16 female). At the developmental stage 
P7.5, a sex-differential expression was obtained for Psd95 (P= 0.001) and Shank1 (P= 0.03) with higher 
expression in female than male mice (n =18 male, 17 female). Shank1, Shank2, Mecp2 and Psd95 expression 
increased in the cortex from E17.5 to P7.5. For Shank3, the expression decreased at P7.5 in both male and 
female mice. The respective gene expression was normalized against five reference genes (18s, Gapdh, Hprt1, 
Hspd1 and Sdha). Error bars indicate SEM (Two-way ANOVA, * P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001; 
Bonferroni correction: n = 5 tests for each developmental stage, P ≤ 0.01). The figure and figure legend were 
adapted from 
152
. 
To confirm the sex-differential expression of Shanks in CD1 mice, the expression level of 
Shanks in total protein lysate from the frontal cortex of male and female mice at E17.5 and P7.5 
was investigated by western blot analysis. In contrast to the Shank mRNA expression analysis, 
significantly higher expression levels for all three Shank proteins was found in the male 
compared with female cortices at both developmental stages (Figure 11) 
152
. Shank expression 
was reduced in females by 50-77% at E17.5 and by 43-47% at P7.5 (Figure 11), indicating that 
Shank expression differences were more pronounced at the earlier stages 
152
.  
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Figure 11: Shank protein analysis in the male and female CD1 mouse cortex 
Levels of Shank1, 2 and 3 proteins in the cortex of male and female CD1 mice at E17.5 (top) and P7.5 
(bottom) (n = 4 of each sex). Error bars indicate SEM (unpaired two-tailed Student‘s t-tests, *P < 0.05). 
Isoform expression differences were observed between the two developmental stages for Shank3. These data 
were provided by Dr. Simone Berkel from the Institute of Human Genetics, Heidelberg University. The figure 
and figure legend were adapted from 
152
.  
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3.2 Functional analysis of SHANK2A and SHANK2A(R462X) overexpression 
in the glutamatergic neurons in the mouse forebrain 
3.2.1 Generation and characterization of Tg
SHANK2A 
and Tg
SHANK2AR462X
 mouse lines 
To enable the study of the molecular, physiological and behavioral effects that originate from 
Shank dysfunctions in the glutamatergic neurons while maintaining the regular SHANK function 
in other cell types, two conditional transgenic Shank2 mouse lines overexpressing human 
SHANK2A, the brain-specific isoform, or the truncated SHANK2A(R462X) isoform, were used. 
The overexpression of these isoforms is suggested to disturb the balanced SHANK-dependent 
organization of postsynaptic proteins. In the two mouse lines, the SHANK2A and 
SHANK2A(R462X) overexpression was achieved by combining two transgenes from  Tg
αCaMKII-
tTA 
mouse line with either the silent transgene that encodes SHANK2A or SHANK2A(R462X) 
together with reporter genes. Tg
αCaMKII-tTA 
mice express the synthetic doxycycline (dox)-
dependent transcriptional activator (tTA) under the control of the forebrain-specific promoter for 
the alpha subunit of Ca
2+
/calmodulin-dependent protein kinase II (αCaMKII) specifically in the 
excitatory neurons 
155,182
 (Figure 12). The transgenes of Tg
SHANK2A
 and Tg
SHANK2AR462X
 mice 
encode a bidirectional expression module composed of the lacZ reporter gene and the 
SHANK2A variant fused by the 2A peptide bridge with Venus. Both lacZ and the Venus2A-
SHANK2 genes were under the control of a bidirectional promoter (Ptet-bi) which can be 
activated by tTA in the absence of dox, and which can be silenced at any time by a dox diet. 
Thus for the activation of the SHANK2 encoding transgenes, the double transgenic lines 
Tg
αCaMKII-tTA
/Tg
SHANK2A 
and Tg
αCaMKII-tTA
/Tg
SHANK2AR462X
 have to be generated
 
by breeding of both 
lines (Figure 12). Double transgenic offspring have to be identified by PCR genotyping and are 
named Tg
SHANK2A 
and Tg
SHANK2AR462X
 for reasons of simplicity.
 
Single transgenic
 
littermates served 
in all experiments as controls. 
 
Figure 12: Schematic of the two transgenes used for the overexpression of SHANK2A and 
SHANK2A(R462X) in the glutamatergic forebrain neurons 
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Schematic drawing of the transgenes in Tg
αCaMKII-tTA
/Tg
SHANK2A 
(left) and Tg
αCaMKII-tTA
/Tg
SHANK2AR462X
 mice 
(right). The transcription activator (tTA) is expressed under the control of αCamKII promoter in the 
glutamatergic neurons in the mouse forebrain. In the presence of the responder transgene, tTA binds to the 
Ptet-bi and activates the expression of the transgenes. These transgenes include the lacZ gene on one side of 
the Ptet-bi and a fusion transcript composed of green fluorescent protein variant (Venus), 2A self-cleaving 
peptide and either SHANK2A or SHANK2A(R462X) on the other side. The overexpression of SHANK2A 
and SHANK2A(R462X), along with reporter proteins, can be switched off when mice are provided with dox, 
dissolved in water. Dox binds to tTA and inhibits its binding to the Ptet-bi, leading to the inactivation of the 
transgene expression. 
The expression of the reporter genes, Venus and lacZ, in Tg
SHANK2A
 and Tg
SHANK2AR462X
 mice was 
confirmed in histological and western blot analyses (Figure 13). The Venus epifluorescence was 
restricted to the forebrain of both mouse lines with no detectable fluorescence in the cerebellum 
(Figure 13A). The β-galactosidase expression of the lacZ gene was detected at the cellular level 
in the cortex and hippocampus in anti-β-galactosidase DAB-immunostains of coronal brain 
section (Figure 13A). The expression of β-galactosidase was also confirmed by the visualization 
of its enzymatic activity via Eosin/X-gal stainings (Figure 13B). Immunoblots of protein lysates 
of different brain regions from Tg
SHANK2A
 and Tg
SHANK2AR462X
 mice revealed the expression of 
Venus, β-galactosidase and either SHANK2A or SHANK2A(R462X) in the olfactory bulb, 
forebrain and hippocampus, but not in the cerebellum (Figure 13C). The highest expression was 
detected in the hippocampus. The levels of mRNA overexpression of both SHANK2A and 
SHANK2A(R462X) transgenes were measured, as represented by the Venus expression level, 
using the nCounter analysis. The expression of Venus mRNA in both Tg
SHANK2A
 and 
Tg
SHANK2AR462X
 mice revealed a ratio of 12 to the endogenous Shank2 and 1.6 to the sum of all 
endogenous Shanks (Shank1,2 and 3) mRNA expression (Figure 13D). Immunoblots of 
hippocampal total protein lysate from Tg
SHANK2A
 and Tg
SHANK2AR462X
 mice revealed no difference 
between SHANK2A and SHANK2A(R462X) expression (Figure 13E), indicating their similar 
level of overexpression consistent with the mRNA results obtained from the nCounter analysis 
(Figure 13D). 
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Figure 13: Forebrain-specific expression of the transgenic controlled β-galactosidase, Venus and 
SHANK2A or SHANK2A(R462X), as exemplified in some representative mice 
(A) The overexpression of the polycistronic SHANK2 transgenes was visualized by the Venus epifluorescence 
in the forebrain of Tg
SHANK2A
 mice (upper row) and of Tg
SHANK2AR462X
 mice (middle row) (scale bar: 2 mm). β-
galactosidase expression of the lacZ gene can be detected at the cellular level in anti-β-galactosidase DAB-
immunostainings of coronal brain section (shown for the cortex and hippocampus; (scale bars: 1 mm). (B, top 
row) The β-galactosidase activity was visualized in sagittal brain section of Tg
SHANK2A
 mice by Eosin/X-gal 
staining. X-gal of slices from control mice on the right shows no blue staining (B, bottom row). Eosin/X-gal 
staining of coronal brain sections from Tg
SHANK2A
 and Tg
SHANK2AR462X
 mice (scale bars: 2 mm). (C) Protein 
lysates of different brain regions from Tg
SHANK2A
 (right) and Tg
SHANK2AR462X
 (left) mice (6 months) were 
analyzed by immunoblotting with the SHANK2, β-galactosidase and Venus antibodies. The hippocampus 
showed the highest expression of both transgenes. HPC: Hippocampus, OB: Olfactory bulb, CB: Cerebellum. 
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(D) The nCounter analysis revealed a ratio of Venus to endogenous Shank2 mRNA expression of 12, and a 
ratio of Venus to all endogenous Shank mRNA expression of 1.6 (n = 8 Tg
SHANK2A
 and 11 control mice; n = 7 
Tg
SHANK2AR462X
 and 7 control mice, 3 – 5 months). (E) Comparable quantification of SHANK2A and 
SHANK2A(R462X) transgene expression in the hippocampus by immunoblotting revealed no significant 
difference between Tg
SHANK2A
 and Tg
SHANK2AR462X
 mouse lines (3 mice per each mouse line, 3 – 5 months). 
3.2.2 Behavioral analysis of Tg
SHANK2A 
mice  
The detailed behavior analysis including general, social and cognitive behavior analysis was 
performed in Tg
SHANK2A
 mice (for a summary, see Appendix 5). Tg
SHANK2A
 pups showed a 50% 
death rate in the first 4 weeks of life. First, the SHIRPA test, as a comprehensive screening 
method for qualitatively abnormal phenotypes in mice, was performed and revealed that the adult 
Tg
SHANK2A
 mice suffered from muscle twitches and that their body weights were 30% less 
compared with their littermate controls (Figure 14A). The general behavior of Tg
SHANK2A
 mice 
was investigated using the LABORAS test, in which the movements of the mice were 
continuously monitored for 24 hrs. Tg
SHANK2A
 mice displayed hyperactivity as shown by an 
increase in locomotion and a higher average speed compared with control mice (Figure 14B). 
They also showed increased duration of eating periods (Figure 14C). Moreover, an increase in 
the number of repetitive rearing was noted (Figure 14D). The duration of drinking, self-
grooming and climbing were not different between Tg
SHANK2A
 and control mice (Figure 14C, D). 
To manually examine the repetitive behavior, the time of jumping, self-grooming and digging in 
their home cages was measured within 6 min. Tg
SHANK2A
 mice displayed an increase in the 
duration of self-grooming and a decrease in the duration of digging compared with control mice 
(Figure 14E). Because building nests is considered a spontaneous home cage behavior of mice 160, 
the nesting behavior of Tg
SHANK2A
 mice was assessed in their home cages during the evening. 
Tg
SHANK2A
 mice were impaired in the nesting test as shown by building less complex nests 
compared to their littermate controls (Figure 14F). 
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Figure 14: Analysis of general and repetitive behaviors in TgSHANK2A mice 
(A) Body weights of Tg
SHANK2A
 mice were 30% less than that of control mice. (B) LABORAS test revealed that 
Tg
SHANK2A
 mice were hyperactive as shown by the increased number of locomotion (left) and average speed 
(right). (C) Tg
SHANK2A
 mice displayed more time for eating (left), but similar drinking time (right) compared 
with control mice in the LABORAS cages. (D) Tg
SHANK2A
 mice showed increased rearing (left), but normal 
self-grooming (middle) and climbing (right). (E) Stereotypical behaviors in the home cage were investigated 
within 6 mins and revealed enhanced self-grooming and decreased digging durations in Tg
SHANK2A
 mice 
compared with control mice. (F) The nests built by Tg
SHANK2A
 mice were less complex as shown by the low 
score in the nesting test (n = 12 Tg
SHANK2A
 and 15 control mice at 6 – 9 months of age). Error bars indicate 
SEM (Two-way ANOVA,*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001). 
In mice with an autistic-like phenotype, hyperactivity is often combined with anxiety. Therefore, 
three different experiments were performed to test anxiety in Tg
SHANK2A
 mice and revealed clear 
signs of increased anxiety. In the dark-light box test, Tg
SHANK2A
 mice showed a significant delay 
to the first entry to the light compartment with fewer total numbers of entries compared with 
control mice (Figure 15A). In the open field test, Tg
SHANK2A
 mice traveled less distance in the 
central zone of a new arena accompanied by fewer visits (Figure 15B). In the neophobia test, 
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Tg
SHANK2A
 mice exhibited more fear of an unfamiliar drink as shown by the fewer contacts and 
the higher latency to the first contact to the unfamiliar drink compared with control mice 
(Figure 15C). 
To test the integrity of hippocampal function, the burrowing test, which measures the ability of 
mice to retrieve food pellets from a tube, was performed. Tg
SHANK2A
 mice retrieved fewer pellets 
from the tube after 2 and 12 hrs compared with control mice, indicating hippocampal 
dysfunction (Figure 15D). Tg
SHANK2A
 mice showed impairment in maintaining their balance in 
two consecutive sessions in the balance test (Figure 15E). Moreover, they showed a high 
impulsive or a lack of inhibition reaction in the cliff avoidance reaction test and fell faster and 
more often from the elevated platform than control mice (Figure 15F).  
 
Figure 15: Characterization of anxiety and impulsivity in TgSHANK2A mice 
(A) The dark-light box test revealed anxiety in Tg
SHANK2A
 mice as shown by the high latency (left) and reduced 
number of visits (right) to the light compartment compared with control mice. (B) Tg
SHANK2A 
mice exhibited 
anxiety in the open field test by showing less traveled distance (left) and fewer visits (right) to the center of a 
new arena than control mice. (C) Tg
SHANK2A
 mice displayed fear of an unfamiliar drink (condensed milk in the 
center of the arena) in the neophobia test as shown by fewer contacts (left) and higher latency (right) to the 
first contact to the unfamiliar drink than control mice. (D) In the burrowing test, Tg
SHANK2A
 mice retrieved 
fewer pellets from the tube after 2 hrs (left) and 12 hrs (right) than control mice. (E) Tg
SHANK2A
 had a 
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significant lower score in two successive sessions in the balance test compared with control mice. (F) 
Tg
SHANK2A
 mice displayed a high impulsive reaction with less cliff avoidance reaction (n = 12 Tg
SHANK2A
 and 15 
control mice at 6 – 9 months of age). Error bars indicate SEM (Two-way ANOVA,*p ≤ 0.05, **p ≤ 0.01, ***p 
≤ 0.001). 
As social impairment is a core phenotype in ASD, the sociability of Tg
SHANK2A
 mice was 
investigated in three different tests. Tg
SHANK2A
 mice showed social impairment in the three-
chamber social test in all three sessions (Figure 16A). They also made fewer contacts to same-
sex unfamiliar mice in the direct social interaction test (Figure 16B). In the novel object 
recognition test, Tg
SHANK2A
 mice showed borderline significant fewer contacts to a novel object in 
the center of an arena than control mice (Figure 16C). Together, these results indicate severe 
impairment of the social behavior of Tg
SHANK2A
 mice. Because cognitive dysfunction is one of the 
comorbidities of ASD, cognitive and memory functions of Tg
SHANK2A
 mice were assessed using 
the puzzle box test. Tg
SHANK2A
 mice displayed a cognitive dysfunction and less ability to solve the 
puzzle in sessions 1, 8 and 10 compared with control mice (Figure 16D). Lastly, the emotional 
learning of Tg
SHANK2A
 mice was assessed by the fear conditioning test which revealed no 
impairment in the context or the cued memories in Tg
SHANK2A
 mice (Figure 16E). 
In summary, the SHANK2A overexpression in the glutamatergic neurons in the mouse forebrain 
caused severe behavioral outcomes. The detailed behavioral analysis of Tg
SHANK2A
 mice revealed 
ASD-like phenotypes including repetitive behavior and social impairment. Moreover, Tg
SHANK2A
 
mice exhibited three comorbidities of ASD, hyperactivity, anxiety and cognitive dysfunction. In 
addition, the integrity of the hippocampal function in Tg
SHANK2A
 mice was affected, leading to a 
difficulty in managing daily activities such as nest building and burrowing. 
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Figure 16: Characterization of the social behavior, cognitive function and emotional learning in 
Tg
SHANK2A 
mice 
(A) Social interaction in the three-chamber social test. The graph shows the number of contacts to an empty 
cage and a caged stranger mouse in the first session, mouse and novel mouse in the second session, mouse and 
opposite-sex novel mouse in the third session. Tg
SHANK2A
 mice displayed fewer contacts to a stranger 1 in 
sessions one and two and fewer contacts to the opposite sex mouse in session three than control mice. (B) The 
direct social interaction test revealed fewer contacts of Tg
SHANK2A
 mice to unfamiliar same-sex mice than 
control mice. (C) The novel object recognition test showed a borderline significant reduction in the number of 
observed contacts to an unfamiliar object by Tg
SHANK2A
 mice. (D) In the puzzle box test, the door was open in 
trial 1, underpass in trials 2–4, underpass filled with sawdust in trials 5–7 and covered by a plug in trials 8–10, 
whereas trial 11 corresponded to trial 1. Tg
SHANK2A
 mice showed high latency to solve the puzzle in trials 1, 8 
and 10. (E) The emotional learning ability was investigated using the fear conditioning test. The test was done 
over 3 days with the first day as an acquisition phase, the second day for testing the context memory and the 
third day for testing the cued memory. Tg
SHANK2A
 mice showed less freezing percentage in the acquisition phase 
compared with control mice but did not reveal any impairment in context or cued memory (n = 12 Tg
SHANK2A
 
and 15 control mice at 6 – 9 months of age). Error bars indicate SEM (Two-way ANOVA,*p ≤ 0.05, **p ≤ 
0.01). 
3.2.3 Behavioral analysis of Tg
SHANK2AR462X 
mice 
The detailed behavior of Tg
SHANK2AR462X
 mice was performed in analogy to the procedures used 
for Tg
SHANK2A
 mice. The SHIRPA test revealed around 10% reduced body weight compared to 
littermate controls (Figure 17A) (for a summary, see Appendix 5). The long term recording 
  3 Results                                                                                                               
53 
 
LABORAS test revealed strong hyperactivity as shown by the increased numbers of locomotion 
and high average speed compared to controls (Figure 17B). Tg
SHANK2AR462X
 and control mice 
showed similar durations of eating and drinking periods (Figure 17C) and a similar number of 
rearing and climbing counts (Figure 17D). In contrast, Tg
SHANK2AR462X
 mice revealed fewer self-
grooming counts than control mice (Figure 17D). By monitoring the activity in the home cage 
within 6 min, Tg
SHANK2AR462X
 mice showed an increase in the duration of jumping periods and a 
decrease in the duration of digging compared with control mice (Figure 17E). In the nesting test, 
no significant difference in the nesting score was found between Tg
SHANK2AR462X
 and control mice, 
indicating normal nesting behavior (Figure 17F). 
 
Figure 17: Analysis of general and repetitive behaviors in TgSHANK2AR462X mice 
(A) Body weights of Tg
SHANK2AR462X
 mice were 10% reduced compared with control mice. (B-D) The 
LABORAS test of Tg
SHANK2AR462X
 mice revealed: (B) hyperactivity due to an increase in the number of 
locomotion events (left) and the average speed (right), (C) no difference in the duration of eating (left) or 
drinking (right) periods, (D) similar rearing (left) and climbing (right) but less self-grooming (middle). (E) 
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The stereotypical behaviors in the home cage were investigated within 6 min and revealed increased duration 
of jumping periods and decreased digging behavior in Tg
SHANK2AR462X
 compared with control mice. (F) 
Tg
SHANK2AR462X
 showed no impairment in the nesting behavior (n = 10 Tg
SHANK2AR462X
 and 16 control mice at 6 – 
9 months of age). Error bars indicate SEM (Two-way ANOVA,*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001). 
In the dark-light box test that measures anxiety level, Tg
SHANK2AR462X
 mice showed a borderline 
significant delay and more visits to the light compartment compared with control mice 
(Figure 18A). In the open field test, Tg
SHANK2AR462X
 and control mice traveled a similar distance 
in the central zone of a new arena with similar numbers of visits, indicating no anxiety 
(Figure 18B). In the neophobia test, Tg
SHANK2AR462X
 mice showed a higher latency to the first 
contact to the unfamiliar drink than control mice but with a similar total number of contacts 
(Figure 18C). 
In the burrowing test, Tg
SHANK2AR462X
 mice were unable to perform the test efficiently and they 
retrieved fewer pellets from the tube after 2 and 12 hrs (Figure 18D). Tg
SHANK2AR462X
 mice were 
able to balance normally in two consecutive sessions in the balance test (Figure 18E) but 
showed impairment in the cliff avoidance reaction test (Figure 18F), which indicates impulsivity 
and/or a lack of behavioral inhibition.  
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Figure 18: Characterization of anxiety and impulsive behaviors in TgSHANK2AR462X mice 
(A) The dark-light box test revealed borderline anxiety in Tg
SHANK2AR462X 
mice with a tendency of increased 
latency (left) and visits (right) to the light compartment. (B) Tg
SHANK2AR462X 
mice showed no anxiety in the 
open field test; they traveled a similar distance in the center of a new arena (left) and made a similar number of 
visits (right) as control mice. (C) Tg
SHANK2AR462X
 and control mice made similar contacts to unfamiliar drink 
(condensed milk in the center of the arena) (left), but  Tg
SHANK2AR462X
 mice had higher latency to the first 
contact (right). (D) In the burrowing test, Tg
SHANK2AR462X
 mice left more pellets in the tube after 2 hrs (left) and 
12 hrs (right). (E) Tg
SHANK2AR462X
 had no impairment in two successive sessions in the balance test. (F) 
Tg
SHANK2AR462X
 mice showed a high impulsive reaction and less cliff avoidance reaction percentage in the cliff 
avoidance reaction test (n = 10 Tg
SHANK2AR462X
 and 16 control mice at 6 – 9 months of age). Error bars indicate 
SEM (Two-way ANOVA,*p ≤ 0.05, ***p ≤ 0.001). 
In the three-chamber social test, Tg
SHANK2AR462X
 and control mice made a similar number of 
contacts to stranger mice in all sessions (Figure 19A). In contrast, Tg
SHANK2AR462X
 mice made 
more social contacts to unfamiliar same-sex mice in the direct social interaction test (Figure 
19B) and to a novel object in the center of an arena in the novel object recognition test (Figure 
19C). The cognitive dysfunction of Tg
SHANK2AR462X
 mice became obvious in their higher latency 
to solve the puzzle box in trials 5–7 compared to control mice (Figure 19D). In the fear 
conditioning test, Tg
SHANK2AR462X
 mice were impaired in the contextual memory but showed no 
impairment in the cued memory (Figure 19E).  
In summary, Tg
SHANK2AR462X
 mice exhibited some ASD/ADHD-like phenotypes including 
repetitive behaviors, hyperactivity and cognitive impairment with a tendency of increasing 
sociability. However, in general, they showed less severe phenotypes compared to Tg
SHANK2A 
mice. 
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Figure 19: Characterization of the social behavior, cognitive function and emotional learning in 
Tg
SHANK2AR462X 
mice 
(A) In the three-chamber social test, Tg
SHANK2AR462X
 and control mice made the same average number of contact 
to all stranger mice in all sessions. (B) The direct social interaction test revealed significant more contacts by 
Tg
SHANK2AR462X
 mice to unfamiliar same-sex mice than control mice. (C) The novel object recognition test 
revealed significant more observed contacts to an unfamiliar object by Tg
SHANK2AR462X
 mice than by control 
mice. (D) In the puzzle box test, Tg
SHANK2AR462X
 mice exhibited less ability and higher latency to solve the 
puzzle in trials 5, 6 and 7. (E) The emotional learning was investigated using the fear conditioning test and 
revealed less freezing percentages in the acquisition and context memory phases in Tg
SHANK2AR462X
 mice  (n = 
10 Tg
SHANK2AR462X
 and 16 control mice at 6 – 9 months of age). Error bars indicate SEM (Two-way ANOVA,*p 
≤ 0.05, **p ≤ 0.01). 
3.2.4 Electrophysiological analysis of Tg
SHANK2A 
and Tg
SHANK2AR462X
 mice 
The results from the behavior analysis of Tg
SHANK2A 
and Tg
SHANK2AR462X
 mice implicated a 
possible disruption of synaptic function and transmission leading to the behavioral abnormalities. 
Therefore, the effects of SHANKA and SHANK2A(R462X) overexpression on the distribution 
of synaptic NMDARs and AMPARs in the hippocampus were evaluated. In collaboration with 
Dr. Andrey Rozov from the Institute of Physiology and Pathophysiology of the Heidelberg 
University, whole-cell voltage clamp recordings in CA1 pyramidal neurons from Tg
SHANK2A
, 
Tg
SHANK2AR462X
 and control mice were performed. First, the contribution of AMPARs to the 
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synaptic response in Tg
SHANK2A
, Tg
SHANK2AR462X
 and control mice was found to be significantly 
higher at synapses located on the apical than on the basal dendrites, as indicated by larger 
AMPA/NMDA ratio values (Figures 20). In Tg
SHANK2A
 mice, a strong enhancement of AMPAR-
mediated currents at the apical inputs was observed, and the ratio was significantly higher than in 
both Tg
SHANK2AR462X
 and control mice. In contrast, the AMPA/NMDA ratios measured at basal 
dendrite synapses were similar in Tg
SHANK2A
, Tg
SHANK2AR462X
 and control mice (Figures 20). 
 
Figure 20: AMPA/NMDA ratio in the apical and basal dendrites in CA1 pyramidal neurons from 
Tg
SHANK2A
 and Tg
SHANK2AR462X
 mice 
Averaged AMPAR (black) and NMDAR (green) mediated EPSCs evoked by stimulation of inputs to the 
apical and to the basal dendrites of CA1 pyramidal neurons. The AMPA/NMDA ratio measurements revealed 
a higher ratio in the apical dendrites in the CA1 hippocampal region from Tg
SHANK2A
 but not Tg
SHANK2AR462X 
mice, compared with control mice. No difference in the AMPA/NMDA ratio was found between Tg
SHANK2A
, 
Tg
SHANK2AR462X 
and control mice in the basal dendrites in CA1 hippocampal region (n = 10 neurons per each 
genotype of mice at 4 – 7 weeks of age). Error bars indicate standard deviation (SD) (unpaired two‐tailed 
Student's t-test,*p ≤ 0.05). Experimental data were provided by Dr. Andrey Rozov. 
Selective enhancement of AMPAR-mediated EPSC at stratum radiatum synapses in Tg
SHANK2A
 
mice indicates either an increase of synaptic channel density or a change of AMPAR subunit 
composition from low conductance GluA2-containing to high conductance GluA2-lacking 
channels. To assess this, the sensitivity of these two inputs to the selective GluA2-lacking 
AMPAR channel blocker, 1-Naphthyl acetyl spermine (Naspm), was tested. After obtaining a 
stable baseline (more than 100 sweeps), Naspm was applied at a concentration of 100 µM. At the 
apical dendrite synapses of Tg
SHANK2AR462X
 and control mice, the drug administration resulted in a 
small reduction of AMPAR-mediated EPSC (Figure 21). However, in the basal dendrite 
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synapses, Naspm caused a robust reduction of EPSC amplitudes, suggesting a high expression of 
GluA2-lacking AMPARs in the basal dendrites. In contrast, AMPAR-mediating input to the 
apical dendrites in Tg
SHANK2A
 gained a strong sensitivity to the blocker, while synapses in stratum 
oriens became totally resistant to the Naspm application (Figure 21).  
 
Figure 21: Analysis of AMPAR-mediated EPSC in the apical and basal dendrites in CA1 pyramidal 
neurons from Tg
SHANK2A
 and Tg
SHANK2AR462X
 mice with selective GluA2-lacking AMPAR channel blocker 
Averaged AMPAR mediated EPSCs before (black) and after (green) Naspm application, a blocker of 
AMPARs lacking the GluA2 subunit, recorded upon stimulation of stratum oriens and stratum radiatum. 
Naspm treatment decreased the current in the apical dendrites of Tg
SHANK2A
 mice, but not of Tg
SHANK2AR462X 
or 
control mice. In the basal dendrites, Naspm treatment decreased the current of Tg
SHANK2AR462X 
and control mice, 
but not Tg
SHANK2A
 mice. This suggests a difference of AMPAR subunit composition in the apical and basal 
dendrites between Tg
SHANK2A
 compared with Tg
SHANK2AR462X 
and control mice (n = 5 neurons per each genotype 
of mice at 4 – 7 weeks of age). Error bars indicate SD (unpaired two‐tailed Student's t-test,*p ≤ 0.05). 
Experimental data were provided by Dr. Andrey Rozov. 
The effect of sub-cellular redistribution of GluA2-lacking AMPAR on the long-term plasticity in 
CA1 pyramidal cells was tested by comparing the levels of LTP evoked at apical or basal 
dendrite synapses between Tg
SHANK2A
, Tg
SHANK2AR462X
 and control mice. At stratum radiatum, 
synapses pairing protocol induced similar LTP in the three genotypes (Figure 22). At the basal 
dendrite synapses in Tg
SHANK2AR462X
 and control mouse slices, pairing triggered small but stable 
potentiation (Figure 22). In contrast, the same induction protocol in Tg
SHANK2A
 mice did not 
result in LTP at stratum oriens synapses (Figure 22).  
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In summary, Tg
SHANK2A
 but not Tg
SHANK2AR462X
 mice revealed impairment on the 
electrophysiological level due to the inhibition of the developmental dependent AMPAR subtype 
switch in the basal dendrites of the hippocampus. 
 
Figure 22: long-term potentiation measurement in CA1 pyramidal neurons from Tg
SHANK2A
, 
Tg
SHANK2AR462X
 and control mice 
(Left) LTP evoked by pairing stimulation of synaptic inputs to the synapses located on CA1 pyramidal cell 
apical dendrites (filled symbols). Inputs to the basal dendrite were used as control pathway (open symbols). 
Tg
SHANK2A
,
 
Tg
SHANK2AR462X
 and control mice had similar induced LTP in the apical dendrites using synapses 
pairing protocol. (Right) Results of pairing stimulation of synaptic inputs to the synapses located on CA1 
pyramidal cell basal dendrites (filled symbols). Inputs to the apical dendrite were used as control pathway 
(open symbols). The same pairing protocol induced stable LTP in Tg
SHANK2AR462X 
and control
 
mice, but not in 
Tg
SHANK2A 
mice (n = 10 neurons per each genotype of mice at 4 – 7 weeks of age). Experimental data were 
provided by Dr. Andrey Rozov. 
3.2.5 Gene expression analysis in the hippocampus of Tg
SHANK2A 
and Tg
SHANK2AR462X
 mice
 
To identify disrupted neural signaling pathways in the hippocampus of Tg
SHANK2A 
and 
Tg
SHANK2AR462X
 mice, the expression levels of key signaling proteins in AMPA-, NMDA-, 
mGluR-, and GABA-pathways were studied on RNA level using the nCounter analysis. The 
comparative expression analysis of Tg
SHANK2A 
and Tg
SHANK2AR462X
 mice revealed a downregulation 
of AMPAR and mGluR genes in both transgenic mouse models (Figure 23). Additionally, 
Tg
SHANK2A
 mice showed a downregulation in the expression of two NMDAR genes Grin2a and 
Grin2b, while Tg
SHANK2AR462X
 mice showed a downregulation of Oxytocin and Serotonin 2A 
receptor gene expression. Both Tg
SHANK2A 
and Tg
SHANK2AR462X
 mice did not show any difference in 
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the expression of endogenous Shank genes or the gene for GABAA receptor subunit alpha 1 gene 
(Gabra1) (Figure 23). 
 
Figure 23: Comparative expression analysis of genes in the hippocampus of TgSHANK2A and 
Tg
SHANK2AR462X 
mice 
Normalized RNA expression analysis of Tg
SHANK2A 
mice using the nCounter analysis revealed a nominal 
significant upregulation of Drd2 and a downregulation of the NMDAR genes (Grin2a and Grin2b), AMPAR 
genes (Gria1 and Gria2), mGluR genes (Grm1 and Grm5), in addition to Dlgap1, and Syngap1 (n= 8 
Tg
SHANK2A
 and 11 control mice, 3 – 5 months). The expression analysis of Tg
SHANK2AR462X
 mice revealed a 
nominal significant downregulation of the AMPAR genes (Gria1, Gria2 and Gria3), Grm5, Serotonin 2A 
receptor (Htr2a) and Oxytocin receptor (Oxtr) genes (n= 7 Tg
SHANK2AR462X
 and 7 control mice, 3 – 5 months). 
Error bars indicate SEM (Unpaired two-tailed Student‘s t-test, *p ≤ 0.05, **p ≤ 0.01). 
The expression level of various proteins in the total protein lysate from the hippocampus of 
Tg
SHANK2A
 and Tg
SHANK2AR462X
 mice was investigated by western blot analysis in order to confirm 
the results obtained on RNA level. In Tg
SHANK2A
 mice, the protein levels of NMDAR subunit 
(GluN2A) and Homer 1 were significantly increased (Figure 24), whereas the levels of the 
AMPAR subunits (GluA1 and GluA2) and mGluR1 were decreased (Figure 24). In 
Tg
SHANK2AR462X
 mice, immunoblots confirmed the downregulation of the AMPAR subunits 
(GluA1 and GluA2) and Serotonin 2A receptor (5-HT2A), which was obtained from the 
nCounter analysis (Figure 24). 
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Figure 24: Protein analysis in the hippocampus of TgSHANK2A and TgSHANK2AR462X mice 
Total protein lysate analysis in the hippocampus of Tg
SHANK2A
 revealed increased levels of GluN2A and 
Homer1, and a decreased amounts of GluA1, GluA2 and mGluR1 (n = 5 mice for each genotype, 3 – 5 months 
old). For Tg
SHANK2AR462X
, total protein lysate analysis of the hippocampus revealed lower GluA, GluA2 and 5-
HT2A levels (n = 6 mice for each genotype, 3 – 5 months). Error bars indicate SEM (Unpaired two-tailed 
Student‘s t-test, *p ≤ 0.05, **p ≤ 0.01). 
The Excitatory/ inhibitory imbalance has been shown to play a role in the pathophysiology of 
ASD 
183-188
. Therefore, the expression of the interneuronal marker, parvalbumin (PV), was 
investigated in the hippocampus of Tg
SHANK2A
,
 
Tg
SHANK2AR462X
 and control mice and revealed 
fewer PV-positive cells in the DG and CA1 regions of the hippocampus of Tg
SHANK2A
 mice 
compared with Tg
SHANK2AR462X
 and control mice (Figure 25).  
In summary, Tg
SHANK2A
 mice showed more severe dysregulation of gene expression in the 
hippocampus compared to Tg
SHANK2AR462X
 mice, which is consistent with the more severe 
behavioral phenotypes observed in Tg
SHANK2A
 mice. 
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Figure 25: Quantitative expression analysis of parvalbumin in the hippocampus of TgSHANK2A and 
Tg
SHANK2AR462X 
mice 
(Left) The numbers of PV-positive cells in the DG, CA1, CA2 and CA3 regions are shown. (Right) The total 
number of PV-positive cells in the whole hippocampus of Tg
SHANK2A
 mice was reduced compared with 
Tg
SHANK2AR462X
 and control mice. The displayed values show the mean values of 3 mice per each group (6 
slices/mouse). Error bars indicate SEM (Unpaired two-tailed Student‘s t-test, *p ≤ 0.05, **p ≤ 0.01). 
3.2.6 Synaptosome and gene ontology analysis in the hippocampus of Tg
SHANK2A
 and 
Tg
SHANK2AR462X
 mice 
Large-scale proteomic analysis of synaptosome was performed in order to check the localization 
of proteins in the synapse using the mass spectrometry. In total, 2466 proteins were identified in 
the synaptosomal fractions from the hippocampus. For the Tg
SHANK2A
 mice, 107 proteins were 
differentially expressed in synaptosomes compared with control mice (p ≤ 0.05) (25 more and 82 
less abundant) (Appendix 4) (data provided by Prof. A.B. Smit). For the Tg
SHANK2AR462X
 mice, 55 
proteins were differentially expressed in synaptosomes compared with control mice (p ≤ 0.05) 
(19 more and 36 less abundant) (Appendix 4) (data provided by Prof. A.B. Smit). Next, the gene 
ontology analysis using the free online database ConsensusPathDB was performed. The Kegg 
pathway analysis of the differentially abundant proteins in the synaptosomes of Tg
SHANK2A
 mouse 
hippocampus suggested that the glutamatergic synapses were affected (Figure 26). For 
Tg
SHANK2AR462X
, the Kegg pathway analysis revealed that the axon guidance pathway was mainly 
disrupted (Figure 26).  
 
Figure 26: Synaptosome and pathway analysis in the hippocampus of TgSHANK2A and TgSHANK2AR462X 
mice The online database ConsensusPathDB predicted the affected pathways in Tg
SHANK2A
  and Tg
SHANK2AR462X
 
mice by the analysis of differentially abundant proteins in the synaptosome of the hippocampus. 
With regard to the biological processes, social, vocalization, learning and memory behaviors 
were predicted to be affected in Tg
SHANK2A
 mice, in addition to an effect on neurogenesis, long 
term synaptic potentiation and regulation of AMPAR activity (Figure 27). In Tg
SHANK2AR462X
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mice, the behavioral functions and the regulation of the molecular functions were predicted to be 
disturbed (Figure 27).  
 
Figure 27: Biological process analysis in the hippocampus of TgSHANK2A and TgSHANK2AR462X mice 
The figure shows a list of the affected biological processes in Tg
SHANK2A
 and Tg
SHANK2AR462X
 mice predicted by 
the online database ConsensusPathDB by the analysis of differentially abundant proteins in the synaptosome of 
the hippocampus. The terms used in the biological process analysis appear at different levels (level 2, 3 and 4). 
The higher the level, the more specific is the respective term. 
With respect to the molecular function, the protein complex scaffold and binding, especially for 
the glutamatergic receptors were predicted to be affected in Tg
SHANK2A
 mice (Figure 28). In 
Tg
SHANK2AR462X
, the semaphorin receptor activity was likely affected (Figure 28). 
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Figure 28: Molecular function analysis in the hippocampus of TgSHANK2A and TgSHANK2AR462X mice  
The molecular function analysis of differentially abundant proteins in the synaptosome of the hippocampus, 
which was done by the online database ConsensusPathDB, predicted affected synaptic protein complex in 
Tg
SHANK2A
 mice and affected semaphorin receptor activity in Tg
SHANK2AR462X
 mice. The terms used in the 
molecular function analysis appear at different levels (level 2, 3 and 4). The higher the level, the more specific 
is the respective term. 
Regarding the cellular components, the synaptic membranes, neuronal parts, postsynaptic density 
and cell projection parts were suggested to be affected in both Tg
SHANK2A
 and Tg
SHANK2AR462X
 mice 
(Figure 29).  
In summary, the synaptic protein composition was altered differently in both mouse lines, 
indicating mainly presynaptic components in SHANK2A(R462X) and more postsynaptic 
components in SHANK2A overexpressing mice. The function of the glutamatergic synapse in 
Tg
SHANK2A
 mice was mainly disturbed, leading to more severe behavioral and 
electrophysiological dysfunction. In contrast, the axon and dendrites branching in Tg
SHANK2AR462X
 
mice were suggested to be dysregulated, which can account for some of the behavioral 
abnormalities of Tg
SHANK2AR462X
 mice. 
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Figure 29: Cellular component analysis in the hippocampus of TgSHANK2A and TgSHANK2AR462X mice 
The cellular component, synaptic membrane, neuron part, postsynaptic density and cell projection part were 
likely affected in both Tg
SHANK2A
 and Tg
SHANK2AR462X
 mice. The terms used in the cellular component analysis 
appear at different levels (level 2, 3 and 4). The higher the level, the more specific is the respective term. 
3.2.7 Switching off the SHANK2A overexpression in adult Tg
SHANK2A
 mice  
To analyze which phenotype described in chapter 3.2.2 can be rescued by the stop of SHANK2A 
overexpression in adulthood, adult Tg
SHANK2A
 mice (5 – 8 months) were received drinking water, 
supplemented with 2 g/l dox and 5% sucrose (Figure 30A). The duration of dox intake was 1 
month to assure the total elimination of the transgene expression and to enable the affected 
synapses to recover. Using immunofluorescence staining, the total absence of Venus expression 
after 1 month of dox intake was confirmed in dox-treated Tg
SHANK2A
 mice (Figure 30B). In 
contrast, Eosin/X-gal staining revealed a low enzymatic activity of β-galactosidase at the cellular 
level in the hippocampus (Figure 30B). The complete absence of SHANK2A and Venus 
overexpression and the low expression of β-galactosidase were confirmed in dox-treated 
Tg
SHANK2A
 mice by immunoblotting of proteins from the cortex, hippocampus and olfactory bulb 
(Figure 30C). 
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Figure 30: Characterization of TgSHANK2A mice after switching off the transgene overexpression in 
adulthood 
(A) Schematic of the transgenes that were used for the overexpression of SHANK2A. The binding between the 
transcription activator (tTA) and the bidirectional Ptet-bi promoter of the SHANK2A responder transgene was 
inhibited by providing the adult mice with 2 g/l dox in water, supplemented with 5% sucrose, for 1 month 
which caused the inactivation of the transgene expression. (B) Eosin/X-gal staining detected some β-
galactosidase expression of the lacZ gene at the cellular level in the hippocampus of Tg
SHANK2A
 mice after 1 
month of dox intake (upper row) (scale bar: 2 mm). In contrast, the Venus expression in the forebrain of 
Tg
SHANK2A
 mice was completely absent (lower row) (scale bar: 2 mm). (C) Protein lysates of different brain 
tissues from adult Tg
SHANK2A 
(Tg
SHANK2A
-dox), dox-treated Tg
SHANK2A
 (Tg
SHANK2A
+dox) and dox-treated control 
mice (Ctr+dox) were analyzed by immunoblotting with SHANK2, β-galactosidase and Venus antibodies and 
revealed no expression of Venus or SHANK2A and a little expression of β-galactosidase in the cortex, 
hippocampus and olfactory bulb of dox-treated Tg
SHANK2A
 mice. (6 – 9 months), HPC: Hippocampus, OB: 
Olfactory bulb, CB: Cerebellum.  
The detailed behavior analysis of dox-treated Tg
SHANK2A
 mice started by applying the SHIRPA 
test (for a summary, see Appendix 5). Dox-treated Tg
SHANK2A
 mice showed a reduced body 
weight compared to dox-treated control mice (Figure 31A). The reduced body weight of dox-
treated Tg
SHANK2A
 mice is similar to the reduced body weight of Tg
SHANK2A
 mice that continuously 
overexpress SHANK2A transgene in adulthood (Figure 14A). Next, the general behavior of 
+ dox 
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dox-treated Tg
SHANK2A
 mice was assessed in the LABORAS test. Dox-treated Tg
SHANK2A
 mice 
were hyperactive (Figure 31B) and had longer eating duration (Figure 31C) and increased 
episodes of repetitive rearing (Figure 31D), similar to the previously shown behavior of 
Tg
SHANK2A
 mice (Figure 14B-D). With regard to the number of self-grooming and climbing in the 
LABORAS cages, there was no difference between dox-treated Tg
SHANK2A 
and dox-treated 
control mice. In the nesting test, the impaired nesting behavior of Tg
SHANK2A
 mice (Figure 14F) 
was not rescued by switching off the SHANK2A overexpression in adulthood by dox intake 
(Figure 31E). 
 
Figure 31: Analysis of general and repetitive behaviors in TgSHANK2A mice after switching off the 
transgene overexpression in adulthood 
(A) Body weight of dox-treated Tg
SHANK2A
 mice was 30% less than of dox-treated control mice. (B-D) The 
LABORAS test of dox-treated Tg
SHANK2A
 mice revealed hyperactivity behavior as shown by the increased 
number of locomotion (B, left) and the average speed (B, right), increased eating (C, left) and decreased 
drinking durations (C right), increased repetitive rearing (D, left) and normal self-grooming (D, middle) and 
climbing (D, right). (E) The nesting behavior was impaired in dox-treated Tg
SHANK2A
 (n = 12 dox-treated 
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Tg
SHANK2A
 and 15 dox-treated control mice at 6 – 9 months of age). Error bars indicate SEM (Two-way 
ANOVA,*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001).  
In the dark-light box and neophobia tests for investigating anxiety, dox-treated Tg
SHANK2A
 mice 
exhibited anxiety (Figure 32A, C), similar to Tg
SHANK2A
 mice without dox treatment 
(Figure 15A, C). On the other hand, the anxiety displayed by Tg
SHANK2A
 mice in the open field 
test (Figure 15B) was rescued by switching off the transgene overexpression in adulthood 
(Figure 32B). 
In the burrowing test, the retrieval of pellets from the tube was impaired in dox-treated Tg
SHANK2A
 
mice after 2 and 12 hrs (Figure 32D) similar to Tg
SHANK2A
 mice that continuously express 
SHANK2A (Figure 15D). In the balance and cliff avoidance tests, the impaired balance ability 
of Tg
SHANK2A
 mice, but not the impulsive behavior, was rescued in dox-treated Tg
SHANK2A
 mice 
(Figure 32E, F). 
 
Figure 32: Characterization of anxiety and impulsive behaviors in TgSHANK2A mice after switching off 
the transgene overexpression in adulthood 
(A) The dark-light box test revealed anxiety in dox-treated Tg
SHANK2A
 as shown by the high latency (left) and 
the decreased number of visits (right) to the light compartment compared with dox-treated control mice. (B) 
Dox-treated Tg
SHANK2A 
and control
 
mice traveled a similar distance (left) and made a similar number of visits 
(right) to the center of a new arena in the open field test. (C) Dox-treated Tg
SHANK2A
 mice exhibited fear of the 
unfamiliar drink (condensed milk in the center of the arena) in the neophobia test by making few contacts. (D) 
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In the burrowing test, dox-treated Tg
SHANK2A
 mice left more pellets in the tube after 2 hrs (left) and 12 hrs 
(right) compared with control mice. (E) Dox-treated Tg
SHANK2A
 had no balance impairment in two successive 
sessions in the balance test. (F) Dox-treated Tg
SHANK2A
 mice had a high impulsive reaction in the cliff 
avoidance test (n = 12 dox-treated Tg
SHANK2A
 and 15 dox-treated control mice at 6 – 9 months of age). Error 
bars indicate SEM (Two-way ANOVA,*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001). 
In the social interaction tests, dox-treated Tg
SHANK2A
 mice exhibited normal social behavior in the 
three-chamber social test (Figure 33A) and the direct social interaction test (Figure 33B). In the 
novel object recognition test, dox-treated Tg
SHANK2A
 and control mice likewise contacted a novel 
object in the center of an arena (Figure 33C). This demonstrated that the restoration of balanced, 
endogenous Shank expression rescued the social impairment of Tg
SHANK2A
 mice in three different 
social tests. Cognitive and memory functions of dox-treated Tg
SHANK2A
 mice were assessed using 
the puzzle box and revealed the inability of dox-treated Tg
SHANK2A
 to perform the test efficiently 
in all trials (Figure 33D). In the fear conditioning test, dox-treated Tg
SHANK2A
 showed increased 
freezing behavior during the cued memory phase compared with dox-treated control mice, 
indicating improved memory retrieval (Figure 33E).  
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Figure 33: Characterization of the social behavior, cognitive function and emotional learning in 
Tg
SHANK2A 
mice after switching off the transgene overexpression in adulthood 
(A) In the three-chamber social test, dox-treated Tg
SHANK2A
 and control mice displayed similar numbers of 
contacts to strangers in all sessions. (B) In the direct social interaction test, dox-treated Tg
SHANK2A
 and control 
mice revealed similar numbers of contacts to unfamiliar same-sex mice. (C) In the novel object recognition 
test, dox-treated Tg
SHANK2A
 and control mice made similar numbers of contacts to an unfamiliar object in the 
center of an arena. (D) In the puzzle box test, dox-treated Tg
SHANK2A
 mice showed less ability and higher 
latency to solve the puzzle in all trials of the test. (E) In the fear conditioning test, dox-treated Tg
SHANK2A
 mice 
showed more freezing percentages in the acquisition and cued memory phases than dox-treated control mice  
(n = 12 dox-treated Tg
SHANK2A
 and 15 dox-treated control mice at 6 – 9 months of age). Error bars indicate 
SEM (Two-way ANOVA,*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001). 
The comparative nCounter expression analysis in dox-treated Tg
SHANK2A 
mice revealed a 
downregulation of the AMPAR genes (Gria1-3), Grm1 and Grm5 (Figure 34). Different from 
Tg
SHANK2A 
mice that express SHANK2A in adulthood
 
(Figure 23), the expression of the 
Serotonin 2A receptor (Htr2a) and Oxytocin receptor (Oxtr) genes in dox-treated Tg
SHANK2A 
mice 
were downregulated, and the expression of Grin2a and Grin2b was normal (Figure 34). 
In summary, stopping SHANK2A overexpression in adulthood revealed a rescue of the social 
impairment that was shown before in Tg
SHANK2A 
mice, but not other ASD-like behaviors. The 
normal social behavior was accompanied by a normal expression of NMDAR genes in the 
hippocampus. 
 
Figure 34: Comparative expression analysis of genes in the hippocampus of TgSHANK2A mice after 
switching off the transgene overexpression in adulthood 
Normalized RNA expression analysis of dox-treated Tg
SHANK2A 
mice using nCounter analysis revealed a 
nominal significant downregulation of the AMPAR (Gria1, Gria2 and Gria3) and mGluR genes (Grm1 and 
Grm5), in addition to Htr2a and Oxtr (n= 7 dox-treated Tg
SHANK2A
 and 8 dox-treated control mice, 3 – 5 
months). Error bars indicate SEM (Unpaired two-tailed Student‘s t-test, *p ≤ 0.05, **p ≤ 0.01). 
3.2.8 Switching off the SHANK2A(R462X) overexpression in adult Tg
SHANK2AR462X
 mice  
The SHANK2A(R462X) overexpression was switched off in adult mice as described above for 
SHANK2A overexpressing mice. Using immunofluorescence staining, the absence of Venus 
expression in the sagittal sections of dox-treated TgSHANK2AR462X mouse brains was confirmed 
(Figure 35B). Moreover, Eosin/X-gal staining revealed no β-galactosidase expression of the 
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lacZ gene (Figure 35B). The complete absence of SHANK2A(R462X), Venus and β-
galactosidase expression was confirmed using immunoblots of total protein lysates from the 
cortex, hippocampus and olfactory bulb (Figure 35C). 
 
Figure 35: Characterization of TgSHANK2AR462X mice after stopping the transgene overexpression in 
adulthood 
(A) Schematic of the transgenes that were used for the overexpression of SHANK2A(R462X). The binding 
between tTA and the bidirectional Ptet-bi promoter of the SHANK2A(R462X) transgene was inhibited by 
providing adult mice with dox in the water for 1 month which inactivated the transgene overexpression. (B) 
Eosin/X-gal staining revealed no β-galactosidase expression of the lacZ gene at the cellular level of 
Tg
SHANK2AR462X
 mice after 1 month of dox intake (upper row) (scale bar: 2 mm). Immunofluorescence of the 
sagittal sections of Tg
SHANK2AR462X
 mouse brains revealed no Venus expression in the forebrain of dox-treated 
Tg
SHANK2AR462X
 mice (lower row) (scale bar: 2 mm). (C) Protein lysates of different brain tissues from adult 
Tg
SHANK2AR462X 
without dox treatment (-dox), dox-treated Tg
SHANK2AR462X
 (Tg
SHANK2AR462X
+dox) and dox-treated 
control mice (Ctr+dox) were analyzed by immunoblotting with SHANK2, β-galactosidase and Venus 
antibodies and revealed the absence of the transgene expression in dox-treated Tg
SHANK2AR462X
 (6 – 9 months), 
HPC: Hippocampus, OB: Olfactory bulb, CB: Cerebellum.  
Dox-treated Tg
SHANK2AR462X
 mice showed no abnormal behavior in the SHIRPA test as noticed 
before for Tg
SHANK2AR462X
 mice (for a summary, see Appendix 5). Only the 10% body weight 
reduction of Tg
SHANK2AR462X
 was blunted, most likely due to the sucrose supplement in the 
+ dox 
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drinking water (Figure 36A). Similarly, in the LABORAS test, dox-treated Tg
SHANK2AR462X
 mice 
showed similar phenotype as SHANK2A(R462X) overexpressing adult mice (Figure 17B-D) 
including hyperactivity (Figure 36B), decreased self-grooming (Figure 36D), normal drinking 
duration (Figure 36C) and a normal number of rearing and climbing (Figure 36D). Moreover,  
dox-treated Tg
SHANK2AR462X
 mice had no impairment in the nesting test (Figure 36E) similar to 
Tg
SHANK2AR462X 
mice (Figure 17F). 
 
Figure 36: Analysis of general and repetitive behaviors in TgSHANK2AR462X mice after switching off the 
transgene overexpression in adulthood 
(A) Body weights of dox-treated Tg
SHANK2AR462X
 mice were similar to dox-treated control mice. (B-D) 
LABORAS test of dox-treated Tg
SHANK2AR462X
 mice revealed hyperactivity as shown increased number of 
locomotion (B, left) and average speed (B, right), increased eating (C, left) but normal drinking (C, right) 
durations, and normal number of rearing (D, left) and climbing (D, right) but less self-grooming (D, middle). 
(E) Dox-treated Tg
SHANK2AR462X
 had no impairment in the nesting test (n = 10 dox-treated Tg
SHANK2AR462X
 and 14 
dox-treated control mice at 6–9 months of age). Error bars indicate SEM (Two-way ANOVA,*p ≤ 0.05, ***p 
≤ 0.001). 
In contrast to Tg
SHANK2AR462X
 mice (Figure 18A-C), the dox-treated Tg
SHANK2AR462X
 mice showed 
high anxiety levels in the dark-light box, open field and neophobia tests (Figure 37A-C). 
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However, they had similar impairment in the burrowing and cliff avoidance tests, and no 
impairment in the balance test (Figure 37D-F)  
 
Figure 37: Characterization of anxiety and impulsive behaviors in TgSHANK2AR462X mice after stopping 
the transgene overexpression in adulthood 
(A) The dark-light box test revealed that dox-treated Tg
SHANK2AR462X
 made fewer visits to the light compartment 
(right) but had similar latency of the first visit (left) compared with dox-treated control mice. (B) Dox-treated 
Tg
SHANK2AR462X 
mice were anxious in the open field test by displaying reduced distance (left) and numbers of 
visits (right) to the center of a new arena compared with dox-treated control mice. (C) Dox-treated 
Tg
SHANK2AR462X
 mice had fear of unfamiliar drink (condensed milk in the center of the arena) in the neophobia 
test by showing high latency to the first contact (right) and reduced numbers of contacts (left) to the 
unfamiliar drink. (D) In the burrowing test, dox-treated Tg
SHANK2AR462X
 mice left more pellets in the tube after 2 
hrs (left) and 12 hrs (right). (E) Dox-treated Tg
SHANK2AR462X
 mice were not impaired in two successive sessions 
in the balance test. (F) Dox-treated Tg
SHANK2AR462X
 mice showed high impulsive behavior and less cliff 
avoidance reaction percentage in the cliff avoidance test (n = 10 dox-treated Tg
SHANK2AR462
 and 14 dox-treated 
control mice at 6 – 9 months of age). Error bars indicate SEM (Two-way ANOVA,*p ≤ 0.05, **p ≤ 0.01, ***p 
≤ 0.001). 
Similarly to Tg
SHANK2AR462X
 mice (Figure 19A), dox-treated Tg
SHANK2AR462X
 mice made a normal 
number of contacts to the same/opposite-sex strangers in all sessions in the three-chamber social 
test (Figure 38A). However, the increase in the number of contacts to same-sex mice in the 
direct social interaction test and to the novel object in the novel object recognition test, shown 
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previously by Tg
SHANK2AR462X
 mice (Figure 19B, C), was rescued after the stop of 
SHANK2A(R462X) overexpression in adulthood (Figure 38B, C). 
The puzzle box test revealed that dox-treated Tg
SHANK2AR462X
 mice were unable to solve the puzzle 
task in trials 5, 6 and 10, where executive performance was tested (Figure 38D). In the fear 
conditioning test, dox-treated Tg
SHANK2AR462X
 and control mice showed a similar freezing 
percentage during acquisition and context memory recall (Figure 38E). This demonstrates that 
the reduced freezing percentage, shown previously in Tg
SHANK2AR462X
 mice (Figure 19E), was 
rescued after turning down the SHANK2A(R462X) overexpression in adults. Additionally, dox-
treated Tg
SHANK2AR462X
 mice showed more freezing percentage during the cued memory phase 
than dox-treated controls, which might indicate a better memory retrieval (Figure 38E).  
 
Figure 38: Characterization of the social behavior, cognitive function and emotional learning in 
Tg
SHANK2AR462X 
mice after switching off the transgene overexpression in adulthood 
(A) Dox-treated Tg
SHANK2AR462X
 and control mice displayed similar numbers of contacts to stranger mice in all 
sessions in the three-chamber social test. (B) Dox-treated Tg
SHANK2AR462X
 and control mice made similar 
numbers of contacts to unfamiliar same-sex mice in the direct social interaction test. (C) Dox-treated 
Tg
SHANK2AR462X
 and control mice made similar numbers of contacts to an unfamiliar object in the novel object 
recognition test. (D) In the puzzle box test, dox-treated Tg
SHANK2AR462X
 mice showed high latency to solve the 
puzzle in trials 5, 6 and 10. On the other hand, they had lower latency to solve the puzzle in the first trial 
compared with dox-treated control mice. (E) Dox-treated Tg
SHANK2AR462X
 mice showed more freezing 
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percentage in the cued memory phase in the fear conditioning test (n = 10 dox-treated Tg
SHANK2AR462X
 and 14 
dox-treated control mice at 6 – 9 months of age). Error bars indicate SEM (Two-way ANOVA,*p ≤ 0.05, **p 
≤ 0.01, ***p ≤ 0.001).  
The nCounter expression analysis of genes in the hippocampus of dox-treated Tg
SHANK2AR462X
 
mice revealed that the  downregulation of AMPAR, mGluR, Serotonin 2A receptor  or Oxytocin 
receptor genes, shown previously in Tg
SHANK2AR462X
 mice (Figure 23), cannot be rescued by 
switching off the SHANK2A(R462X) overexpression in adult Tg
SHANK2AR462X
 mice (Figure 39).  
In summary, stopping SHANK2A(R462X) overexpression in adulthood was able to rescue the 
unusual social behavior of Tg
SHANK2AR462X
 mice but resulted in higher anxiety levels.  However, 
the expression pattern of genes that encode synaptic proteins in the hippocampus was not 
different between dox-treated and dox-naive Tg
SHANK2AR462X
 mice. 
 
Figure 39: Comparative expression analysis of genes in the hippocampus of TgSHANK2AR462X mice after 
stopping the transgene overexpression in adulthood 
Normalized RNA expression analysis in dox-treated Tg
SHANK2AR462X 
mice
 
using nCounter analysis revealed a 
nominal significant downregulation of the AMPAR (Gria1, Gria2 and Gria3) and the mGluR5 gene (Grm5), 
in addition to Htr2a and Oxtr (n= 8 dox-treated Tg
SHANK2AR462X
 and 8 dox-treated control mice, 3 – 5 months). 
Error bars indicate SEM (Unpaired two-tailed Student‘s t-test, *p ≤ 0.05). 
3.2.9 SHANK2A overexpression after the critical developmental stage 
ASD is known to be a neurodevelopmental disorder which is noticed in the first 3 years of life 
189
. However, whether some autistic-like behaviors can still be developed after the critical 
developmental stage is still unknown. As shown above, the behavioral symptoms of Tg
SHANK2A
 
mice include the typical ASD-like phenotypes, including social impairment and repetitive 
behavior, along with anxiety, hyperactivity and cognitive dysfunction. To analyze which of those 
ASD-like phenotypes are developmentally mediated, the SHANK2A overexpression was 
induced in juvenile mice after the critical developmental stage which starts at the beginning of 
embryonic stage until P21 (for a detailed explanation of the developmental stage, see 
https://embryology.med.unsw.edu.au/embryology/index.php/Mouse_Timeline_Detailed).  
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Pregnant female mice received the described dox diet (50 mg/l) to inactivate tTA in embryos. 
Immunoblots of total protein lysates from the forebrains of P0 dox-treated Tg
SHANK2A 
mice 
detected β-galactosidase first at P20, while Venus became immuno-visible 10 days later (Figure 
40A). After all, the hippocampal Venus, β-galactosidase and transgenic SHANK2A protein 
levels were comparable between Tg
SHANK2A
 and P0 dox-treated Tg
SHANK2A 
mice (Figure 40B). 
However, immunofluorescence and Eosin/X-gal stainings revealed that the patterns of Venus and 
β-galactosidase overexpression in the hippocampus of P0 dox-treated Tg
SHANK2A 
mice was 
different from the positive control, showing more localized signals in the hippocampal CA1 and 
CA2 regions, but not in the DG (Figure 40C). 
 
Figure 40: Characterization of TgSHANK2A mice that overexpress SHANK2A after development 
(A) Total protein lysates from forebrains of pups at different developmental stages, when their dams were 
treated with dox until labor, were analyzed by immunoblotting with β-galactosidase and Venus antibodies. The 
expression of the Venus transgene started at P30. (B) Total protein lysates of different brain tissues from adult 
Tg
SHANK2A
, P0 dox-treated Tg
SHANK2A 
and control mice were analyzed by immunoblotting with SHANK2, β-
galactosidase and Venus antibodies. (5 months) HPC: Hippocampus, OB: Olfactory bulb, CB: Cerebellum. (C) 
Expression of SHANK2A transgene was visualized by the Venus epifluorescence in the forebrain of 
Tg
SHANK2A
-doxP0
 
mice (upper row) (scale bar: 2 mm). Immunofluorescence staining revealed Venus 
+ dox 
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expression at the cellular level in coronal brain sections of P0 dox-treated Tg
SHANK2A 
mice (middle row) (scale 
bar: 2 mm). The β-galactosidase expression could be detected at the cellular level of P0 dox-treated Tg
SHANK2A 
mice by Eosin/X-gal staining (lower row) (scale bar: 2 mm).  The patterns of Venus and β-galactosidase 
overexpression in the hippocampus of  P0 dox-treated Tg
SHANK2A 
mice were different from the positive control, 
and the signals were more localized in the CA1 and CA2 regions, but not in DG. 
Despite the prenatal exposure to the dox/sucrose by the dox diet of the dams, the body weights of 
P0 dox-treated Tg
SHANK2A 
mice was still 10% lower than P0 dox-treated control mice (Figure 
41A). In the LABORAS test, adult P0 dox-treated Tg
SHANK2A
 mice were hyperactive (Figure 
41B) and showed increased repetitive rearing (Figure 41D) similar to Tg
SHANK2A
 animals (Figure 
14 B, D). In contrast to Tg
SHANK2A
 mice, the duration of eating and the nesting behaviors were not 
affected when SHANK2A overexpression was induced in adolescence (Figure 41C, E) (for a 
summary, see Appendix 5). 
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Figure 41: General and repetitive behaviors in TgSHANK2A mice that overexpress SHANK2A after 
developmental  
(A) The body weight of P0 dox-treated Tg
SHANK2A
, when their dams were treated with dox until labor, was 10% 
less than of control mice. (B-D) The LABORAS test of P0 dox-treated Tg
SHANK2A
 mice showed an increased 
number of locomotion events (B, left) and a high average speed (B, right). P0 dox-treated Tg
SHANK2A
 mice 
showed no difference in the duration of eating (C, left) or drinking (C, right). P0 dox-treated Tg
SHANK2A
 mice 
exhibited repetitive rearing (D, left), but no difference in the number of self-grooming (D, middle) or climbing 
(D, right) compared with P0 dox-treated control mice. (E) P0 dox-treated Tg
SHANK2A
 mice showed no 
impairment in the nesting test. (n = 14 P0 dox-treated Tg
SHANK2A
 and 16 P0 dox-treated control mice at 6 – 9 
months of age). Error bars indicate SEM (Two-way ANOVA,*p ≤ 0.05). 
To test anxiety in P0 dox-treated Tg
SHANK2A
 mice, three different experiments were performed. P0 
dox-treated Tg
SHANK2A
 mice exhibited high anxiety level in the dark-light box (Figure 42A), open 
field (Figure 42B) and neophobia (Figure 42C) tests similar to Tg
SHANK2A
 mice (Figure 15 A-
C).  
To test the integrity of hippocampal function, the burrowing test was performed and revealed the 
inability of P0 dox-treated Tg
SHANK2A
 mice to perform the test efficiently with more remaining 
pellets in the tube after 2 hr, but not after 12 hrs (Figure 42D). P0 dox-treated Tg
SHANK2A
 mice 
were able to maintain their balance in two consecutive sessions in the balance test (Figure 42E) 
in contrast to Tg
SHANK2A
 mice (Figure 15E). The induction of SHANK2A overexpression after 
the developmental stage in P0 dox-treated Tg
SHANK2A
 mice was still correlated with high 
impulsivity in the cliff avoidance reaction test (Figure 42F).  
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Figure 42: Characterization of anxiety and impulsive behaviors in TgSHANK2A mice that express 
SHANK2A after development 
(A) The dark-light box test revealed anxiety in P0 dox-treated Tg
SHANK2A
 as shown by increased latency (left) 
and reduced numbers of visits (right) to the light compartment compared with P0 dox-treated control mice. (B) 
P0 dox-treated Tg
SHANK2A
 mice displayed anxiety in the open field test and showed less traveled distance (left) 
and fewer numbers of visits (right) to the center of a new arena than P0 dox-treated control mice. (C) P0 dox-
treated Tg
SHANK2A
 mice exhibited fear of unfamiliar drink (condensed milk in the center of the arena) in the 
neophobia test by showing higher latency to the first contact (right), but a similar number of contacts (left) to 
the unfamiliar drink. (D) In the burrowing test, P0 dox-treated Tg
SHANK2A
 mice showed more remaining pellets 
in the tube after 2 hrs (left), but not after 12 hrs (right) than controls exposed to dox till P0. (E) P0 dox-treated 
Tg
SHANK2A
 mice showed no balance impairment in two successive sessions in the balance test. (F) P0 dox-
treated Tg
SHANK2A
 mice showed impulsive behavior with less cliff avoidance reaction percentage in the cliff 
avoidance reaction test than P0 dox-treated control mice. (n = 14 P0 dox-treated Tg
SHANK2A
 mice and 16 P0 
dox-treated control mice at 6 – 9 months of age). Error bars indicate SEM (Two-way ANOVA,*p ≤ 0.05). 
The social behavior of P0 dox-treated Tg
SHANK2A
 mice was assessed by performing the three-
chamber social test, the direct social interaction and the novel object recognition tests. In contrast 
to Tg
SHANK2A
 mice with SHANK2A overexpression during the developmental stage (Figure 16A-
C), P0 dox-treated Tg
SHANK2A
 mice were not impaired in these three tests (Figure 43A-C). In the 
puzzle box, P0 dox-treated Tg
SHANK2A
 mice showed a cognitive impairment and high latency to 
solve the puzzle in trials 1, 8, 9 and 10 (Figure 43D). The emotional learning revealed no 
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impairment in the context or the cued fear memory in P0 dox-treated Tg
SHANK2A
 mice 
(Figure 43E) similarly to Tg
SHANK2A
 mice (Figure 16E).  
 
Figure 43: Characterization of the social behavior, the cognitive function and the emotional learning in 
Tg
SHANK2A 
mice that overexpress SHANK2A after development 
(A) In the three-chamber social test, P0 dox-treated Tg
SHANK2A
 and control mice displayed similar numbers of 
contacts to strangers in all sessions. (B) In the direct social interaction, P0 dox-treated Tg
SHANK2A
 and control 
mice revealed similar numbers of contacts to unfamiliar same-sex mice. (C) In the novel object recognition 
test, P0 dox-treated Tg
SHANK2A
 and control mice showed similar numbers of observed contacts to an unfamiliar 
object. (D) In the puzzle box test, P0 dox-treated Tg
SHANK2A
 mice showed higher latency to solve the puzzle in 
trials 1, 8, 9 and 10 than P0 dox-treated control mice. (E) In the fear conditioning test, P0 dox-treated 
Tg
SHANK2A
 and control mice showed similar freezing percentages in the acquisition, context and cued memory 
phases. (n = 14 P0 dox-treated Tg
SHANK2A
 mice and 16 P0 dox-treated control mice at 6 – 9 months of age). 
Error bars indicate SEM (Two-way ANOVA,*p ≤ 0.05, **p ≤ 0.01). 
The expression analysis of genes in the hippocampus of P0 dox-treated Tg
SHANK2A
 mice was 
investigated on RNA level using nCounter analysis. The comparative expression analysis 
revealed a downregulation of the AMPAR genes (Gria2 and Gria3), Grm1 and Dlg4 (Figure 
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44). However, the activation of SHANK2A overexpression after development did not reveal the 
reduced expression of NMDAR genes, previously found in Tg
SHANK2A
 mice (Figure 23).  
In summary, P0 dox-treated Tg
SHANK2A
 mice displayed specific ASD-like features including 
hyperactivity, anxiety, repetitive behavior and cognitive dysfunction similar, but with less 
severity, to Tg
SHANK2A
 mice that overexpress SHANK2A during development. However, they did 
not show any social impairment in contrast to Tg
SHANK2A
 mice. The normal social interaction in 
P0 dox-treated Tg
SHANK2A
 mice was accompanied by a normal expression of NMDAR genes in 
the hippocampus. 
 
Figure 44: Comparative expression analysis of genes in the hippocampus of TgSHANK2A mice that 
overexpress SHANK2A after development 
Normalized RNA expression analysis of P0 dox-treated Tg
SHANK2A
 mice
 
using the nCounter analysis revealed a 
nominal significant downregulation of the AMPAR (Gria2 and Gria3) and mGluR1 (Grm1), in addition to 
Dlg4 genes. (n= 7 P0 dox-treated Tg
SHANK2A
 mice and 8 P0 dox-treated controls, 3 – 5 months). Error bars 
indicate SEM (Unpaired two-tailed Student‘s t-test, *p ≤ 0.05, **p ≤ 0.01). 
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4.1 The influence of sex hormones on SHANK expression 
A clear link between testosterone and ASD has emerged from studying synaptic dysfunction 
56
. 
As SHANKs are postsynaptic scaffolding proteins and known to be linked to ASD pathology 
124
, 
an influence of testosterone on their expression was suggested. Testosterone is metabolized in 
the brain into DHT or converted into 17β-estradiol by the enzyme aromatase (CYP19A1). 
Therefore, the effect of testosterone‘s metabolites on SHANK gene expression was investigated 
in a SH-SY5Y cell model, a widely used neuronal cell model to investigate hormonal influences 
of androgens and estrogens on the expression of genes 
66,174,190,191
. Treating SH-SY5Y cells with 
DHT and 17β-estradiol, AR and ERα, respectively, revealed different expression levels and 
patterns, confirming their different signaling cascades in SH-SY5Y cells, as shown previously in 
humans 
192
. Both DHT and 17β-estradiol increased SHANK mRNA expression, with a more 
pronounced effect of DHT (35%), compared to the effect of 17β-estradiol (15%). Moreover, the 
effect of DHT but not 17β-estradiol on SHANK expression was present on the protein level with 
a 50% increase in the level of SHANK protein isoforms. The increase in SHANK expression on 
protein level more than on mRNA level in response to DHT treatment indicates either reduced 
mRNA stability or that the major effect of DHT is at the level of translation 
152
. The general 
regulatory influence of DHT and 17β-estradiol was modest, indicating a role as transcriptional 
fine-tuners 
152
. In previous studies, the postsynaptic scaffolding protein PSD95 was shown to be 
regulated as well by sex hormones 
176-178
. Moreover, the AMPAR subunits, GluA1 and GluA2, 
were reported to be androgen-responsive 
193
. These results underline the important role of sex 
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hormones in regulating the expression of multiple synaptic proteins. Despite the small effect of 
sex hormones on individual gene expression, synergistic effects on several genes could influence 
the synaptic composition substantially, leading to the notable differences observed between male 
and female phenotypes. 
The effect of DHT and 17β-estradiol on SHANK expression was absent in the presence of AR 
and ER antagonists. This suggests that the modulation of sex hormones on SHANK expression is 
mainly direct via androgen and estrogen receptor signaling, although other indirect effects of sex 
hormones on the regulation of SHANK expression can still be present. The direct contribution of 
AR signaling on the regulation of SHANK gene expression was confirmed by the reduced 
expression of Shank genes in the cortex of Ar
NesCre
 mice at P7.5, supporting the role of Ar 
activity in the regulation of Shank expression during mouse brain development. Surprisingly, 
Ar
NesCre
 and littermate control mice revealed similar expression levels of Shank genes at E17.5, 
which can be explained by the low level of Ar expression in the cortex of control mice at E17.5. 
Moreover, deletion of Ar by Nestin-Cre might need a longer duration before modulating the 
Shank gene expression. The period between E17.5 and P7.5 is considered a critical period for 
brain development 
152
. In a previous study, sex differences in the spatiotemporal expression of 
Ar, Erα and Erβ in the mouse brain as well as differences in testosterone levels were reported, 
suggesting their interrelated roles in shaping the brain structure and synaptic function 
181
. 
Therefore, it is not surprising that the human cortex differs in size between males and females, 
which can be correlated with sex hormone levels 
194,195
. Moreover, the genetic involvement of 
androgen dysregulation in ASD has been previously reported 
196
. A polymorphism in the 
androgen receptor gene (SRD5A2), which catalyzes the conversion of testosterone into DHT, was 
found in a Slovak cohort of ASD children, suggesting a direct role of AR impairment in ASD 
pathology 
196
.  
Previous data has shown that Ar and Shank genes have overlapping expression patterns. This 
comprises of the cortex along with other brain regions including the striatum and hippocampus, 
suggesting a correlation between their functions 
125,151,197
. Moreover, genes encoding for other 
proteins, that are known to be involved in the function of the glutamatergic synapses, were found 
to be regulated by androgens and estrogens in other brain regions such as the medial preoptic 
area and the ventromedial hypothalamus 
198
. The effect of anti-androgenic treatment, estrogenic 
treatment and a combination of both treatments on the Shank gene expression was investigated in 
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male and female rats and revealed an alteration in Shank1 and Shank2 expression levels in males 
at P6. In females, the expression of Shank2 and Shank3 was modulated in response to anti-
androgenic and estrogenic treatments 
198
. In a previous study, SHANK promoters and enhancers 
were found to contain palindromic and dihexameric motifs of androgen responsive elements 
199
, 
and an AR-binding site was also identified in an intron and in the distant promoter region of 
SHANK2 by ChIP-Seq 
200
. Given these aforementioned studies, there is growing evidence that 
the effect of sex hormones on SHANK expression is direct via androgen and estrogen receptors.  
In humans, the male cerebral cortex has more neurons than the female one. Those neurons are 
densely packed in the cerebral cortex of males but not in other brain regions 
201
. The dense 
packing of neurons in the male brain is associated with more intrahemispheric white matter, 
suggesting a pattern of increased local connectivity and decreased interhemispheric connectivity 
in the male brain 
202,203
. Furthermore, it is known that the size of the human cortex and its sex 
hormone levels differ between males and females 
204,205
, which may suggest a sex-differential 
expression of genes that encode for important neuronal and synaptic proteins. Therefore, the 
expression of Shank genes and proteins was investigated in the cortex of male and female wild-
type CD1 mice. qPCR analysis showed a significant reduction of Shank1 mRNA expression in 
the cortex of male compared to female mice at P7.5. In contrast, immunoblots revealed higher 
levels of all SHANKs in the cortex of male mice. This discrepancy between RNA and protein 
results suggests that they do not always correlate with each other, especially in proteins with a 
long half-life. Also, a negative feedback mechanism can sometimes occur when the increase in 
protein level decreases the expression of mRNA. Furthermore, a previous genome-wide study 
reported that the cellular abundance of a protein is predominantly controlled at the level of 
translation 
206
.  
The sex-differential Shank expression can be explained by a different Ar expression and 
testosterone level between male and female brains during the critical developmental stage 
181
. 
Male mouse embryos have about three times higher blood testosterone levels than female 
embryos at E17 
180
 and show significantly higher testosterone levels in the brain of CD1 mice at 
E19 
181
. The finding that male mice brains with high testosterone levels have elevated Shank 
protein expression is consistent with the finding that DHT increases SHANK mRNA and protein 
expression in SH-SY5Y cells. However, caution is advised when comparing an in vitro to an in 
vivo model. Moreover, SH-SY5Y cells may not entirely reflect the regulatory potential regarding 
  4 Discussion                                                                                                               
85 
 
testosterone signaling in cortical neurons, which are a heterogeneous population of cells that may 
respond differently to DHT 
152
.  
In humans, the prenatal stage and the first few years in life are the most vulnerable times for 
ASD 
207
. Showing that Shank expression in the cortex is different between male and female mice 
at two developmental stages indicates that the sex differences in the cortex intersect with ASD 
etiological pathways. The sex-differential expression of Shanks acts either as a male-risk factor 
or as a female-protective factor. Many studies support the female-protective factors hypothesis as 
female ASD patients usually carry a greater etiological load than affected males 
208-214
, indicating 
that females are able to withstand higher genetic liability than males without being affected 
39
. 
The complementary model of the high male-specific risk for ASD was supported by many 
studies, suggesting a link between prenatal exposure to high fetal testosterone and ASD 
58,60
. 
Therefore, male and female sex hormones may play a role in female protection or male 
susceptibility to ASD 
215
. Males show higher prenatal and postnatal testosterone levels than 
females 
31,60
, which is suggested to increase the ―masculinization‖ of the brain 
215
. In one study, 
girls with congenital adrenal hyperplasia, a congenital condition associated with abnormally high 
levels of testosterone, showed autistic behavioral manifestations 
216
. Moreover, it has been 
demonstrated that children with ASD have significantly elevated androgen levels 
56,217-219
. In 
addition, a high testosterone level in children was found to be associated with moodiness, low 
attachment, and low sociability in prepubertal ages 
220
, which are common observations in 
children with ASD. Physiologically higher SHANK protein expression levels in males compared 
to females implicate that genetic variants can have a higher penetrance in males, resulting in a 
larger proportion of males diagnosed with ASD 
152
. Although SHANK2 and SHANK3 variants are 
randomly distributed across male and female subjects, CNV deletions encompassing SHANK1 
segregated only in male carriers with high-functioning autism 
26
. Most ASD individuals that have 
been identified with SHANK deletions and various point mutations are very likely to have 
reduced levels of SHANK. However, it cannot be excluded that a general dysregulation of 
SHANK expression contributes to ASD pathology, as SHANK3 gene duplications have also been 
identified in individuals with Asperger syndrome 
25
.  
Gene expression in the neocortex of human postmortem tissues was previously compared 
between males and females 
44,193
. No evidence was obtained for sex-differential expression of 
SHANKs or other ASD-associated genes like RORA and FOXP1 in the prenatal (16-22 weeks) or 
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the adult stages. However, these two stages do not match the investigated developmental 
windows in the presented study. This suggests that the regulation of SHANK expression is very 
sensitive to sex hormones in the days shortly before or after birth. In a very recent study, the 
DNA methylation patterns of ASD risk genes, including NRXN1-3, FDE4A and SHANK2, and 
ASD-related pathways were found to be sex-biased in human postmortem prefrontal cortical 
tissues in the adult stage 
221
. This suggests that sex hormones may have an effect on DNA 
methylation, which impacts sexually different characteristics of the human brain. In a previous 
study, a DNA hypermethylation value of 5 CpG positions within the SHANK2 gene was found in 
a male patient with ID and developmental delay 
138
. In addition, SHANK3 CpG islands were 
highly methylated in tissues where protein expression is low and vice versa 
222
. By performing an 
in-depth investigation of the SHANK3 locus in human and mouse, it has been shown that DNA 
methylation patterns in SHANK3 regulate intragenic promoter activity, leading to a tissue-
specific differential expression 
223
. These results indicate that the expression of SHANK genes is 
sensitive to the DNA methylation pattern. As DNA methylation is the upstream regulator of the 
gene expression, comprehensive analyses that combine methylation and gene expression are 
crucial to reach a better understanding of the sex bias in ASD 
221
. 
Taken together, the data presented here revealed an effect of sex hormones on SHANK gene 
expression in addition to a sex-differential Shank expression in mice cortices. This can provide a 
novel insight into the understanding of the sex bias in the pathophysiology of ASD. 
4.2 SHANK2A and SHANK2A(R462X) overexpression in the glutamatergic 
neurons in the mouse forebrain  
Mutations in SHANK genes are associated with different severities of ASD, with SHANK1 
mutations displaying a mild phenotype, while SHANK2 and SHANK3 exhibit profound and 
severe phenotypes 
124,224
. This suggests that SHANK proteins have different but complementary 
interrelated functions at the excitatory glutamatergic synapses during the course of mammals‘ 
development. By the overexpression of SHANK2A isoform or the truncated SHANK2A(R462X) 
in transgenic mice Tg
SHANK2A
 and Tg
SHANK2AR462X
, respectively, the developmental and 
physiological regulation of endogenous SHANK expression was bypassed. Thus, in contrast to 
the traditional Shank knock-out mouse models, compensatory mechanisms of the remaining 
endogenous Shank genes had a very minor impact on the phenotype of Tg
SHANK2A
 and 
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Tg
SHANK2AR462X
 mice. Moreover, the expression of endogenous Shank genes in the hippocampus 
of Tg
SHANK2A
 and Tg
SHANK2AR462X 
mice was not altered, as shown by the nCounter analysis. Thus, 
the phenotypes of both transgenic mice were directly mediated by the transgenic SHANK2A 
variants. As indicated by the 12-fold overexpression of the transgenic SHANK2A variants (when 
compared to the endogenous SHANK2), the structure and organization of the SHANK scaffold 
was dominated by the transgenic, SHANK2A or SHANK2A(R462X). Nevertheless, the total 
hippocampal transgenic SHANK2A and SHANK2A(R462X) overexpression was only 1.6 fold 
relative to the total hippocampal SHANK1-3 expression, suggesting that the protein overload 
was still in a physiological and not in a toxic range. The transgenic overexpression of 
SHANK2A proteins might critically disrupt the postsynaptic organization in the brain regions 
that are known to be implicated in ASD - such as cortex, hippocampus and striatum 
225-232
. This 
enabled the direct study of molecular, physiological and behavioral effects that originated from 
the transgenic SHANK2A-mediated dysfunctions in the glutamatergic neurons in mice. Due to 
the high complexity of the SHANK scaffold, cell-type specific Shank knock-out models could 
not solve the crucial function of the different Shank2 genes and their isoforms. This is best 
exemplified by the mild ASD-like behavior of two mouse lines with a specific SHANK2 
depletion in excitatory αCaMKII expressing neurons 
143,147
. Shank2
Δex15-16–CaMK2a-Cre
 mice 
showed mild hyperactivity, and Shank2
Δex24–CaMK2a-Cre
 did not reveal any hyperactivity. 
Compared to Tg
SHANK2A 
and Tg
SHANK2AR462X
 mice, Shank2
Δex15-16–CaMK2a-Cre
 mice revealed normal 
body weight and no repetitive behaviors 
147
. In contrast, the overexpression of SHANK variants 
in the same αCaMKII expressing neuronal population of Tg
SHANK2A
 and Tg
SHANK2AR462X
 mice 
showed a severe ASD-like phenotypes, demonstrating a more severe disruption of the SHANK 
organization compared to the loss of only Shank2 in Shank2
Δex15-16–CaMK2a-Cre
 and Shank2
Δex24–
CaMK2a-Cre
 mice, which justifies the overexpression approach for the analysis of gene function in a 
complex protein networks. 
4.2.1 Autistic-like behavior and dysregulated gene expression in Tg
SHANK2A
 and 
Tg
SHANK2AR462X
 mice 
The analysis of locomotor activity, stereotypic, anxiety, social and cognitive behavior of 
Tg
SHANK2A
 and Tg
SHANK2AR462X
 mice revealed that both lines expressed a behavioral phenotype 
described for most of the published Shank2 knock-out mice lines.  Mice from both Tg
SHANK2A
 and 
Tg
SHANK2AR462X
 lines exhibited line-specific impairments in the balancing performance and 
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stereotypic self-grooming and jumping behavior. A similar line-specific difference in the 
repetitive behavior has been shown before in the two related Shank2 knock-out mouse models, 
Shank2
Δex15-16 
and Shank2
Δex16
, which were actually expected to reveal very similar phenotype as 
both express a truncated version of SHANK2 due to a frameshift in the PDZ domain (Figure 3) 
133
. Shank2
Δex15-16
 mice exhibited increased jumping and upright scrabbling in the home cage and 
increased self-grooming in the novel object recognition arena 
141,145
. In contrast, Shank2
Δex16
 
mice showed increased self-grooming in the home cage 
146
. Self-grooming and jumping are 
associated with several brain regions including cortex, hypothalamus, striatum, cerebellum and 
amygdala 
233,234
. This discrepancy suggests already the role of a small genetic variation of the 
SHANK2 gene mutation on the expression of ASD-like symptoms in mice by potentially 
affecting different signaling pathways in different brain regions. 
In both Tg
SHANK2A
 and Tg
SHANK2AR462X
 mice, the SHANK2A variant overexpression was 
associated with different levels of increased locomotor activity. The locomotion speed in the 24 
hrs LABORAS recording was found to be increased in both lines. The hyperactivity might also 
explain the reduced cliff avoidance reaction in Tg
SHANK2A
 and Tg
SHANK2AR462X
 mice. However, in 
the context of other behavioral impairments, the decreased cliff avoidance reaction was more 
likely due to a lack of behavioral inhibition that is closely linked to the attention and sociability 
deficits seen in animal models for ADHD 
235-237
 and ASD 
238-241
. 
In the tests for the ‗activities of daily living‘, the burrowing and nesting tests, Tg
SHANK2A
 mice 
performed very poorly. For Tg
SHANK2AR462X
 mice, the score for the nesting behavior was only 
slightly reduced. Since poor nest building is also recognized as a proxy for sociability 
242
, this 
result might already indicate a minor impairment in the sociability of Tg
SHANK2AR462X
 mice. 
In the context of cognitive dysfunction, as a comorbidity of ASD, Tg
SHANK2A
 and Tg
SHANK2AR462X
 
mice showed impairment in executive tasks in the puzzle box. The high latency to solve the 
puzzle by Tg
SHANK2AR462X
 mice is in line with a previous pilot study that showed cognitive 
dysfunction in mice with rAAV-mediated SHANK2A(R462X) overexpression 
136
. This suggests 
a dominant negative effect exerted by the SHANK2A(R462X) truncated isoform on intra-
hippocampal pathways that play a role in the formation and storage of memory 
243
. 
Unfortunately, the cognitive behavior was analyzed for the Shank2 knock-out mice just in the 
Morris water maze and for the transgenic animals just in the Puzzle box and therefore, the 
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detailed comparison of the cognitive impairment still needs to be analyzed. The cognitive 
dysfunction in both transgenic mouse lines was accompanied by a downregulation of AMPAR 
subunit expression in the hippocampus. Reduced function of AMPAR has been shown to induce 
cognitive impairments associated with ASD and SCZ symptoms 
244,245
. Moreover, the loss of 
GluA1 subunit in GluA1 knock-out mice significantly impaired the problem-solving ability in 
the puzzle box 
246
. Similar downregulation of AMPAR subunit expression was found in the 
hippocampus of Shank2 knock-out mice: GluA1 subunit in Shank2
Δex15-16 
and Shank2
Δex16
 mice 
146,247
 and both GluA1 and GluA2 subunit in Shank2
Δex24
 mice 
143
. 
In the memory of fear, the SHANK2A and SHANK2A(R462X) overexpression provided 
inconsistent results. Tg
SHANK2A 
mice associated the tone and the context with the painful electric 
shock, while Tg
SHANK2AR462X 
mice responded just in the context with reduced freezing. The 
impaired contextual fear memory in Tg
SHANK2AR462X
 but not Tg
SHANK2A
 mice may be a result of the 
downregulation of Serotonin receptor 2A subunit or Oxytocin receptor expression in the 
hippocampus of Tg
SHANK2AR462X
 mice. Serotonin and oxytocin are known to modulate contextual 
fear memory in mice 
248-252
, which is suggested to be a function of hippocampus activation, 
especially in DG and CA3 regions 
253
. DG is suggested to impose a distinct firing pattern on the 
CA3 region which forms an auto-associative network through the extensive collaterals present in 
that region 
254,255
. On the other hand, the role of the CA1 region is not completely understood, 
but it is thought to host a variety of both essential and modulatory functions including memory 
consolidation 
256
, generalization 
257
 and encoding of specific items and their inter-relation within 
the context 
258-260
. Therefore, the DG and CA3 regions form the initial memory framework that 
supports rapid conditioning 
261,262
, and all other hippocampal regions subsequently expand upon 
this framework to create a more comprehensive representation as the session continues 
253
. For 
the cued fear memory which is known to require amygdala function, Tg
SHANK2A 
and 
Tg
SHANK2AR462X
 mice did not reveal any impairment. This suggests that the amygdala is not 
affected in both mouse lines 
263
. Tg
SHANK2A 
and Tg
SHANK2AR462X
 mice showed a decrease in the 
freezing percentage in the acquisition phase, which can be explained by the hyperactivity of both 
mouse lines in the new arena. 
In summary, the line-specific alterations in the profiles of stereotypic behavior, hyperactivity, 
anxiety, life performance, fear conditioning and poor cognition of Tg
SHANK2A 
and Tg
SHANK2AR462X
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mice are reminiscent to the heterogeneous ASD-like phenotypes in the three Shank2 knock-out 
mouse models Shank2
Δex15-16
, Shank2
Δex16
 and Shank2
Δex24
 (for a review, see 
133
).  
The most radical behavioral difference between the two transgenic lines was found in their 
response to novel objects and unfamiliar mice. Tg
SHANK2A 
mice showed the typical ASD-like 
ignorance to novelty and were not interested in social contacts in the three-chamber and the 
direct social interaction test. Tg
SHANK2AR462X 
exhibited exactly the opposite activity pattern with 
increased contacts to novel objects and interactions to unfamiliar mice. Social novelty 
recognition of an old vs. new social stranger in the three-chamber social test could be observed 
neither in Tg
SHANK2A
, Tg
SHANK2AR462X
 nor control mice, which was also observed in the PV-neuron 
cell type-specific knock-out of Shank2 
264
. Thus, the overexpression of two related SHANK2A 
variants was associated with very selective and different phenotypic behaviors, similarly to the 
diverse SHANK2 patients, who were diagnosed with different neuropsychiatric disorders as SCZ-
like or ASD-like phenotypes. The dramatic opposite social behavior of Tg
SHANK2A 
and 
Tg
SHANK2AR462X
 mice is novel in Shank mutant mice. According to this parameter, Tg
SHANK2A
 mice 
showed a pure ASD-like phenotype, while the phenotype of Tg
SHANK2AR462X
 mice might belong to 
ADHD 
235-237
 since both ASD and ADHD mouse models share the lack of behavioral inhibition 
"ADHD 
235-237
 and ASD 
238-241
". The discrepancy in the social behavior between Tg
SHANK2A
 and 
Tg
SHANK2AR462X
 mice suggests opposite effects of the two isoforms on the social circuits in the 
forebrain, e.g. the prefrontal-hippocampal-amygdala pathway. Moreover, the social impairment 
in Tg
SHANK2A
 but not Tg
SHANK2AR462X
 mice was accompanied by a downregulation of NMDAR 2A 
and 2B subunit expression in the hippocampus. As NMDAR-mediated neurotransmission is 
important in the regulation of normal sociability in mice 
265-268
, the dysregulation of NMDAR 
expression in the hippocampus may account for the severe social impairment in Tg
SHANK2A
 mice. 
In previous studies, Shank2 knock-out mouse models showed a dysregulation in NMDAR 
subunit expression. GluN1 subunit expression was reduced in the hippocampus of Shank2
Δex15-16
 
and Shank2
Δex24
 knock-out mice but increased in Shank2
Δe16
 
141-143
. On the other hand, both 
GluN2A and GluN2B subunit expression was increased in the hippocampus of Shank2
Δe16
 and 
Shank2
Δex24
 knock-out mice 
141-143
. The reason for this discrepancy between these mice is still 
unknown, and the question is open as to whether the differential expression is a result of the loss 
of Shank2 or acts as a compensatory mechanism by other Shank members. 
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The imbalance of the excitatory and inhibitory signals and disturbance in network synchrony 
play a role in ASD manifestation 
183-188,269,270
. Therefore, the interneuronal marker PV, known to 
be implicated in brain excitation and rhythms, as well as brain dysfunctions 
271-276
, was 
investigated in Tg
SHANK2A
 and Tg
SHANK2AR462X
 mice. The PV immunosignal in the hippocampus of 
Tg
SHANK2A
 mice was reduced compared to Tg
SHANK2AR462X
 and control mice. The observed 
reduction in the PV immunosignal can be either a result of a decrease in gene expression levels 
and/or a decrease in the numbers of PV-positive neurons due to perturbed developmental state or 
premature cell death 
277
. If there is a decrease in the PV expression, it can result in enhanced 
inhibition 
277
. In contrast, the loss of the PV-positive neurons can cause reduced inhibition 
277
. 
One way to answer this question is to perform staining for Vicia Villosa Agglutinin (VVA) which 
recognizes the specific extracellular matrix enwrapping the PV-positive neurons 
278
. The reduced 
expression of PV was previously shown in many mouse models of ASD including two Shank1 
and Shank3 knock-out mouse lines 
277,279,280
. However, the level of PV expression was not 
investigated before in conventional Shank2 knock-out mouse models. Shank proteins were 
also found to be expressed in PV-positive neurons, and limiting the Shank2 deletion to these 
neurons has led to hyperactivity, enhanced self-grooming and suppressed brain excitation, 
indicating a direct link between Shank and PV and that Shank2 may regulate PV expression at 
the transcriptional level.   
4.2.2 AMPAR conductance imbalance in the apical and basal dendrites in the CA1 
hippocampal region of Tg
SHANK2A 
mice 
The electrophysiological studies in the hippocampal CA1 cells were used to identify the 
alternation in the fast glutamatergic neurotransmission at the synaptic level. The 
electrophysiological recordings of Tg
SHANK2A 
mice revealed an impaired AMPA/NMDA ratio in 
the apical dendrites of the hippocampal CA1 region. AMPARs are composed of four types of 
subunits, designated as GluA1, GluA2, GluA3, and GluA4, which form tetramers 
281,282
. Most 
AMPARs are heterotetrameric, consisting of symmetric 'dimer of dimers' of GluA2 and either 
GluA1, GluA3 or GluA4 
283,284
. The AMPAR impermeability to Ca
2+
 is mediated by the GluA2 
subunit 
285
. The increase in AMPA/NMDA ratio in the apical dendrites in Tg
SHANK2A 
mice is due 
to either an increase in the number of AMPARs or switching the type of AMPARs into the 
GluA2-lacking Ca
2+
 permeable channels. The effect of the drug Naspm, which specifically 
blocks the Ca
2+
 permeable channels, revealed increased Ca
2+
 permeable channels in the apical 
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dendrites as EPSCs were reduced after the drug treatment. Moreover, the effect of Naspm on 
EPSCs in the basal dendrites was absent in Tg
SHANK2A 
mice in contrast to control mice, suggesting 
an increase in the number of Ca
2+ 
impermeable channels in the basal dendrites of Tg
SHANK2A 
mice. 
The switch of AMPAR subunit between the apical and basal dendrites in Tg
SHANK2A 
mice led to 
an absence of LTP in basal dendrites. However, the increase of GluA2-lacking channels in the 
apical dendrites and their decrease in the basal dendrites need to be confirmed by the 
immunostaining of GluA2 subunit. Recently, it has been shown that Shank proteins can mediate 
Zn
2+
-dependent regulation of AMPAR function by allowing the AMPAR subunit switch in the 
developing neurons from GluA2-lacking to GluA2-containing AMPARs, which contributes to 
synaptic maturation and plasticity 
286
. The SHANK protein family plays a major role in retaining 
and maintaining AMPAR at synapses by anchoring endocytic zones adjacent to the PSD 
287,288
. 
Moreover, the SH3 protein domain of SHANKs has been shown to be important in AMPAR 
trafficking through interaction with GluA2 via GRIP or by direct modulation of GluA1 
trafficking via the Rich2- or mGluR- dependent pathways 
34,91,289-291
. Mutations in GRIP1 have 
been found in ASD patients 
292
. These mutations are suggested to have either a gain of function 
effect leading to accelerated GluA2 recycling 
292
 or a loss of function one resulting in delayed 
GluA2 recycling in primary neurons 
293
. Shank3 knockout mice revealed a reduction in GluA1 
clusters and protein levels in the hippocampus, and an alteration in activity-dependent AMPAR 
synaptic plasticity 
294,295
. In hippocampal neurons knocked down for Shank3, a reduction in cell 
surface expression of GluA1 without a reduction in its protein expression was noticed which was 
correlated with the reduced mEPSC frequency, reflecting impairment in activity-dependent 
synaptic recruitment of AMPARs at basal conditions 
290
. Moreover, in the CA1 region of the 
hippocampus, Shank2
Δex15-16 
and Shank2
Δex24
 knockout mice showed increased AMPA/NMDA 
ratio 
141,143
. In contrast, Shank2
Δex16
 mice showed a decreased AMPA/NMDA ratio which had 
subsequently an effect on the AMPAR function and synaptic development leading to ASD-like 
phenotypes in mice 
142
. Therefore, SHANK2 is critical for AMPAR recruitment and functionality 
in multiple brain circuits and any change in this normal developmental process of AMPARs is 
likely to be particularly vulnerable to risk factors for ASD. 
In contrast to Tg
SHANK2A 
mice, Tg
SHANK2AR462X
 mice had no impairment on the electrophysiological 
level. Previously, the rAAV-mediated SHANK2A(R462X) overexpression in the forebrain of P0 
mice revealed an increase in the total number of AMPARs and AMPAR clusters in the stratum 
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radiatum of the hippocampus, which is thought to be mediated by alterations in the distribution 
of synaptic and extrasynaptic AMPAR 
136
. Also, a reduced localization of AMPAR in spine 
heads was detected 
136
. The effect of SHANK2A(R462X) overexpression demonstrated also a 
reduced average mEPSC amplitude, suggested to be caused by the postsynaptic reduction in the 
density of AMPARs 
136
. In Tg
SHANK2AR462X
 mice, however, no effect on EPSC amplitude or 
AMPA/NMDA ratio was detected. The discrepancy between these results can be explained by 
the overexpression of SHANK2A(R462X) only in the excitatory neurons in Tg
SHANK2AR462X
 mice, 
while it was expressed in all neurons under the control of synapsin 1 promoter in rAAV-
mediated SHANK2A(R462X).  
4.2.3 Synaptosome proteomic analysis in Tg
SHANK2A
 and Tg
SHANK2AR462X
 mice  
The effect of the SHANK2A and SHANK2A(R462X) overexpression on the expression of the 
synaptic proteins was investigated using mass spectrometry. The analysis of synaptosome 
proteomic can give insight into the synaptic dysfunction in Tg
SHANK2A
 and Tg
SHANK2AR462X
 mice. 
The overexpression of SHANK2A revealed a higher effect than SHANK2A(R462X) on the 
abundance of synaptic proteins, suggesting more synaptic dysfunction in  Tg
SHANK2A
 mice. In 
Tg
SHANK2A
 mice, the total SHANK2 level at the synapse was 2.5 fold its level in control mice 
(Figure 45). As suggested by the nCounter analysis measuring Venus expression on RNA level, 
SHANK2A expression is 12 times higher than that of the endogenous Shank2. This indicates that 
either not all the expressed SHANK2A transgene is localized in the PSD due to its size limitation 
or most of the overexpressed SHANK2A is degraded after translation. Due to the lack of an 
efficient Shank2 antibody that binds to both human and mouse Shank2 proteins with the same 
affinity, these hypotheses yet have to be confirmed. In Tg
SHANK2AR462X
 mice, the abundance of 
SHANK2 protein in the synapses of the hippocampus was not different from the control mice 
(Figure 45). This can be a result of the inefficiency of the mass spectrometry to identify the 
truncated form of SHANK2. Another explanation is that SHANK2A(R462X) does not localize 
in the spines but localizes mainly in the soma and dendrites where it exerts a dominant negative 
effect, as shown in the rAAV-mediated SHANK2A(R462X) overexpression 
136
. The localization 
of SHANK2A(R462X) in the soma and not in spines where synapses are formed is consistent 
with the normal electrophysiological measurements in Tg
SHANK2AR462X
 mice. To this end, another 
pathway of the effect of SHANK2A(R462X) overexpression leading to the behavioral 
abnormalities is considered. By taking a closer look at the proteins which were differentially 
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abundant, the organization of SHANK proteins in the PSD of Tg
SHANK2A
 mice is clearly affected 
due to a 30% reduced localization of both Shank1 and Shank3 protein in response to the high 
abundance of SHANK2A (for a list of differentially expressed proteins, see Appendix 4). This 
suggests the close relationship between the three SHANK proteins and the compensation of their 
expression and function by each other. Previously, brain–region-specific biochemical analysis of 
synaptosomes in Shank2
Δe16 
knockout mice revealed that the loss of Shank2 results in synaptic 
upregulation of Shank3. Most interestingly, this phenomenon also happens after the transient 
knock-down of Shank2 in rat primary hippocampal cultures and is only seen on the protein level 
implying a local regulatory mechanism, which may be a potential target for pharmacological 
intervention 
142
. By comparing these results to the effect of SHANK2A overexpression on the 
expression of other SHANK members on RNA level, the endogenous Shank1 and Shank3 
expression was not affected. Because mRNA was extracted from the whole hippocampus, the 
small difference in the expression level of Shank1 and Shank3 in specific cell types between 
Tg
SHANK2A
 and control mice may be diluted. Moreover, the SHANK2A overexpression may have 
a specific effect only on the localization of other Shank members in the PSD but not on the 
expression level. In Tg
SHANK2AR462X 
mice, no abundance difference of Shank1 or Shank3 was 
detected confirming the non-localization of SHANK2A(R462X) in the PSD (Figure 45).  
 
Figure 45: Putative Shank1-3 organization in the postsynaptic synaptosome compartment of the 
excitatory glutamatergic neurons in Tg
SHANK2A
, Tg
SHANK2AR462X 
and control
 
mice 
Schematic diagrams of the putative PSD in Tg
SHANK2A
, Tg
SHANK2AR462X
 and control mice. In control mice, the 
Shank3 expression is the highest compared to the expression of other Shank protein family members. In 
Tg
SHANK2
 mice, the organization of Shank proteins in the PSD is dominated by SHANK2A, and the expression 
of the endogenous Shank1 and Shank3 was 30% reduced compared to their expression control mice. In 
Tg
SHANK2AR462X
 mice, the expression of SHANK2A(R462X) was not localized mainly in the synaptosome and 
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had no effect on the expression of the endogenous Shank1 or Shank3. However, other negative effects exerted 
by the SHANK2A(R462X) overexpression may dominate some functions of the Shank protein family. 
The pathway analysis and molecular gene ontology of differentially abundant proteins in 
Tg
SHANK2A
 and Tg
SHANK2AR462X
 mice were performed using the online software ConsensusPathDB 
in order to study the most likely affected pathways. The analysis revealed a disruption of 
glutamatergic synapses and glutamate receptor binding affecting mainly the synaptic membrane 
in the spines of Tg
SHANK2A
 mice. The dysfunction of glutamatergic synapses is well known to be 
associated with ASD phenotypes (for a review, see 
296
). For the biological process analysis, 
mouse behaviors including social and learning and memory were predicted to be affected which 
is consistent with the behavioral analysis of Tg
SHANK2A
 mice. Moreover, the regulation of 
AMPAR activity and LTP were suggested to be disturbed, consistent with the 
electrophysiological results of the AMPAR subunit switch in the apical and basal dendrites. The 
pathway and gene ontology analysis of differentially abundant proteins in the synaptosomes of 
Tg
SHANK2AR462X 
mice revealed that axon and dendrites‘ branching due to the dysfunction of 
semaphorin receptor activity is most likely affected. Semaphorins are a class of secreted and 
membrane proteins that play an important role in neural system development by guiding axons to 
their target regions in the brain 
297,298
. In a previous study, changes in the numbers and sizes of 
axons were found in the cortex of ASD patients 
299
. Alterations of the morphology of dendrites 
were also found in human and mouse models of ASD (for a review, see 
300
). Moreover, axon 
guidance pathways strongly influence human speech and language, and deficits in language and 
communication are hallmarks of ASD 
301
. These findings stress the importance of normal axons 
and dendrites formation for proper brain development and provide a mechanism of the excessive 
connections between neighboring areas in the brain of ASD patients. These excessive 
connections may explain why individuals with ASD show the phenotypes of inability to shift 
attention, engaging in repetitive behavior and social impairment 
299
.  
By performing biological process analysis of the differentially abundant proteins in the 
hippocampus of Tg
SHANK2A
 and Tg
SHANK2AR462X 
mice using the ConsensusPathDB software, both 
mouse lines are predicted to have abnormal behaviors. This indicates that ASD phenotypes are 
not exclusive to the synaptic dysfunction, and that the impairment in axon and dendrites‘ 
branching leading to excessive neurons that cause local over-connectivity could be a key feature 
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of ASD pathophysiology 
302
. Therefore, the effect of the transgene overexpression on the 
structure of axons, dendrites and spines should be further investigated in detail by Golgi staining. 
4.2.4 Rescue of some autistic phenotypes in Tg
SHANK2A
 and Tg
SHANK2AR462X
 mice after 
switching off the transgene overexpression in adulthood 
It has been suggested that some symptoms of ASD are due to prenatal processes, like impaired 
neuronal migration during early gestation, for example, that cannot be reversed in adulthood. The 
temporal control of the transgene overexpression in Tg
SHANK2A
 and Tg
SHANK2AR462X
 mice allowed 
the investigation of the reversibility of autistic features in adulthood by recovering the SHANK 
organization and the normal level of the polycistronic SHANK2 expression. Here four weeks of 
dox diet in water was applied on adult mice (5 – 8 months), instead of one-week treatment 
303
, to 
switch off the tTA-dependent transgene expression.  
In Tg
SHANK2A
 and Tg
SHANK2AR462X
 mice, the decrease and increase of the social interaction, 
respectively, were rescued after the stop of the transgene overexpression in adulthood. This 
indicates that certain circuits related to autistic features have a plasticity that can be rescued after 
the critical developmental stage. Thus, although SHANK2A overexpression inhibited the 
formation of networks involved in social learning during development, the action of the 
sociability network could be rebuilt when the genetic reason was eliminated. The rescue of the 
social impairment in dox-treated Tg
SHANK2A
 was accompanied by a rescue of the reduced 
expression of NMDAR subunits in the hippocampus. This is consistent with a previous study 
showing that the activation of NMDAR or enhancing its function using NMDAR agonists or via 
mGluR5 activation in adult mouse brains can rescue the social impairment but not other 
behavioral abnormalities in a Shank mouse model of ASD 
141
. In that study, the treatment of 
Shank2
Δex15-16
 knock-out mice with D-cycloserine as a partial agonist at the glycine-binding site 
of NMDAR showed a rescue of the NMDA/AMPA ratio and social impairments 
141
. Moreover, a 
positive allosteric modulator of mGluR5, (3-cyano-N-(1,3-diphenyl-1H-pyrazol-5-yl) 
benzamide) (CDPPB), which enhances the NMDAR function via mGluR5 activation, led to a 
normalization of NMDA/AMPA ratio and a restoration of the impaired LTP and LTD at Schaffer 
collateral-CA1 pyramidal (SC-CA1) synapses in the hippocampus of Shank2
Δex15-16
 mice 
141
. 
Importantly, CDPPB did not rescue other autistic features like repeated jumping, anxiety-like 
behaviors or hyperactivity, which suggests that reduced NMDAR signaling in the hippocampus 
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leads to impaired social interaction but not other autistic-like behaviors. Another way to activate 
NMDAR in Shank2
Δex15-16
 knock-out mice was performed by the postsynaptic Zn
2+
 elevation 
induced by a Zn
2+
 chelator called clioquinol 
304
. Zn
2+
 is mainly derived from presynaptic pools 
and activates NMDAR through postsynaptic activation of the tyrosine kinase Src 
305
. Treating 
Shank2 knock-out mice with clioquinol (2 hrs before the behavior experiment) has been shown 
to enhance social interaction 
304
. On the other hand, the NMDA/AMPA ratio in the hippocampus 
of Shank2
Δe-16
 knock-out mice was increased with enhancing LTP and upregulation of NMDAR 
subunits 
142
. In this regard, it certainly has to be further clarified whether the loss of Shank2 leads 
to NMDAR hyper- or hypofunction and if the observed NMDAR upregulation can, therefore, be 
interpreted as causative or compensatory with respect to the corresponding physiological 
phenotype 
133
. In general, it can be concluded that maintaining a normal range of NMDAR 
function in the brain is important, as both over- and under- regulation of NMDAR transmission 
may result in abnormal behavioral phenotypes 
133
.  
The rescue of other SHANK2 overexpression-linked behaviors was not as clear-cut. The 
repetitive behavior patterns, hyperactivity, anxiety, impulsive behavior and cognitive dysfunction 
were not rescued in Tg
SHANK2A
 or Tg
SHANK2AR462X
 mice after the stop of the transgene 
overexpression in adulthood. Moreover, the non-rescue of cognitive dysfunction was 
accompanied by no rescue of the downregulation of AMPAR subunit expression in the 
hippocampus, confirming their role in the learning and memory 
306,307
. In the fear conditioning 
test, both dox-treated Tg
SHANK2
 and Tg
SHANK2AR462X
 mice showed higher memory retrieval in the 
cued phase compared to their dox-treated littermates for unknown reasons.  
In conclusion, continued neural plasticity is present in the adult mouse brain, especially 
regarding the social circuits. This can pave the way to rescue at least some ASD symptoms in 
adulthood. Moreover, the irreversible behavioral deficits may also be improved with early 
postnatal intervention, which should be further investigated.  
4.2.5 Specific autistic-like behaviors in mice caused by SHANK2A overexpression after 
development 
The SHANK2A overexpression in Tg
SHANK2A
 mice was temporally controlled after development 
to test whether some autistic-like behaviors can still be developed after the critical 
developmental stage. In a previous study, it has been shown that the expression of the GFP 
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transgene by tTA-dependent tetracycline promoter was already present at P0, which indicated 
that the functional activity of the αCaMKII-tTA
 
transgene was already present in newborn mice 
308
. Pregnant mice were given dox until labor to switch off the SHANK2A overexpression during 
the embryonic and early postnatal stages, confirming the absence of the transgene expression 
during most of the critical developmental period. Immunoblotting of protein lysates from 
different brain regions of adult P0 dox-treated Tg
SHANK2A
 mice, when their mothers were given 
dox until birth, revealed high expression levels of SHANK2A and other reporter proteins, but 
lower than the transgenic SHANK2A expression in Tg
SHANK2A
 mice that expressed SHANK2A 
during development. This indicates that the tTA-dependent tetracycline promoter did not return 
back to its complete efficiency due to its silencing during development in the absence of the 
active tTA, as shown previously 
309
. According to that study, the tTA-dependent tetracycline 
promoter can be unsilenced only in cell types with very high tTA activity after the full washout 
of dox 
309
.  
The behavioral analysis of adult P0 dox-treated Tg
SHANK2A 
mice revealed hyperactivity, anxiety 
and repetitive rearing. Moreover, they displayed cognitive dysfunction accompanied by a 
downregulation of AMPAR subunits expression in the hippocampus. However, these mice 
exhibited no social impairment. This suggests that not all aspects of autistic disorders are 
mediated by early neurodevelopment, while social circuits may be formed mainly during the 
early developmental stage. This hypothesis is supported by studies showing that the preterm birth 
is associated with social difficulties in infants and increased risk of ASD 
310-312
  (for a review, see 
313
). 
The normal social interaction in these mice was accompanied by a normal NMDAR expression 
in the hippocampus. This confirms again that the social impairment in Tg
SHANK2A 
mice is due to 
the NMDAR dysfunction, although NMDAR-independent mechanisms may also play a role.  
In all performed behavioral tests, adult P0 dox-treated Tg
SHANK2A 
mice did not show such a severe 
phenotype as Tg
SHANK2A 
mice that express the transgene during development. This is in line with 
the study which revealed that autistic patients with late ASD manifestations were found to 
exhibit less severe and global developmental disruption 
314
. This again highlights that ASD is 
mainly a neurodevelopmental disorder, however, some features with reduced severity can still be 
developed later in life. 
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4.2.6 Conclusion 
The high prevalence of non-synonymous SHANK mutations in ASD and the variable 
phenotypes reported for different Shank mouse mutants suggest a broad repertoire of possible 
functional alterations in the SHANK-mediated organization that contribute to ASD. The 
approach used in this study provided a comprehensive model of synaptic alterations mediated by 
the disruption of SHANK proteins in the glutamatergic neurons. One conclusion from this study 
is that the disturbance in the expression of SHANKs has consequences on the function of the 
glutamatergic neurons and on the general, cognitive and social functions, ranging from ASD-
like to ADHD-like phenotypes when SHANK2A variants are not localized in the PSD. 
SHANK proteins play an important role in AMPAR trafficking in specific tissues, which 
leads to balanced and organized AMPAR signaling, By the overexpression of SHANK2 
variants, the AMPAR levels seem to be reduced, which is associated with the irreversible 
hyperactivity and cognitive dysfunction. Notably, not all affected neuronal circuits in 
SHANK-related ASD/ADHD are due to neurodevelopmental dysfunctions, hence, they can be 
reversed or treated in adulthood. The finding that a balanced NMDAR subunit expression in the 
hippocampus is necessary for a normal social behavior is of great interest and can pave the way 
for the development of novel molecular diagnoses and treatments for Shankopathies in ASD. In 
conclusion, a balanced expression and a proper dosage of SHANK2 along with other SHANK 
members throughout life are necessary for appropriate organization of synaptic proteins and 
receptors and for normal brain function.  
4.2.7 Future perspective 
This study has demonstrated that the truncated versions of SHANK2 can have dominant negative 
effects even when they are not localized at the PSD. Therefore, the expression of residual 
truncated Shank2 isoforms in the previously generated Shank knock-out mice should be further 
investigated, which can explain the distinct phenotype in these mice. Moreover, the full battery 
of behavioral analysis covering ASD, SCZ, mania and ADHD has to be applied to cover the 
wide range of expected phenotypes. In addition, male and female littermates need to be 
compared to unravel gender effects on the expression of the phenotypes. 
Knock-in mice with genetic variants in Shank genes resembling the identical genetic defects of 
human ASD patients should contribute to explaining the distinct human phenotypes and help to 
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discover the affected crucial neuronal circuits and cell types underlying the abnormalities. An 
investigation as to whether there is a critical period of the affected circuits and underlying 
phenotypes should be carried out in these mice. The affected neuronal populations in these mice 
can then be targeted and analyzed in great detail during the behavioral analysis by novel 
physiological technologies, e.g. multicellular recordings and optogenetics. Once the impairments 
in these circuits are confirmed, strategies for effective treatment can be developed. However, the 
ultimate goal remains the translation of these new findings into treatment options for human. 
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         Appendix 
 
Appendix 1: Primer sequences 
All primers were designed with the Primer3, Primer-BLAST tools or taken from the 
Universal Probe Library Assay Design Center (Roche). 
Cre-Primer:         F: 5‘-GCGATTATCTTCTATATCTTCAGG-3‘ 
    R: 5‘-GCCAATATGGATTAACATTCTCCC-3‘ 
Arflox primer:     F: 5‘-AGCCTGTATACTCAGTTGGGG-3‘ 
                            R: 5‘-AATGCATCACATTAAGTTGATACC-3‘ 
Sry-primer:          F: 5‘-TATGGTGTGGTCCCGTGGTG-3‘ 
     R: 5‘-ATGTGATGGCATGTGGCTTCC-3‘ 
Ca25-primer:  5‘-GCTCAGAAGCCCCAAGCTCG-3‘   
Casli3-primer:   5‘-TAAGCAGCTCTAATGCGCTGTTA-3‘ 
Cas25as-primer: 5‘-CAGCGCCTAACTCTGGACACC-3‘ 
β-globin 1-primer: 5‘-CAGTGGTATTTGGCCAGGGCA-3‘        
β-globin as1-primer: 5‘-ATAATTTGTCAGCAGTTTAAGGTTGCAAAC-3‘ 
β-globin as2-primer: 5‘-GAATATTTCTGCATATAACTGGCTGGCG-3‘ 
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Primer sequences of qPCR are given in the following table 
Primer Sequence (5’-3’) 
18S_F GATGGGCGGCGGAAAATAG 
18S_R GCGTGGATTCTGCATAATGGT 
GAPDH_F CTGGGCTACACTGAGCACC 
GAPDH_R AAGTGGTCGTTGAGGGCAATG 
HPRT1_F TGATAGATCCATTCCTATGACTGTAGA 
HPRT1_R AAGACATTCTTTCCAGTTAAAGTTGAG 
HSPD1_F GATGGAGAAGCTCTAAGTACACT 
HSPD1_R GCTGGTTCTTTCTATTGTCACCA 
SDHA_F TGGGAACAAGAGGGCATCTG 
SDHA_R CCACCACTGCATCAAATTCATG 
SHANK1_F CTCCCTGCGTTCCAAATCTA 
SHANK1_R GGCTGCTGCTCGTACTCC 
SHANK2_F CTTTGGATTCGTGCTTCGAG 
SHANK2_R CATCCACGGACTCCAGGTA 
SHANK3_F TTCCACGGACCAAGTCTGTA 
SHANK3_R GTCTTGCATCGAGGTGCTC 
MECP2_F GTGGAGTTGATTGCGTACTTCG 
MECP2_R CCCTCTCCCAGTTACCGTGAA 
PSD95_F TCACAACCTCTTATTCCCAGCA 
PSD95_R CATGGCTGTGGGGTAGTAGTCG 
18s_F CTTAGAGGGACAAGTGGCG 
18s_R ACGCTGAGCCAGTCAGTGTA 
Gapdh_F ACAGTCCATGCCATCACTGCC 
Gapdh_R GCCTGCTTCACCACCTTCTTG 
Hprt1_F TCCTCCTCAGACCGCTTTT 
Hprt1_R CCTGGTTCATCATCGCTAATC 
Hspd1_F AGCTGTTACAATGGGGCCAA 
Hspd1_R ATCCCCAGCCTCTTCGTTTG 
Sdha_F CATGCCAGGGAAGATTACAAA 
Sdha_R GTTCCCCAAACGGCTTCT 
mShank1_F GTCCTACCAGGCGCAAGGCG 
mShank1_R CCCAGAAGCCTCCTTCCCCGA 
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mShank2_F TGCTGCCAGTGACTGCATTATTGA 
mShank2_R CAGGGCTGGAAATGCTGGCGT 
mShank3_F AGGGAACCGTGAAGGGCCGA 
mShank3_R TGGCGGAAGAGACGCTTCGT 
Mecp2_F GCGAGGAGGAGAGACTGGA 
Mecp2_R TTCTTGTCTTTCTTCGCCTTCT 
Psd95_F CTCTGCGAAGCAACCCCAA 
Psd95_R TCTTCGTCGCTGGCGTCAATTA 
mAr_F GCCTCCGAAGTGTGGTATCC 
mAr_R TGGTCCCTGGTACTGTCCAA 
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Appendix 2: Buffers recipes  
Buffers recipes for gel electrophoresis  
50x TAE 
2420 g Tris 
571 ml acetic acid 
186.12 g EDTA 
→ 10 L H2O 
20x E-Buffer 
484.4 g (800 mM) Tris  
164.0 g (400 mM) Sodium acetate 
74.4 g (40 mM) EDTA 
—> dissolve in ddH2O, adjust pH to 8.3 with acetic acid (100 %) 
—> 5 L ddH2O 
 
Buffer recipes for western blot 
RIPA buffer (cell lysis buffer for protein isolation) 
0.606 g Tris 
0.877 g NaCl 
1 ml 10% SDS 
5 ml 10% Sodium deoxycholate 
1 ml NP-40 
→ 100 ml H2O 
5x SDS protein loading dye 
0.225 M Tris-HCl 
50% Glycerol 
5% SDS 
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0.05% bromophenol blue 
0.25 M DTT 
10x Running Buffer 
10.09 g SDS 
30.3 g Tris 
144 g Glycine 
—> 1 L ddH2O 
10x TBS 
88 g NaCl 
24.2 g Tris 
700 ml ddH2O 
—> adjust pH to 7.6 with HCl 
—> 1 L with ddH2O 
1x TBS-T 
Dilute 10x TBS 1:10 in ddH2O to make 1 L of 1x TBS and add 1 ml of tween 
10x Transfer buffer 
144 g Glycine 
30.3 g Tris 
2000 ml Methanol 
50 ml 10% SDS 
—> 1 L with ddH2O 
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  Resolving Tris Glycine gel 8%          Stacking Tris Glycine gel  
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
H2O 4.6 ml 
30% acrylamide mix 2.7 ml 
1.5 M Tris (pH 8.8) 2.5 ml 
10% SDS 100 µl 
10% ammonium 
persulfate 100 µl 
TEMED 6 µl 
H2O 1.4 ml 
30% acrylamide mix 330 µl 
1 M Tris (pH 6.8) 250 µl 
10% SDS 20 µl 
10% ammonium 
persulfate 20 µl 
TEMED 2 µl 
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Appendix 3: nCounter probe sequences 
 nCounter probe sequences for Ar
NesCre
 mice 
 
 
 
 
 
 
  Gene     Probe Sequence 
  Gapdh A ATGGGCTTCCCGTTGATGACAAGCTTCCCATTCTCCCTCAAGACCTAAGCGACAGCGTGACCTTGTTTCA 
 B CGAAAGCCATGACCTCCGATCACTCATTTGATGTTAGTGGGGTCTCGCTCCTGGAAGATGGTG 
  Hspd1 A CACAGTTCTTCCCTTTGGCCCCATTGTAACAGCTACAGCATCTGCTAAAACATCCTCTTCTTTTCTTGGTGTTGAGAAGATGCTC 
 B CGAAAGCCATGACCTCCGATCACTCGTGACCCCATCTTTTGTTACTTTGGGACTTCCCCAACTCTGTTCAATAAT 
Sdha A GTAATCATACTCATCGACCCGCACTTTGTAATCTTCCCTGGCATGGGCTCCACAATTCTGCGGGTTAGCAGGAAGGTTAGGGAAC 
 B CGAAAGCCATGACCTCCGATCACTCCAGTGTTCCCCAAACGGCTTCTTCTGCTGTCCCTGGATGGGCTTGGA 
 Hprt1 A AACAAATCTAGGTCATAACCTGGTTCATCATCGCTAATCACGACGCTGGGCTGTTGAGATTATTGAGCTTCATCATGACCAGAAG 
 B CGAAAGCCATGACCTCCGATCACTCGAGGAATAAACACTTTTTCCAAATCCTCGGCATAATGATTAGGTATACAA 
   Shank1 A TCACCGCCATGAAGGAGCGACCGGGTACCGCTGAATAGAGCTTCCTACGTCTTTCGGGTTATATCTATCATTTACTTGACACCCT 
 B CGAAAGCCATGACCTCCGATCACTCCTTTACTCAGAGAGATCTCCCCCTCGCCTTGCGCCTGGTAGGACT 
   Shank2 A TCCACGGACTCCAGGTACTGCAGGGCTGGAAATGCTGGCGTGGGTGTGAACAACAGCCACTTTTTTTCCAAATTTTGCAAGAGCC 
 B CGAAAGCCATGACCTCCGATCACTCTCCTTAGTCCGGCTTGCCATGCCACCCCACCTTCA 
   Shank3 A CTTCGTCCGGTCCTCTCTGGTTTCATGCCGGGTGTCATACTGTCGCACCGTGTGGACGGCAACTCAGAGATAACGCATAT 
 B CGAAAGCCATGACCTCCGATCACTCTGTGAAGTGAGGCTGTCATAGGAACCCACAGTGTAGTGGCGGAAGAGACG 
   Mecp2 A TGAACACCTTCTGATGCTGCTGCCTTTGGTCTCCCAGCCTGGAGTTTATGTATTGCCAACGAGTTTGTCTTT 
 B CGAAAGCCATGACCTCCGATCACTCGCATCTTGACAACAAGTTTCCCAGGGCTCTTCTCCAGGACCCTTTTCACC 
  Psd95 A GGCCTGGCTCAAGAAACCGCAGTCCTTGGTCTTGTCGTAGTCAAACAAACTGGAGAGAGAAGTGAAGACGATTTAACCCA 
 B CGAAAGCCATGACCTCCGATCACTCTCGTCGCTGGCGTCAATTACATGAAGCACATCCCCAAAGTGGAAGCTCAG 
Erα A AGGCTTCACTGAAGGGTCTAGAAGGATCATATTCAGAATAGATCATGGGCCCAGCAGACCTGCAATATCAAAGTTATAAGCGCGT 
 B CGAAAGCCATGACCTCCGATCACTCCTCCCTATCTGCTAGGTTGGTCAATAAGCCCATCATTG 
Erβ A GCCAGACGGACTGACTGCTGCTGGGAAGAGATTCCACTCTTCGAAATCACCCTGCCAATGCACTCGATCTTGTCATTTTTTTGCG 
 B CGAAAGCCATGACCTCCGATCACTCTGCCCTTGTTACTGATGTGCCTGACATGAGAAAGAAGCATCAGGAGGTTG 
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nCounter probe sequences for Tg
SHANK2A
 and Tg
SHANK2AR462X 
mice 
Gene Probe Sequence 
Gapdh A ATGGGCTTCCCGTTGATGACAAGCTTCCCATTCTCCCTCAAGACCTAAGCGACAGCGTGACCTTGTTTCA 
 
B CGAAAGCCATGACCTCCGATCACTCATTTGATGTTAGTGGGGTCTCGCTCCTGGAAGATGGTG 
Hspd1 A CACAGTTCTTCCCTTTGGCCCCATTGTAACAGCTACAGCATCTGCTAAAACATCCTCTTCTTTTCTTGGTGTTGAGAAGATGCTC 
 
B CGAAAGCCATGACCTCCGATCACTCGTGACCCCATCTTTTGTTACTTTGGGACTTCCCCAACTCTGTTCAATAAT 
Sdha A GTAATCATACTCATCGACCCGCACTTTGTAATCTTCCCTGGCATGGGCTCCACAATTCTGCGGGTTAGCAGGAAGGTTAGGGAAC 
 
B CGAAAGCCATGACCTCCGATCACTCCAGTGTTCCCCAAACGGCTTCTTCTGCTGTCCCTGGATGGGCTTGGA 
Hprt1 A CTCCGGAAAGCAGTGAGGTAAGCCCAACGCTCTCCCTGTTGAGATTATTGAGCTTCATCATGACCAGAAG 
 
B CGAAAGCCATGACCTCCGATCACTCCAAAAAGCGGTCTGAGGAGGAAGCCGGCGGAGGAGGTGCTACCG 
Pgk1 A GAGGAGAACAGCGCGGCAGACGTGCGCTTTTGAAGCGTGCAGAATGCCAAAGACGCCTATCTTCCAGTTTGATCGGGAAACT 
 
B CGAAAGCCATGACCTCCGATCACTCAAGCGACATTTTGGCAACACCGTGAGGTCGAAAGGCCCGGAGATGAGGAA 
Gpi1 A GGCCCCCAGAATGAAGGGTGTCAGCTTGGTAAACACAATAGAGTTGGTCGCGAACCTAACTCCTCGCTACATTCCTATTGTTTTC 
 
B CGAAAGCCATGACCTCCGATCACTCTCCCACATGATGCCCTGAACAAAGATCTTGTGCTCATACATGGCAATCAA 
Shank1 A GAAGGCCGGTCATAACTTGGCTGGGAGCGGTGGTGAGGATCAAAGCTCGACTTTCGGGTTATATCTATCATTTACTTGACACCCT 
 
B CGAAAGCCATGACCTCCGATCACTCCGATAGATTTCTGCCGGAGCATAAGGCCAGGTCCGGGAGGCAGGAAA 
Shank2 A GCAGAAATAAAGACAGCAAGTTAAGCAAGCAGGGCACGATCCTGTCCACACAACAGCCACTTTTTTTCCAAATTTTGCAAGAGCC 
 
B CGAAAGCCATGACCTCCGATCACTCAACTCCGTGTGACTTCATTTTGGCCACCCTGGAATTATGCTAATCTGTTT 
Shank3 A CTTCGTCCGGTCCTCTCTGGTTTCATGCCGGGTGTCATACTGTCGCACCGTGTGGACGGCAACTCAGAGATAACGCATAT 
 
B CGAAAGCCATGACCTCCGATCACTCTGTGAAGTGAGGCTGTCATAGGAACCCACAGTGTAGTGGCGGAAGAGACG 
Venus A GGCTGTTGTAGTTGTACTCCAGCTTGTGCCCCAGGATGTTGCCTGGAGTTTATGTATTGCCAACGAGTTTGTCTTT 
 
B CGAAAGCCATGACCTCCGATCACTCGTTGGCCTTGATGCCGTTCTTCTGCTTGTCGGCGGTGATATAGACGTTGT 
Homer1 A ACTGAAGATCTCCTCCTGCTGATTCCTGTGAAGGGGTACTGCAGATAAGGTTGTTATTGTGGAGGATGTTACTACA 
 
B CGAAAGCCATGACCTCCGATCACTCGGGTGTTCTCTCATCGTCTGTCCCATTGATACTTTCTGGTGTCAAAGGAG 
Dlgap1 A TTCGTCGTCCTGGGAGCAGCCCTTTTCGATGGCCCGCACATAGCTGTGCTTCCTTCCTGTGTTCCAGCTACAAACTTAGAAAC 
 
B CGAAAGCCATGACCTCCGATCACTCCTCACGGTGGTGGTTGTGCGTGGAGGGGAGGACGACCGCAGCGACACGCA 
Grm5 A TGAGAGTGTCATATTTGGGAGAGGATGGGATGCAGAGGGCATAAAATTGGTTTTGCCTTTCAGCAATTCAACTT 
 
B CGAAAGCCATGACCTCCGATCACTCGTTTCCAGTGGCTCACAACGATGAAGAACTCTGCGTGTAATCTCTGATGA 
Slc17a7 A TTTGGCAGATAAATCCTCCAGGAATCTGAGTGACAATGTAGCCCCAGAAACTGGTCAAGACTTGCATGAGGACCCGCAAATTCCT 
 
B CGAAAGCCATGACCTCCGATCACTCTGGAGGTAGCCACAATGGCAAAGCCAAAGACCCTGTTGGCTGCGAATT 
Slc17a6 A GCCAACTGTTGTAGTTGTGCTCTCTAAAATGGTGATGGGTCCAACGAATACTTTCGTTGGGACGCTTGAAGCGCAAGTAGAAAAC 
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B CGAAAGCCATGACCTCCGATCACTCATGATCCAGTAGCTTTGGCTTCCTAACTTCTGTAGGATGACATGT 
Grin1 A CGTAGACCTGGCTAGAGATGAGGTCCTCACACACTGACAGCCAGCAGACCTGCAATATCAAAGTTATAAGCGCGT 
 
B CGAAAGCCATGACCTCCGATCACTCAGTGAAGTGGTCGTTGGGAGTAGGCGGGTGACTAACTAGGATAG 
Grin2a A AAGACCAGGCCCCAGAGGAGCCATATAGCTTTTCCAATGGTAAAAGAAGGCCTGCCAATGCACTCGATCTTGTCATTTTTTTGCG 
 
B CGAAAGCCATGACCTCCGATCACTCCTGGTTGTGCCTTTAGGATTCTGGACGGGCACAGAATTGTTG 
Dlg4 A GGCCTGGCTCAAGAAACCGCAGTCCTTGGTCTTGTCGTAGTCAAACAAACTGGAGAGAGAAGTGAAGACGATTTAACCCA 
 
B CGAAAGCCATGACCTCCGATCACTCTCGTCGCTGGCGTCAATTACATGAAGCACATCCCCAAAGTGGAAGCTCAG 
Grin2b A CACCCTACTGTAATGGCTCTTTCACAAAGCCTTATACGAAGAGCTTTCCCCTGAGGCTGTTAAAGCTGTAGCAACTCTTCCACGA 
 
B CGAAAGCCATGACCTCCGATCACTCCCCCTTTCTCACTAACCCTACCGTTAATGACTAAAAACATCCCCCTCTCT 
Gria1 A AACTCGATTAAGGCAACCAGCATGGCCAATCCCAGCCCTCTAGGACGCAAATCACTTGAAGAAGTGAAAGCGAG 
 
B CGAAAGCCATGACCTCCGATCACTCTCAAACAGAAACCCTTCATCCGCTTCGACTCGCTACGGGATTTGTAGCAG 
Gria2 A CTTCTTTGACCGTTTTCCTCAGCAAATTAGATCCTCTGCATTTTGAGGCCACGCGATGACGTTCGTCAAGAGTCGCATAATCT 
 
B CGAAAGCCATGACCTCCGATCACTCAAAAGTAGAGCATCCACAAAATATCCCCTCGTTTCCCTTTCCTCCTTTTC 
Gria3 A TCAGTGGTGTTCTGGTTGGTGTTGTATAACTGCACAGCAAAGCGGAAAGCCATTTGGAATGATGTGTACTGGGAATAAGACGACG 
 
B CGAAAGCCATGACCTCCGATCACTCTATTGGAGGAATCCAAGTGGTCTACGTGGTAGTTCAAATGGAAGGGCTTC 
Syngap1 A TCATGAAGCCCAGGAAGTCCTCCTTTGAGGTAAACTTGGAAAAGTTGGCCCACAAGAATCCCTGCTAGCTGAAGGAGGGTCAAAC 
 
B CGAAAGCCATGACCTCCGATCACTCCTCATACAAGAACTGCTGCATAGAGCCCCACTCCAGCTCCAGAAACTCAT 
Drd2 A CGATGGAGGAGTAGACCACGAAGGCAGGGTTGGCAATGATACACTCATTCCTTGACGTAGATTGCTATCAGGTTACGATGACTGC 
 
B CGAAAGCCATGACCTCCGATCACTCGATTTTGATATAGACCAGCAGGGTGACGATGAAGGGCACGTAGAACGAGA 
Htr2a A AAGTTTTGTATCCGGTGAGAATCTTTCAGCCAATTCTCGGGTTGGATATGCTTACAGATCGTGTGCTCATGACTTCCACAGACGT 
 
B CGAAAGCCATGACCTCCGATCACTCAGCAGTGTGGAGCATTTGGAGACACAAACGTGTTCCTGGTTAAGGAAGAA 
Oxtr A TAAGTCCAGAATTAAGTCTGGGTATTTCAAAGGGACTCCAGAGTGCACAGCAGCAAGAAGGAGTATGGAACTTATAGCAAGAGAG 
 
B CGAAAGCCATGACCTCCGATCACTCGTGGATCTACAGATTCTAGGCTTTTTGGAAGCGCCCTTGATATATTTCAG 
Gabra1 A CTGGTCTCAGACGATTGTCATAACCGTCCAGCAGTCGGTCCAAAATTCCGGGAATCGGCATTTCGCATTCTTAGGATCTAAA 
 
B CGAAAGCCATGACCTCCGATCACTCACTGGTGACGAAAATGTCGGTCTTCACTTCAGTTACACGCTCTCCCAAAC 
Grm1 A CTATGTCACTCCACTCGAGGTAACGGATAGTAATGGGCTCACAGCCGCTATGCAGACGAGCTGGCAGAGGAGAGAAATCA 
 
B CGAAAGCCATGACCTCCGATCACTCTAGCGTCACGAGGATGCCCAGGCAAGAAAAGGCGATGGCTATGATGGATT 
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Appendix 4: Synaptosome proteomic analysis in the hippocampus of Tg
SHANK2A
 
and Tg
SHANK2AR462X
 mice 
For Tg
SHANK2A
 
Gene 
Control vs Tg
SHANK2A 
| log2 
fold change 
Control vs Tg
SHANK2A 
| FDR adjusted 
p-values 
Kif1a 1.122474884 1.14E-09 
Eva1a 0.635968261 2.18E-07 
Rae1 0.597712327 4.16E-07 
Shank3 -0.592462511 4.16E-07 
Pgls 0.680475358 6.77E-07 
Mycbp2 0.811999939 1.92E-05 
Map7d2 0.47887933 6.17E-05 
Shank2 1.258631909 7.34E-05 
Ndrg3 0.315048213 0.000106211 
Apba2 0.40003458 0.000136591 
Shank1 -0.428723287 0.000250898 
C1qc -0.586927084 0.000307778 
Slc6a7 -0.347217651 0.000526456 
Serpinb1a -0.841930491 0.000829553 
Cadm3 -0.390571275 0.001254315 
Rgs14 -0.497653943 0.001389282 
Cd44 -0.346112006 0.001575027 
Homer2 0.376288701 0.00190151 
Mapk10 0.221912197 0.002903784 
Rasgrp1 -0.355467726 0.003147952 
Nptxr -0.281252663 0.003191833 
Grm3 -0.457778491 0.003526421 
Cyb5r1 -0.352127373 0.004473184 
Dkk3 -0.297810886 0.005653321 
Pgm2l1 0.565646527 0.00621139 
Stxbp6 -0.66412202 0.007668076 
Slc18a2 -0.238766089 0.007850403 
Idh2 0.321774881 0.009811683 
Snph -0.284572087 0.009811683 
Sccpdh -0.27468463 0.010398508 
Slc25a22 -0.342067674 0.010398508 
Epha4 -0.263419979 0.010548993 
Rasal1 -0.27179138 0.012534902 
Snx27 0.266420027 0.012630323 
Slc16a1 -0.412377332 0.012630323 
Rmnd1 -0.274691876 0.013283452 
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Ptprn2 -0.694571215 0.013283452 
S100a13 -0.312927979 0.01329418 
Nwd2 -0.317893646 0.01329418 
Fam171a2 -0.312149199 0.013555972 
Tmem132a -0.417145822 0.013555972 
Cntnap1 -0.225628975 0.014006395 
Traf3 -0.631770347 0.014798405 
2010300c02rik 0.470547125 0.015369165 
Rac3 -0.287101422 0.015433729 
Stxbp5 -0.282052748 0.016913791 
Vti1a -0.258452469 0.016983656 
Rab15 -0.974290132 0.016983656 
Ptprs -0.281267124 0.017272138 
Dgkb -0.344567694 0.01799354 
Atp8a1 -0.212135869 0.018101232 
Gltp -0.341492081 0.019484466 
Lman1 0.250195508 0.019917694 
Baiap2 -0.217700561 0.020319399 
Scamp4 -0.312880145 0.020319399 
Abhd3 -0.361977256 0.020319399 
Pip4k2c 0.450513784 0.021473279 
Stx16 -0.287488552 0.021473279 
Rimbp2 -0.217296232 0.024377846 
Syt17 -0.492892907 0.024377846 
Cacng8 -0.262163524 0.024647245 
Mlf2 -0.31437065 0.024647245 
Gria1 -0.30045553 0.026246019 
2310061i04rik -0.334277601 0.027688403 
Nos1 -0.255445978 0.028245011 
Them4 -0.189069975 0.028717854 
Ppap2b -0.28285279 0.029058358 
Unc5c -0.458229666 0.029058358 
Coro2b -0.292554824 0.029177482 
Calu 0.283983932 0.029547219 
Itm2b -1.040993344 0.029547219 
Myadm -0.17252979 0.029774913 
Rtn4ip1 -0.347207271 0.029874312 
Cpne5 -0.267101556 0.030369767 
Cpne6 -0.279278566 0.030369767 
Smpd3 -0.363975358 0.030369767 
Kcnn2 -0.275269374 0.031125458 
Rab11fip2 -0.253095199 0.031721149 
Il1rap -0.268933682 0.032073907 
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Plxna1 -0.262771204 0.032683728 
Rmdn3 -0.29787384 0.032683728 
Synpr -0.358142355 0.032683728 
Rpl13a 0.320273311 0.037105449 
Bsg -0.199095201 0.037224236 
Atp6v0d1 -0.211354153 0.037224236 
Txnl1 0.40481663 0.042397632 
Pycrl -0.307193967 0.042397632 
Plxna2 -0.390853418 0.042397632 
Samm50 -0.217931489 0.04375461 
Gm996 -0.296431502 0.04375461 
Svop -0.430162468 0.044266769 
Myo18a 0.547427858 0.04644443 
Gng7 -0.296499281 0.04644443 
Vdac1 -0.186149907 0.04852333 
Mark4 -0.213873421 0.04852333 
Syt12 -0.238310408 0.04852333 
Mtch2 -0.286659187 0.04852333 
Slc6a11 -0.395320579 0.04852333 
Ipo5 0.238257927 0.048562036 
Map1lc3b -0.161568702 0.048778909 
Pmm1 0.445271034 0.048889438 
Pdcl -0.248255577 0.048889438 
Gpx1 0.16857488 0.050092878 
Fam210a -0.243252202 0.050092878 
Wfs1 -0.426432596 0.050092878 
Tpm4 0.341181093 0.050298941 
Gprc5b -0.237953556 0.050298941 
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For Tg
SHANK2AR462X
 
Gene 
Control vs Tg
SHANK2AR462X 
| log2 
fold change 
Control vs Tg
SHANK2AR462X 
| FDR 
adjusted p-values 
Kif1a 0.870412262 4.63E-09 
Ndrg3 0.306349697 3.41E-05 
Rae1 0.495970752 0.000274634 
Apba2 0.289942235 0.000499013 
Mycbp2 0.685342092 0.000722405 
Pgm2l1 0.597170306 0.002230564 
Rgs14 -0.474542693 0.002230564 
Cpne4 -0.294877801 0.002830756 
Ermp1 -0.245749763 0.008358106 
Pgls 0.254343851 0.010176294 
Lancl1 0.231332812 0.013645122 
Rimbp2 -0.270407782 0.013645122 
Epha4 -0.196126477 0.013645122 
Nwd2 -0.350761804 0.013645122 
Serpinb1a -0.448180145 0.013645122 
Anxa11 -0.401698302 0.022434897 
Ca4 1.635201324 0.027671 
Plxna1 -0.317544143 0.027671 
Map7d2 0.309353916 0.027864551 
Pld3 0.205933469 0.027864551 
Lxn 0.355360482 0.029387066 
Ech1 -0.339782174 0.029387066 
Gria1 -0.288694363 0.029387066 
Nos1 -0.188663274 0.029595978 
Ptprn2 -0.664626969 0.030111267 
Scn8a -0.221685002 0.030268813 
Acot13 -0.212144629 0.030289017 
Rhoa;rhoc 0.287678648 0.030289017 
Ppm1f -0.195102468 0.030289017 
Pex11b -0.200591863 0.032101342 
Kit -0.508559449 0.032101342 
Plxna4 -0.249105577 0.032101342 
Wbscr17 -0.26710312 0.033011016 
Stxbp6 -0.563376886 0.033011016 
Clcn6 0.171758858 0.033737627 
Uchl1 0.400391828 0.034195896 
Rtn4ip1 -0.348146309 0.034195896 
Cadm3 -0.289321917 0.034195896 
Cryz -0.236269806 0.036849927 
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Ccdc177 -0.192598836 0.037525782 
Slc35f1 0.632444371 0.040580386 
Gpr56 0.33786522 0.040580386 
Pgbd5 -0.219782996 0.040580386 
Them6 -0.289408107 0.041542566 
6330403a02rik -0.218986619 0.041542566 
Gm20671;pisd -0.333491941 0.041542566 
Cpne7 -0.413482633 0.041542566 
Cntnap1 -0.204233402 0.041542566 
Cpne5 -0.281118121 0.041542566 
Hsd17b8 -0.208092459 0.044621876 
Pde1a 0.316988873 0.04541138 
Vps16 0.135736026 0.048906198 
Tnks1bp1 -0.221357526 0.048906198 
Slc7a14 -0.245379863 0.048906198 
Cpne6 -0.279941823 0.049821894 
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Appendix 5: Summary of the behavioral analysis 
Name of the behavioral 
experiment 
Parameter TgSHANK2A 
TgSHANK2A+ 
dox 
TgSHANK2A+ 
P0 dox 
  TgSHANK2AR462X 
TgSHANK2AR462X 
+dox 
SHIRPA Weight  ↓30 % ↓30 % ↓10 %   ↓10 %   
  Body position             
  Spontaneous activity ↑ ↑ ↑       
  Tremor             
  Twitches ↑ ↑         
  Defecation             
  Urination             
  Visual Placing             
  Body Tone             
  Pinna Reflex             
  Corneal Reflex ↑ ↑ ↑       
  Toe Pinch              
  Crossed extensor reflex             
  Suspended hind limb splay             
  Trunk curl             
  Limb grasp             
  Horizontal rotation response             
  Catalepsy     ↑       
  Negative geotaxis             
Balance test Score ↓           
LABORAS Number of locomotion ↑ ↑ ↑   ↑ ↑ 
  Average speed ↑ ↑ ↑   ↑ ↑ 
  Duration of eating ↑ ↑       ↑ 
  Duration of drinking   ↓         
  Number of rearing ↑ ↑ ↑       
  Number of self-grooming         ↓ ↓ 
  Number of climbing             
Visual stereotypic  Jumping   n.a.  n.a.    ↑ n.a.  
behavior Self-grooming ↑ n.a.  n.a.      n.a.  
  Digging ↓ n.a.  n.a.    ↓ n.a.  
Open field test 
Number of visits to the center of the 
arena 
↓    ↓      ↓  
  Distance in the center of the arena ↓   ↓     ↓ 
Dark/light compartment Latency to visit  light ↑ ↑ ↑   ↑?   
  Number of visits to light ↓ ↓ ↓   ↑? ↓  
Neophobia Number of contacts ↓ ↓       ↓ 
  Latency to the first contact ↑   ↑   ↑ ↑  
Cliff avoidance CAR ↓ ↓ ↓   ↓ ↓ 
Nesting Score ↓ ↓         
Burrowing Remaining food pellets after 2h ↑ ↑ ↑   ↑ ↑ 
                                                                                                                 
138 
 
  Remaining food pellets after 12h ↑ ↑     ↑ ↑ 
Novel object recognition Number of contacts ↓?       ↑   
Three-chamber social 
test 
Number of all contacts ↓             
Direct social interaction Number of all contacts ↓       ↑   
Puzzle box (session) Latency ↑ 1, 8, 10 ↑ 1-10   ↑1, 8-10   ↑  5,6, 7 ↑ 5,6, 10 
Fear conditioning Acquisition ↓ ↑     ↓   
  Context memory         ↓   
  Cued memory   ↑       ↑ 
↑: increase, ↓: decrease, n.a. : not applicable, empty space: no difference compared to control mice 
 
 
 
 
